<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000218" GROUP_ID="INFECTN" ID="064799103021441747" MERGED_FROM="" MODIFIED="2008-10-26 14:35:27 +0100" MODIFIED_BY="Reive Robb" REVIEW_NO="FFOR" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2008-10-09 16:21:23 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Interventions for treating trichomoniasis in women</TITLE>
<CONTACT>
<PERSON ID="14295" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Fatu</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Forna</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>fatuforna@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gynecology and Obstetrics</DEPARTMENT>
<ORGANISATION>Emory University School of Medicine</ORGANISATION>
<ADDRESS_1>69 Butler Street, S.E.</ADDRESS_1>
<ADDRESS_2/>
<CITY>Atlanta</CITY>
<ZIP>30303</ZIP>
<REGION>Georgia</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 404 6163540</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-10-08 10:42:55 +0100" MODIFIED_BY="Harriet MacLehose">
<PERSON ID="14295" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Fatu</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Forna</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>fatuforna@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gynecology and Obstetrics</DEPARTMENT>
<ORGANISATION>Emory University School of Medicine</ORGANISATION>
<ADDRESS_1>69 Butler Street, S.E.</ADDRESS_1>
<ADDRESS_2/>
<CITY>Atlanta</CITY>
<ZIP>30303</ZIP>
<REGION>Georgia</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 404 6163540</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15905" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>A Metin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gülmezoglu</LAST_NAME>
<SUFFIX/>
<POSITION>Scientist, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)</POSITION>
<EMAIL_1>gulmezoglum@who.int</EMAIL_1>
<EMAIL_2/>
<URL>http://www.who.int/reproductive-health/rhl/index.html</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT>
<ORGANISATION>World Health Organization</ORGANISATION>
<ADDRESS_1>20 Avenue Appia</ADDRESS_1>
<ADDRESS_2/>
<CITY>Geneva</CITY>
<ZIP>1211</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 22 7913417</PHONE_1>
<PHONE_2/>
<FAX_1>+41 22 7914171</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-08 10:42:55 +0100" MODIFIED_BY="Harriet MacLehose">
<UP_TO_DATE>
<DATE DAY="13" MONTH="1" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="11" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2008-10-08 13:13:39 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-08 13:13:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-09 16:21:23 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-10-09 16:21:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="1" YEAR="2003"/>
<DESCRIPTION>
<P>Included one new trial comparing oral metronidazole to intravaginal nonoxynol-9 (<LINK REF="STD-Antonelli-2000" TYPE="STUDY">Antonelli 2000</LINK>), and excluded one trial for lack of randomisation (<LINK REF="STD-Wladeck--1981" TYPE="STUDY">Wladeck 1981</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-09 16:19:31 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="11" YEAR="2002"/>
<DESCRIPTION>
<P>New studies found and included or excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>National Perinatal Epidemiology Unit, Oxford, UK</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>HRP - UNDP/UNFPA/WHO/World Bank Special Programme in Human Reproduction, Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Duke University School of Medicine, North Carolina</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Maternal &amp; Child Health, University of North Carolina-Chapel Hill</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Nuffield Provincial Hospitals Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>European Commission (Directorate General XII)</NAME>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-09 16:31:26 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Nitroimidazole drugs are effective in the treatment of trichomoniasis in women.</TITLE>
<SUMMARY_BODY>
<P>Trichomoniasis is a sexually transmitted infection that affects about 120 million women worldwide every year. This review examines the effectiveness of various treatments and found that oral nitroimidazole drugs are effective in treating trichomoniasis in women. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-08 13:13:45 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-10-08 13:13:45 +0100" MODIFIED_BY="[Empty name]">
<P>Around 120 million women worldwide suffer from<I> Trichomonas vaginalis</I> vaginitis every year. The infection is sexually transmitted and is believed to facilitate HIV transmission.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of various treatment strategies for trichomoniasis in women.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Central Register of Controlled Trials , MEDLINE, and EMBASE. Trials were also identified from reference lists of reviews, through pharmaceutical companies, and by informal discovery. Only published data were used in this review. Date of the most recent search: November, 2002.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised or quasi-randomised trials of different treatment strategies in women with trichomoniasis. Different antitrichomonal drugs or doses were eligible, as were comparisons of treatment with no treatment or placebo.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Trial quality was assessed and data extracted by two reviewers independently using standard criteria.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Fifty-four trials were included. Nitroimidazole drugs seem to be effective in achieving parasitological cure in short term follow up. Partner treatment can be effective in decreasing longer term reinfection rates.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Parasitological cure can be achieved by single oral dose of nitroimidazole. Further research should focus on developing effective partner treatment strategies to prevent reinfections and reduce trichomoniasis prevalence.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-09 16:31:26 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-08 13:13:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Trichomonas vaginalis</I> vaginitis is one of the most common sexually transmitted diseases, with around 120 million women worldwide estimated to suffer from trichomoniasis every year (<LINK REF="REF-WHO-1994" TYPE="REFERENCE">WHO 1994</LINK>). It has been shown to be a common infection in some communities in developing countries (<LINK REF="REF-WHO-1994" TYPE="REFERENCE">WHO 1994</LINK>).</P>
<P>Trichomoniasis infection is characterised by green-yellow frothy vaginal discharge, pain on sexual intercourse, vulvovaginal soreness and itching, and pain on urination. However, many women with trichomoniasis have no symptoms (asymptomatic). Clinical diagnosis is not specific and laboratory confirmation is necessary. The parasite can be found in vaginal secretions, glands (both Bartholin's gland and Skene's gland), and the urethra. The wet mount smear is a cheap and quick diagnostic method but its sensitivity depends on the experience of the examiner and the amount of parasites in the vagina. Standard culture, transport/culture kits, enzyme immunoassay, nucleic acid amplification, and immunofluorescence methods are also available.</P>
<P>T. vaginalis vaginitis requires prompt and effective treatment. Metronidazole and other nitroimidazole drugs (such as ornidazole, tinidazole, nimorazole, and carnidazole) have been used as antitrichomonal agents for more than 30 years. Despite their widespread use, resistance has been relatively rare and generally managed by either higher doses or other nitroimidazoles. Clotrimazole, povidone-iodine, and nonoxynol-9 have been used as local intravaginal applications. Although oral medication is generally preferred, because of the presence of infection in the vaginal glands and urethra, therapeutic blood concentrations are also achieved with local (vaginal or rectal) application of metronidazole. The usual dose of metronidazole is a 2 g single dose or 250 mg three times daily for seven days. However, there are many variations of dose and duration of treatment with metronidazole and other nitroimidazoles. Repeat testing at 5-7 days and at around 30 days may be done to evaluate the immediate success of the treatment and the short term recurrence rate respectively. In clinical practice, however, repeat testing is rarely done unless treatment failure is suspected.</P>
<P>Treatment strategies aim to treat infected women and ensure that sexual partners are also treated. Recurrence of infection is thought to be mainly caused by reinfection from a partner or failure to complete the treatment course. In addition to the morbidity caused by the infection, a main concern about the high prevalence of trichomoniasis is the possibility that reproductive tract infections (ulcerative or non-ulcerative) increase the transmission rate of HIV. If this is so with trichomoniasis, high prevalence rates of the infection in some populations means the infection may be important in facilitating HIV transmission.</P>
<P>This review attempts to evaluate the evidence with regard to the most effective treatment strategy for T. vaginalis vaginitis in women.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the effectiveness of various treatment strategies for trichomoniasis in women who are not pregnant.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-09 16:28:43 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-08 14:52:42 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-08-21 11:11:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Any trial where an attempt is made to allocate different forms of trichomoniasis treatment by a random or quasi-random method was considered for inclusion.</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-08 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Symptomatic or asymptomatic women, including adolescents, with confirmed (by a laboratory technique) <I>Trichomonas vaginalis</I> vaginitis. The setting where participants were enrolled (such as gynaecology outpatient, sexually transmitted disease or family planning clinic) was noted, as were other indicators of risk status (e.g. commercial sex workers).</LI>
<LI>Exclusion criteria: trials during pregnancy; trials in men; prophylactic interventions; interventions aimed at symptomatic relief only.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-08 14:52:42 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Any treatment versus no treatment</LI>
<LI>Short (single dose, repeat doses up to 1-2 days) versus longer (5-10 day) treatment</LI>
<LI>Systemic versus local treatment</LI>
<LI>Partner treatment versus no treatment</LI>
<LI>Different partner treatment strategies (giving the medication to the women or seeing and counselling partners individually)</LI>
<LI>Comparison of two different agents</LI>
<LI>Comparison of different doses of the same agent</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-21 11:10:52 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Parasitological cure</LI>
<LI>Clinical cure (clearance of discharge, soreness, itching)</LI>
<LI>Side effects and complications of treatment</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-08 14:52:50 +0100" MODIFIED_BY="[Empty name]">
<P>Electronic literature search of MEDLINE and EMBASE. Standard three-stage Cochrane search strategy was used for the MEDLINE search from 1966 to 2002 with the following disease terms: <I>Trichomonas vaginalis</I> (explode/all subheadings); <I>Trichomonas vaginitis</I> (explode/all subheadings); <I>Trichomonas</I> infections (explode/all subheadings); Trichomon*, Trichomon*, in title or abstract.</P>
<P>EMBASE was searched from 1980 to 2002 using "trichomonas" and "treatment" as search terms. African Index Medicus was searched to 1996. The specialised register of the Cochrane Infectious Diseases Group and the reference lists of identified trials and current reviews were searched. Manufacturers of metronidazole and tinidazole in the UK were contacted.</P>
<P>Letters were sent to authors of reviews on trichomoniasis treatment and staff at the Centers for Disease Control and Prevention (Sexually Transmitted Disease Control Programme) were contacted.</P>
<P>The Cochrane Central Register of Controlled Trials was searched in each successive issue of <I>The Cochrane Library</I> using the search term trichomon* . The latest search was in November 2002.</P>
<P>No study was excluded on the basis of the language in which it was written.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-09 16:28:43 +0100" MODIFIED_BY="[Empty name]">
<P>All trials identified were considered for inclusion and are referenced in this review. Trials with objectives other than treatment of trichomoniasis in women where no indication of any kind of random allocation could be found were excluded without further evaluation. Authors were contacted if there were doubts about randomisation or the data were not in a suitable form for analysis. The risk of bias in eligible trials was evaluated in terms of allocation concealment, generation of the allocation sequence, blinding, and inclusion of all randomised participants according to the Cochrane Infectious Diseases Group guidelines.</P>
<P>In addition to prespecified outcomes, the following characteristics of trials were extracted:<BR/>
</P>
<UL>
<LI>Country</LI>
<LI>Characteristics of the study population</LI>
<LI>Exclusion criteria</LI>
<LI>Partner treatment measures</LI>
<LI>Loss to follow up</LI>
<LI>Women excluded from analyses</LI>
<LI>Diagnostic procedures used</LI>
</UL>
<P>Data were extracted independently from a random sample of trials that met the inclusion criteria (n = 4). This was done by an editor in the Infectious Diseases Group and compared with the data entered by the reviewer as part of routine quality monitoring. In the most recent update of this review duplicate data extraction has been done by the two reviewers for the newly included trials.</P>
<P>Treatment with a single dose, or two doses 12 to 48 hours apart, were regarded as "short" treatment regimens. Others ranging from 5 to 10 days were regarded as "long" treatment regimens.</P>
<P>In trials with multiple arms comparing different dosages of the same drug, these arms have been reduced to two for analysis purposes (e.g. metronidazole 1 g or less versus metronidazole greater than 1 g).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-09 16:31:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-08 14:47:20 +0100" MODIFIED_BY="[Empty name]">
<P>Fifty-four studies are included in this review. Ten of these were conducted in developing countries in Asia and Africa. Details are given in the table of '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. This review excluded treatment during pregnancy. There were few studies which combined pregnant and non-pregnant women; when it was not possible to obtain separate data these studies were excluded (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>').</P>
<P>Of the trials included in this review the majority (40/54) compared different antitrichomonal drugs and/or different doses. Other treatment strategies included short versus long treatment (four trials), vaginal versus oral plus vaginal treatment (one trial), oral versus oral plus vaginal treatment (four trials), oral versus vaginal treatment (two trials), partner treatment versus no treatment (one trial), and comparison with a no treatment group (six trials). Some trials had more than one arm with different treatments versus control (i.e. no treatment). In all short versus long treatment trials metronidazole was used in the long treatment arm, compared to short treatment with metronidazole in two (<LINK REF="STD-Hager-1980" TYPE="STUDY">Hager 1980</LINK>, <LINK REF="STD-Thin-1979" TYPE="STUDY">Thin 1979</LINK>), ornidazole in one (<LINK REF="STD-Nygaard-1977" TYPE="STUDY">Nygaard 1977</LINK>). and tinidazole in one (<LINK REF="STD-Aimakhu-1975" TYPE="STUDY">Aimakhu 1975</LINK>).</P>
<P>Study populations were heterogeneous. Women attending emergency departments, venereal disease clinics, gynaecology outpatient clinics, cancer screening clinics, prisons, and private practices were recruited in different trials.</P>
<P>All trials used at least one laboratory method for diagnosis.</P>
<P>Partner treatment measures are generally mentioned briefly. One trial (<LINK REF="STD-Lyng-1981" TYPE="STUDY">Lyng 1981</LINK>) randomised partners of women with trichomoniasis to treatment or placebo. Others, in general, did not focus on partner treatment as part of the intervention although most attempted to treat the partners if they were available.</P>
<P>Some trials used extensive exclusion criteria such as the presence of other sexually transmitted diseases, poor general health, any other illnesses, and presumed promiscuity. This created rather atypical study populations. These were generally dose comparison trials possibly motivated by pharmaceutical companies. On the other hand, trials which looked at treating women who came for care (<LINK REF="STD-Hager-1980" TYPE="STUDY">Hager 1980</LINK>, <LINK REF="STD-Chunge-1992" TYPE="STUDY">Chunge 1992</LINK>, <LINK REF="STD-Tidwell-1994" TYPE="STUDY">Tidwell 1994</LINK>) as well as others, had either high losses to follow up or exclusions which resulted in small proportions of enrolled women remaining for analysis. These women were also more likely to have concurrent sexually transmitted diseases. High losses to follow up, exclusions, and concurrent infections and treatments raise questions about the comparability of study groups within trials and the possibility of bias should be kept in mind when interpreting the results.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-08 14:47:20 +0100" MODIFIED_BY="[Empty name]">
<P>Of 54 trials, 16 were classified as category A for allocation concealment, 30 as category B, and 8 as category C. Trials were given a quality score of A if they used secure concealment methods such as central randomisation, or sealed, opaque, envelopes. Inadequately concealed trials, such as those with open randomisation methods, received a score of C. Trials in category B described allocation as randomised but gave no further details on how allocation concealment was done. Some of these trials were reported as double blind. Since no further details were provided these trials were classified as randomised, allocation concealment unclear.<BR/>
<BR/>Trials were generally small and only two that met the inclusion criteria had comparator arms containing more than 100 patients (<LINK REF="STD-Forster-1963" TYPE="STUDY">Forster 1963</LINK>, <LINK REF="STD-Saeed-1976" TYPE="STUDY">Saeed 1976</LINK>).</P>
<P>The small dose/drug comparison trials had very few losses to follow up, while trials which studied higher risk women (venereal disease, emergency clinics) had higher loss to follow up rates (11-62%). In the Hager trial, where short and long treatment regimens were compared, only 38% of the 468 women attended the follow up visit.</P>
<P>Only 13 trials (13/54) specifically reported that outcome assessment was blinded. It was not possible to ascertain whether outcome assessment was blinded in the others.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-09 16:31:26 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Treatment versus no treatment</HEADING>
<P>
<LINK REF="STD-Forster-1963" TYPE="STUDY">Forster 1963</LINK> conducted a placebo controlled trial where the intervention groups were given oral metronidazole alone, or oral combined with vaginal metronidazole, over 10 days. At six weeks follow up there was a parasitological failure rate of 6% (18/287) in the treatment group. <I>Trichomonas</I> was still detected in 78% (111/142) of women in the placebo group.</P>
<P>Two trials (<LINK REF="STD-Gorlero-1992" TYPE="STUDY">Gorlero 1992</LINK>, <LINK REF="STD-Gorlero-1994" TYPE="STUDY">Gorlero 1994</LINK>) compared two different doses of fenticonazole vaginal ovules with a placebo group. Fenticonazole was given as a single dose in the first trial and as two doses on consecutive days in the second trial. Follow up parasitological examination was between days 4 and 7. The two different dose arms in each trial were grouped together for this comparison. Treatment resulted in a significantly higher number of women with parasitological cure (53/105 v 8/51). Of note is the relatively low overall cure rate with treatment (50%).</P>
<P>One trial (<LINK REF="STD-Csonka-1963" TYPE="STUDY">Csonka 1963</LINK>) compared metronidazole with no treatment, two other trials (<LINK REF="STD-Rees-1974" TYPE="STUDY">Rees 1974</LINK>, <LINK REF="STD-Mati-1974" TYPE="STUDY">Mati 1974</LINK>) compared tinidazole with no treatment, while another trial (<LINK REF="STD-Lean-1972" TYPE="STUDY">Lean 1972</LINK>) compared metronidazole, tinidazole, and placebo. All these studies showed evidence of effective parasitological cure by nitroimidazoles.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Short versus longer duration of treatment</HEADING>
<P>Two trials (<LINK REF="STD-Thin-1979" TYPE="STUDY">Thin 1979</LINK>, <LINK REF="STD-Hager-1980" TYPE="STUDY">Hager 1980</LINK>) compared a single 2 g oral dose of metronidazole with 5-7 day course of metronidazole. Parasitological cure was achieved in 88% and 92% of women with short and long treatments, respectively. Side effects were mainly gastrointestinal (nausea, vomiting) and more frequent with the single dose (15% vs 7%). Although the Hager trial was relatively large (468 women enrolled), only 38% attended the follow up visit.</P>
<P>
<LINK REF="STD-Hager-1980" TYPE="STUDY">Hager 1980</LINK> also compared failure rates in subgroups of women who said that their partners took the treatment versus those whose partners did not, and those who admitted to sexual intercourse (they were advised against it) versus those who did not. No difference was found in either comparison (7-21 days after treatment). However, high loss to follow up raises concern about the comparability of the two groups.</P>
<P>Two studies (<LINK REF="STD-Aimakhu-1975" TYPE="STUDY">Aimakhu 1975</LINK>, <LINK REF="STD-Nygaard-1977" TYPE="STUDY">Nygaard 1977</LINK>) compared a standard one week course of metronidazole with short course tinidazole and ornidazole, respectively.</P>
<P>Overall, short treatment was comparable to long treatment in terms of no parasitological cure (RR 1.12, 95% CI 0.58 to 2.16). Side effects however, especially nausea/vomiting and dizziness, were significantly more frequent with short treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral versus intravaginal treatment</HEADING>
<P>Two trials (<LINK REF="STD-Tidwell-1994" TYPE="STUDY">Tidwell 1994</LINK>, <LINK REF="STD-DuBouchet-1998" TYPE="STUDY">DuBouchet 1998</LINK>) compared oral versus intravaginal treatment. Tidwell enrolled only culture-positive women which (as they had to be called back) resulted in the loss of one third of eligible women. DuBouchet also lost 27% of participants by the first follow up visit, and 44% by the second follow up visit. Data from the first follow up visit were used. Our analysis showed that oral treatment was more successful in achieving parasitological cure.</P>
<P>One trial (<LINK REF="STD-Forster-1963" TYPE="STUDY">Forster 1963</LINK>) compared oral metronidazole treatment with oral and intravaginal treatment together (both long term) and found the combined regimen more effective.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral versus oral plus intravaginal treatment</HEADING>
<P>Four trials (<LINK REF="STD-Chung-1978" TYPE="STUDY">Chung 1978</LINK>, <LINK REF="STD-Diwald-1971" TYPE="STUDY">Diwald 1971</LINK>, <LINK REF="STD-Forster-1963" TYPE="STUDY">Forster 1963</LINK>, <LINK REF="STD-Gummerus-1983" TYPE="STUDY">Gummerus 1983</LINK>) compared oral versus oral plus intravaginal treatment. All of the trials except one (<LINK REF="STD-Diwald-1971" TYPE="STUDY">Diwald 1971</LINK>) found combined oral and intravaginal treatment more effective.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Partner treatment versus no partner treatment</HEADING>
<P>One trial (<LINK REF="STD-Lyng-1981" TYPE="STUDY">Lyng 1981</LINK>) randomised partners of women with trichomoniasis (who received standard treatment with tinidazole 2 g) to treatment (tinidazole 2 g single dose) or placebo. Although there was no difference in parasitological results at the first follow up, significantly more women (3/59 vs 14/59) whose partners received placebo were <I>Trichomonas </I>positive by the second follow up at around two months compared with women whose partners were treated. History of intercourse did not affect the results.</P>
<P>No trials were identified that examined other different partner treatment strategies such as seeing or counselling partners individually.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Drug/dose comparisons</HEADING>
<P>A number of small trials compared the effectiveness of different doses of the same drug, or compared various nitroimidazole drugs with each other.</P>
<P>Metronidazole was compared with tinidazole in eight studies (<LINK REF="STD-Anjaneyulu-1977" TYPE="STUDY">Anjaneyulu 1977</LINK>, <LINK REF="STD-Begum-1980" TYPE="STUDY">Begum 1980</LINK>, <LINK REF="STD-Gabriel-1982" TYPE="STUDY">Gabriel 1982</LINK>, <LINK REF="STD-Garud-1978" TYPE="STUDY">Garud 1978</LINK>, <LINK REF="STD-Lean-1972" TYPE="STUDY">Lean 1972</LINK>, <LINK REF="STD-O_x002d_Prasertsawat-1992" TYPE="STUDY">O-Prasertsawat 1992</LINK>, <LINK REF="STD-Rao-1978" TYPE="STUDY">Rao 1978</LINK>, <LINK REF="STD-Sandvei-1979" TYPE="STUDY">Sandvei 1979</LINK>). Except for one study (<LINK REF="STD-Lean-1972" TYPE="STUDY">Lean 1972</LINK>), all compared short regimens of each drug. There were no parasitological failures in two of the trials; however, our meta-analysis results indicate a statistically significant higher treatment failure rate (RR 3.24, 95% CI 1.66 to 6.32), higher clinical failure rate (RR 3.81, 95% CI 1.83 to 7.90), and higher side effect rate (RR 1.65, 95% CI 1.35 to 2.02) with metronidazole. These results should be interpreted with caution as blind assessment of outcomes was reported in only one of the eight trials (<LINK REF="STD-Gabriel-1982" TYPE="STUDY">Gabriel 1982</LINK>). There was no statistical difference in parasitological or clinical outcomes in this trial.</P>
<P>Six trials compared tinidazole with ornidazole (<LINK REF="STD-Hillstroem-1977" TYPE="STUDY">Hillstroem 1977</LINK>, <LINK REF="STD-Chaisilwattana-1980" TYPE="STUDY">Chaisilwattana 1980</LINK>, <LINK REF="STD-Serup-1978" TYPE="STUDY">Serup 1978</LINK>, <LINK REF="STD-Chunge-1992" TYPE="STUDY">Chunge 1992</LINK>, <LINK REF="STD-Sesti-1990" TYPE="STUDY">Sesti 1990</LINK>, <LINK REF="STD-Sandvei-1979" TYPE="STUDY">Sandvei 1979</LINK>). These trials showed no difference in parasitological cure, and the one trial that reported on clinical cure showed no difference. The ornidazole group had a higher incidence of side effects, most notably fatigue (RR 0.18, 95% CI 0.05 to 0.58).</P>
<P>In most trials single dose treatment with any nitroimidazole drug resulted in parasitological cure rates above 90%. Although rarely severe, side effects seem to be relatively common and dose related.</P>
<P>Two trials (<LINK REF="STD-Spence-1997" TYPE="STUDY">Spence 1997</LINK>, <LINK REF="STD-Austin-1982" TYPE="STUDY">Austin 1982</LINK>) compared different doses of short treatment metronidazole. One trial (<LINK REF="STD-Austin-1982" TYPE="STUDY">Austin 1982</LINK>) compared 1 g with 2 g, whereas the other (<LINK REF="STD-Spence-1997" TYPE="STUDY">Spence 1997</LINK>) compared 0.5 g, 1 g, 1.5 g, and 2 g. For the purpose of this review meta-analysis was conducted comparing high (1.5 g or more) with low (1 g or less) dose treatment regimens. Lower dose treatment was found to be inferior to high dose (or rather standard dose) metronidazole in terms of failure to achieve parasitological cure (RR 2.97, 95% CI 1.92 to 4.59) with similar rates of side effects. Laboratory assessments were blinded in both trials.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-08 13:14:50 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Strength of the evidence</HEADING>
<P>This review includes multiple small trials that examine parasitological outcomes in comparisons of effectiveness between different nitroimidazole drugs, different doses, and different regimens. Such variation among the trials lend significant heterogeneity to the meta-analysis, and results should be cautiously interpreted.</P>
<P>Only two trials had comparison groups of more than 100 women. Only one trial examined broader aspects of effective care in trichomoniasis by evaluating the effectiveness of partner treatment in reducing persistent infection.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Treatment effectiveness</HEADING>
<P>The included trials showed that almost any nitroimidazole drug given as a single dose or over a longer period results in parasitological cure in 90% of cases. Oral single dose treatment with any nitroimidazole seems to be effective in achieving short term parasitological cure, but is associated with more frequent side effects than either longer oral or intravaginal treatment. Intravaginal treatment showed parasitological cure rates around 50% which is unacceptably low. The data on symptomatic relief from intravaginal treatment compared with oral treatment are not consistent. However, the trial by Bremond (<LINK REF="STD-Bremond-1987" TYPE="STUDY">Bremond 1987</LINK>), which was excluded from the review because the focus was on symptomatic relief rather than parasitological cure, showed significant benefit from locally applied anti-inflammatory treatment.</P>
<P>It is not possible to conclude that tinidazole is superior to metronidazole from the evidence reviewed. Outcome assessments were blinded in only one study that showed no difference between the two drugs. One argument in favour of tinidazole has been its longer half-life in the body, hence possibly longer duration of effect when compared to metronidazole.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Partner treatment</HEADING>
<P>Although effective clinical treatments exist, <I>Trichomonas vaginalis</I> vaginitis is still one of the most common sexually transmitted diseases. Reinfection by partners appears to be a major problem, and the one trial that examined partner treatment showed that this intervention reduced reinfection significantly. One other trial, which examined differential cure rates by a history of whether the partner had been treated, showed no difference. The latter data, however, are based on reported treatment history, are not from randomised comparisons, and have been gathered from short term follow up studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Drug resistance</HEADING>
<P>Another problem that may not be as widespread as reinfection is drug resistance. Metronidazole is probably the most widely used nitroimidazole for trichomoniasis, and several case reports of resistance have been published although the true extent of this is not known.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Applicability</HEADING>
<P>Effective treatment of trichomoniasis is important internationally, but particularly important in some developing countries where HIV transmission is high and resources for health care are scarce. The results suggest that reinfection is common if partners are not treated. Since many women in developing countries attend clinics alone it is not clear whether giving the medication to the woman to take to her partner is effective or not. Partner notification, on the other hand, can be time consuming, expensive, and difficult to achieve. These problems are similar for all sexually transmitted diseases, but the mild symptoms and non-specific symptoms of <I>Trichomonas</I> infection in men means that compliance with partner treatment is less likely. Another problem that confronts all sexually transmitted disease control strategies is that those groups at greatest risk of these diseases (including commercial sex workers, users of commercial sex workers, and people with multiple concurrent sexual partners) are often difficult to follow up.</P>
<P>By looking at the number of trials published in recent years, enthusiasm for research in the treatment of trichomoniasis seems to be low. This is most probably because of the successful short term parasitological cure that is achieved by drug treatment. However, T. vaginitis remains one of the most common sexually transmitted diseases, and the possibility of an increase in HIV transmission because of vaginitis makes it even more important to investigate effective strategies to decrease the prevalence of the disease.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Nitroimidazoles seem to be effective in achieving short term parasitological cure. Single dose treatment is adequate but patients should be warned about the side effects; compliant patients may be offered a longer treatment regimen with less risk of side effects. Women with severe symptoms may benefit from intravaginal nitroimidazoles or anti-inflammatory agents in addition to oral treatment. Every effort should be made to treat partners.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>From the limited evidence reviewed here there seems to be little difference between drugs. </P>
<P>Strategies to ensure effective partner treatment for the reduction of disease prevalence should be investigated. Future trials should be designed appropriately for this purpose. It is difficult and probably unrealistic to expect women and their partners to attend long term follow up, which makes immediate partner treatment strategies more important. Such trials need to be conducted in settings where infected women are most likely to be seen, such as sexually transmitted disease clinics or gynaecology outpatient clinics. The challenge is to test strategies to increase partner treatment, with longer follow up to evaluate the success of treatment in those settings. Trials could usefully investigate giving partner treatment to women compared with tracing partners by letter, telephone or through extension workers. Using financial incentives to encourage follow up, such as paying for transport and health service fee exemption, could also be researched.</P>
<P>Although it is not a priority for health services research, a carefully conducted metronidazole versus tinidazole comparison with blind assessment of outcomes in settings where both drugs are used and available may be worthwhile. The sample size in such a trial should take into account that both drugs are likely to achieve high rates of parasitological cure and the difference between them would be rather small.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Thanks to Mrs Barbara Aaronson, Dr Michel Boulvain, Dr Ellen Ingham, Dr Regina Kulier, Dr Helena von Hertzen, and Dr Stanislaw Orzeszyna for assistance with translation; to Rhone-Poulenc Rorer (UK) and Pfizer (UK) for providing articles from their database; to the authors for providing additional information, and to Nicola Dollimore (late) for her constructive criticisms and comments in earlier versions of this review. Thanks also to Dr George Schmid for his critical review and comments on the latest version of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>We certify that we have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (e.g. employment, consultancy, stock ownership, honoraria, expert testimony). </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Metin Gülmezoglu wrote the initial version of the review. Fatu Forna is currently the responsible author for the review. She contributed to updating the review by extracting data from studies not included before and by revising the text of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-08 14:51:49 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-08 14:51:49 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-10-08 14:51:49 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aimakhu-1975" NAME="Aimakhu 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aimakhu VE</AU>
<TI>Vaginal trichomoniasis: One stat dose of tinidazole compared with a seven-day course of metronidazole</TI>
<SO>West Afr Med J,</SO>
<YR>1975</YR>
<VL>23</VL>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anjaneyulu-1977" NAME="Anjaneyulu 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anjaneyulu R, Gupte SA, Desai DB</AU>
<TI>Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole</TI>
<SO>J Int Med Res,</SO>
<YR>1977</YR>
<VL>5</VL>
<PG>438-441</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antonelli-2000" NAME="Antonelli 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antonelli NM, Diehl SJ, Wright JW</AU>
<TI>A randomized trial of intravaginal nonoxynol 9 versus oral metronidazole in the treatment of vaginal trichomoniasis</TI>
<SO>Am J Obstet Gynecol</SO>
<YR>2000</YR>
<VL>182</VL>
<PG>1008-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Austin-1982" NAME="Austin 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Austin TW, Smith EA, Darwish R, Ralph ED, Pattison FLM</AU>
<TI>Metronidazole in a single dose for the treatment of trichomoniasis. Failure of a 1-g single dose</TI>
<SO>Br J Vener Dis,</SO>
<YR>1982</YR>
<VL>58</VL>
<PG>121-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ralph ED, Darwish R, Austin TW, Smith EA, Pattison FLM</AU>
<TI>Susceptibility of Trichomonas vaginalis strains to metronidazole: response to treatment</TI>
<SO>Sex Trans Dis,</SO>
<YR>1983</YR>
<VL>10</VL>
<PG>119-122</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnes-1957" NAME="Barnes 1957" YEAR="1957">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnes J, Boutwood A, Haines E, Levington W, Lister E, Haram BJ</AU>
<TI>Oral treatment of trichomonas vaginitis with aminitrozole</TI>
<SO>Br Med J,</SO>
<YR>1957</YR>
<VL>1</VL>
<PG>1160-1162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Begum-1980" NAME="Begum 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Begum SF, Ali SE, Ali S</AU>
<TI>Short course nitroimidazole in the treatment of vaginal trichomoniasis</TI>
<SO>Curr Ther Res,</SO>
<YR>1980</YR>
<VL>28</VL>
<PG>922-926</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Block-1972" NAME="Block 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Block E</AU>
<TI>The effect of nifuratel and metronidazole in the treatment of trichomoniasis</TI>
<SO>Lakartidningen,</SO>
<YR>1972</YR>
<VL>69</VL>
<PG>5210-5212</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaisilwattana-1980" NAME="Chaisilwattana 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaisilwattana P, Bhiraleus P, Patanaprnich P, Bhadrakom C</AU>
<TI>Double blind comparative study of tinidazole and ornidazole as a single dose treatment of vaginal trichomoniasis</TI>
<SO>J Med Assoc Thailand,</SO>
<YR>1980</YR>
<VL>63</VL>
<PG>448-452</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhuri-1980" NAME="Chaudhuri 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhuri P, Drogendijk AC</AU>
<TI>A double-blind controlled clinical trial of carnidazole and tinidazole in the treatment of vaginal trichomoniasis</TI>
<SO>Eur J Obstet Gynecol Reprod Biol,</SO>
<YR>1980</YR>
<VL>10</VL>
<PG>325-328</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chung-1978" NAME="Chung 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chung SO, Yoo BI, Park YD, Lasserre R</AU>
<TI>Single-day treatment of trichomonas vaginitis with low dose of ornidazole</TI>
<SO>Southeast Asian J Trop Med Pub Health,</SO>
<YR>1978</YR>
<VL>9</VL>
<PG>74-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chunge-1992" NAME="Chunge 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chunge CN, Kangethe S, Pamba HO, Owate J</AU>
<TI>Treatment of symptomatic trichomoniasis among adult women using oral nitroimidazoles</TI>
<SO>East Afr Med J,</SO>
<YR>1992</YR>
<VL>69</VL>
<PG>398-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Csonka-1963" NAME="Csonka 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Csonka GW</AU>
<TI>Long-term aspect of treatment with metronidazole (flagyl) in trichomonal vaginitis</TI>
<SO>Brit J Vener Dis,</SO>
<YR>1963</YR>
<VL>39</VL>
<PG>258-260</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diwald-1971" NAME="Diwald 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Divald VJ</AU>
<TI>Trichomoniasis - behandlung der frau mit tinidazol</TI>
<SO>Wien Med Wochen,</SO>
<YR>1971</YR>
<VL>24</VL>
<PG>492-494</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DuBouchet-1997" NAME="DuBouchet 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>duBouchet L, Spence MR, Rein MF, Danzig MR, McCormack WM</AU>
<TI>Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis</TI>
<SO>Sex Trans Dis,</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>156-160</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DuBouchet-1998" NAME="DuBouchet 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>duBouchet L, McGregor JA, Ismail M, McCormack WM</AU>
<TI>A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of Trichomonas vaginalis vaginitis</TI>
<SO>Sex Trans Dis,</SO>
<YR>1998</YR>
<VL>25</VL>
<PG>176-179</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eriksson-1976" NAME="Eriksson 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson G, Wanger L</AU>
<TI>Treatment of trichomoniasis in females with and without gonorrhoea</TI>
<SO>Br J Vener Dis,</SO>
<YR>1976</YR>
<VL>52</VL>
<PG>276-278</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1970" NAME="Evans 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans BA, Catterall RD</AU>
<TI>Nifuratel compared with metronidazole in the treatment of trichomonal vaginitis</TI>
<SO>Br Med J,</SO>
<YR>1970</YR>
<VL>1</VL>
<PG>335-336</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1971" NAME="Evans 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans BA, Catterall RD</AU>
<TI>Nitrimidazine compared with metronidazole in the treatment of vaginal trichomoniasis</TI>
<SO>Br Med J,</SO>
<YR>1971</YR>
<VL>4</VL>
<PG>146-147</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forster-1963" NAME="Forster 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forster SA, Ramirez OG, Rapoport AH</AU>
<TI>Metronidazole and trichomonal vaginitis</TI>
<SO>Am J Obstet Gynecol,</SO>
<YR>1963</YR>
<VL>87</VL>
<PG>1013-1023</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fugere-1983" NAME="Fugere 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fugere P, Verschelden G, Caron M</AU>
<TI>Single dose of ornidazole in women with vaginal trichomoniasis</TI>
<SO>Obstet Gynecol,</SO>
<YR>1983</YR>
<VL>62</VL>
<PG>502-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gabriel-1982" NAME="Gabriel 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gabriel G, Robertson E, Thin RN</AU>
<TI>Single dose treatment of trichomoniasis</TI>
<SO>J Int Med Res,</SO>
<YR>1982</YR>
<VL>10</VL>
<PG>129-130</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garud-1978" NAME="Garud 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garud M, Lulla M, Saraiya U, Vaidya S</AU>
<TI>Oral single dose therapy of trichomonal vaginitis: comparison of tinidazole and metronidazole</TI>
<SO>J Obstet Gynaecol India,</SO>
<YR>1978</YR>
<VL>28</VL>
<PG>347-350</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gjonnaess-1969" NAME="Gjonnaess 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gjonnaess H, Aure JC</AU>
<TI>Treatment of trichomonas vaginitis with nifuratel</TI>
<SO>Acta Obstet Gynecol Scand,</SO>
<YR>1969</YR>
<VL>48</VL>
<PG>85-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorlero-1992" NAME="Gorlero 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorlero F, Bosco P, Barbieri M, Bertulessi C, Pulici L, Polvani F, De Cecco L</AU>
<TI>Fenticonazole ovules in the treatment of vaginal trichomonas infections. A double-blind randomized pilot clinical trial</TI>
<SO>Curr Ther Res,</SO>
<YR>1992</YR>
<VL>51</VL>
<PG>367-376</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorlero-1994" NAME="Gorlero 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorlero F, Macchiavello S, Pellegatta L, Airoldi ML, Gaffuri B, Pulici L, De Cecco L</AU>
<TI>Evaluation of the efficacy and tolerability of two different dosages of fenticonazole vaginal ovules (600 mg and 1000 mg) in patients with vaginal trichomoniasis: A controlled, double-blind, randomized clinical trial versus placebo</TI>
<SO>Curr Ther Res,</SO>
<YR>1994</YR>
<VL>55</VL>
<PG>510-518</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gummerus-1983" NAME="Gummerus 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gummerus M</AU>
<TI>Tinidazole in vaginal trichomoniasis</TI>
<TO>Trikomonaskolpiitin hoito tinidatsolilla</TO>
<SO>Suomen Laakarilehti</SO>
<YR>1983</YR>
<VL>38</VL>
<NO>13</NO>
<PG>1216-1217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hager-1980" NAME="Hager 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hager WD, Brown ST, Kraus SJ, Kleris GS, Perkins GJ, Henderson M</AU>
<TI>Metronidazole for vaginal trichomoniasis</TI>
<SO>JAMA,</SO>
<YR>1980</YR>
<VL>244</VL>
<PG>1219-1220</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayward-1976" NAME="Hayward 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayward MJ, Roy RB</AU>
<TI>Two-day treatment of trichomoniasis in the female. Comparison of metronidazole and nimorazole</TI>
<SO>Br J Vener Dis,</SO>
<YR>1976</YR>
<VL>52</VL>
<PG>63-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hillstroem-1977" NAME="Hillstroem 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hillstroem L, Pettersson L, Palsson E, Sandstroem SO</AU>
<TI>Comparison of ornidazole and tinidazole in single-dose treatment of trichomoniasis in women</TI>
<SO>Br J Ven Dis,</SO>
<YR>1977</YR>
<VL>53</VL>
<PG>193-194</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iannino-1975" MODIFIED="2008-10-08 14:51:49 +0100" MODIFIED_BY="[Empty name]" NAME="Iannino 1975" YEAR="1975">
<REFERENCE MODIFIED="2008-10-08 14:51:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iannino A, Testa P</AU>
<TO>Sul trattamento locale delle vaginiti da T. vaginalis. Richerche comparative con metil-patricina e metronidazolo</TO>
<SO>Minerva Ginecol</SO>
<YR>1975</YR>
<VL>27</VL>
<PG>929-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korner-1978" NAME="Korner 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korner B, Nygaard B, Jensen RH</AU>
<TI>A controlled trial of single-dose treatment with ornidazol (Tiberal) for vaginal trichomoniasis in general practice</TI>
<TO>Engangsbehandling med ornidazol (Tiberal) ved vaginal trichomoniasis</TO>
<SO>Ugeskr Laeg,</SO>
<YR>1978</YR>
<VL>140</VL>
<PG>1485-1487</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lean-1972" NAME="Lean 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lean TH, Vengadasalam D</AU>
<TI>Treatment of vaginal trichomoniasis with a new anti-protozal compound (oc-chloromethyl-2-methyl- 5-nitro-1-imidazole-ethanol)</TI>
<SO>Br J Vener Dis,</SO>
<YR>1973</YR>
<VL>49</VL>
<PG>69-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyng-1981" NAME="Lyng 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyng J, Christensen J</AU>
<TI>A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis</TI>
<SO>Acta Obstet Gynecol Scand,</SO>
<YR>1981</YR>
<VL>60</VL>
<PG>199-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahony-1975" NAME="Mahony 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahony JDH, Harris JRW, Farrer CJ</AU>
<TI>Nimorazole and metronidazole in the treatment of trichomonal vaginitis</TI>
<SO>Br J Clin Pract,</SO>
<YR>1975</YR>
<VL>29</VL>
<PG>71-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manth-1989" NAME="Manth 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manth SM, Rindt W, Schnitker J, Weigerding A, Colli E, Scatigna M</AU>
<TI>Fenticonazole in the treatment of vaginal trichomonas infections</TI>
<SO>Curr Ther Res,</SO>
<YR>1989</YR>
<VL>45</VL>
<PG>1060-1066</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mati-1974" NAME="Mati 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mati JKG, Wallace RJ</AU>
<TI>The treatment of trichomonal vaginitis using a single dose of tinidazole by mouth</TI>
<SO>East Afr Med J,</SO>
<YR>1974</YR>
<VL>51</VL>
<PG>883-888</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McClean-1972" NAME="McClean 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McClean AN</AU>
<TI>Nitrimidazine (Naxogin) compared with metronidazole (Flagyl) in the treatment of trichomonal vaginitis</TI>
<SO>Br J Vener Dis,</SO>
<YR>1972</YR>
<VL>48</VL>
<PG>69-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Notowicz-1977" NAME="Notowicz 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Notowicz A, Stolz E, de Koning GA</AU>
<TI>First experiences with single-dose treatment of vaginal trichomoniasis with carnidazole (R 25831)</TI>
<SO>Br J Ven Dis,</SO>
<YR>1977</YR>
<VL>53</VL>
<PG>129-131</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nygaard-1977" NAME="Nygaard 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nygaard B, Kjaersgaard H, Korner B, Hammer Jensen R</AU>
<TI>Single-dose treatment with ornidazole (Tiberal(R)) and seven-day treatment with metronidazole (Flagyl(R)) in vaginal trichomoniasis</TI>
<SO>Ugeskr Laeg,</SO>
<YR>1977</YR>
<VL>139</VL>
<PG>524-526</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x002d_Prasertsawat-1992" NAME="O-Prasertsawat 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O-Prasertsawat P, Jetsawangsri T</AU>
<TI>Split-dose metronidazole or single-dose tinidazole for the treatment of vaginal trichomoniasis</TI>
<SO>Sex Trans Dis,</SO>
<YR>1992</YR>
<VL>19</VL>
<PG>295-297</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rao-1978" NAME="Rao 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rao HTM, Shenoy DR</AU>
<TI>Single-dose oral treatment of vaginal trichomoniasis with tinidazole and metronidazole</TI>
<SO>J Int Med Res,</SO>
<YR>1978</YR>
<VL>6</VL>
<PG>46-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-1974" NAME="Rees 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rees PH, McGlashan HE, Mwega V</AU>
<TI>Single-dose treatment of vaginal trichomoniasis with tinidazole</TI>
<SO>East Afr Med J,</SO>
<YR>1974</YR>
<VL>51</VL>
<PG>782-785</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roncuzzi-1972" NAME="Roncuzzi 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roncuzzi R, Fortuna A</AU>
<TO>Ricerca controllata sul trattamento della tricomoniasi vaginale con nimorazolo (nitrimidazina) o metronidazolo</TO>
<SO>Giornale Italiano Di Chemioterapia,</SO>
<YR>1972</YR>
<VL>19</VL>
<PG>69-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roy-1975" NAME="Roy 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roy RB, Laird SM, Heasman L</AU>
<TI>Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole</TI>
<SO>Br J Vener Dis,</SO>
<YR>1975</YR>
<VL>51</VL>
<PG>281-284</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saeed-1976" NAME="Saeed 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saeed A, Roy RB, Huq MA</AU>
<TI>Two-day treatment of trichomoniasis in the female - A comparison of metronidazole and nimorazole</TI>
<SO>Br J Clin Pract,</SO>
<YR>1976</YR>
<PG>41-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandvei-1979" NAME="Sandvei 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandvei R, Hernborg K</AU>
<TO>Behandling av trichomonas vaginalis</TO>
<SO>Tidsskr Nor Loegeforen</SO>
<YR>1979</YR>
<VL>99</VL>
<PG>316-317</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schnell-1974" MODIFIED="2008-10-08 14:51:39 +0100" MODIFIED_BY="[Empty name]" NAME="Schnell 1974" YEAR="1974">
<REFERENCE MODIFIED="2008-10-08 14:51:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnell JD, Ruether C</AU>
<TO>Therapie kombinierter vaginal infektionen von trichomonas vaginalis und sprosspilzen</TO>
<SO>Geburtsh Frauenheilk</SO>
<YR>1974</YR>
<VL>34</VL>
<PG>551-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-08 14:51:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnell JD</AU>
<TI>The incidence of vaginal candida and trichomonas infections and treatment of trichomonas vaginitis with clotrimazole</TI>
<SO>Postgrad Med J</SO>
<YR>1974</YR>
<VL>July Suppl</VL>
<PG>79-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serup-1978" NAME="Serup 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serup J, Jensen RH</AU>
<TI>Treatment of trichomoniasis vaginalis with single oral dose of ornidazole (Tiberal) and tinidazole (Fasigyn). A controlled investigation</TI>
<SO>Ugeskr Laeg,</SO>
<YR>1978</YR>
<VL>140</VL>
<PG>1483-1484</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sesti-1990" NAME="Sesti 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sesti F, Valli E, Troisi C, Ciancio F, Piccione E</AU>
<TI>Comparative clinical study of the therapeutic efficacy of tinidazole and ornidazole in the treatment of vaginal trichomoniasis</TI>
<TO>Studio clinico comparativo sull'efficacia terapeutica di tinidazolo vs. ornidazolo nel trattamento della trichomoniasi vaginale</TO>
<SO>Giorn It Ost Gin,</SO>
<YR>1990</YR>
<VL>12</VL>
<PG>83-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spence-1997" NAME="Spence 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spence MR, Harwell TS, Davies MC, Smith JL</AU>
<TI>The minimum single oral metronidazole dose for treating trichomoniasis: a randomized blinded study</TI>
<SO>Obstet Gynecol,</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>699-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thin-1979" NAME="Thin 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thin RN, Symonds MAE, Booker R, Cook S, Langlet F</AU>
<TI>Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis</TI>
<SO>Br J Ven Dis,</SO>
<YR>1979</YR>
<VL>55</VL>
<PG>354-356</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tidwell-1994" NAME="Tidwell 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tidwell BH, Lushbaugh WB, Laughlin M, Cleary JD, Finley RW</AU>
<TI>A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis</TI>
<SO>J Infect Dis,</SO>
<YR>1994</YR>
<VL>170</VL>
<PG>242-246</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tinkler-1974" NAME="Tinkler 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tinkler AE</AU>
<TI>Nimorazole compared with metronidazole in the treatment of vaginal trichomoniasis</TI>
<SO>Practitioner,</SO>
<YR>1974</YR>
<VL>212</VL>
<PG>115-119</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wigfield-1975" NAME="Wigfield 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wigfield AS</AU>
<TI>Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole</TI>
<SO>Br J Vener Dis,</SO>
<YR>1975</YR>
<VL>51</VL>
<PG>54-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Akinla-1975" NAME="Akinla 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akinla O, Ogunbi O</AU>
<TI>Treatment of trichomonal vaginitis with single dose tinidazole (Fasigyn)</TI>
<SO>West Afr J Pharmac Drug Res,</SO>
<YR>1975</YR>
<VL>2</VL>
<PG>31-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ali-1975" NAME="Ali 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ali SE</AU>
<TI>Clinical evaluation of a single dose of tinidazole in trichomoniasis</TI>
<SO>Curr Ther Res,</SO>
<YR>1975</YR>
<VL>18</VL>
<PG>669-672</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-1975" NAME="Andersen 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen HJ</AU>
<TO>Behandling af trichomoniasis urogenitalis med en engagngsdosis af tinidazolum</TO>
<SO>Ugeskr Laeg,</SO>
<YR>1975</YR>
<VL>137</VL>
<PG>676-678</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apte-1978" NAME="Apte 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apte VV, Packard RS</AU>
<TI>Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis</TI>
<SO>Drugs,</SO>
<YR>1978</YR>
<VL>15</VL>
<NO>Suppl. 1</NO>
<PG>43-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnold-1974" NAME="Arnold 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnold M</AU>
<TO>Vergleich von Nifuratel und Tinidazol bei Trichomonadenvaginitis</TO>
<SO>Ther Umsch,</SO>
<YR>1974</YR>
<VL>31</VL>
<PG>202-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Arya-1974" NAME="Arya 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Arya OP, Alergant CD</AU>
<TI>Comparison of magmilor with flagyl compaq in women with trichomoniasis and candidiasis</TI>
<SO>Unpublished</SO>
<YR>1974</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aubert-1982" NAME="Aubert 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aubert JM, Sesta HJ</AU>
<TI>Treatment of vaginal trichomoniasis: Single, 2-gram dose of metronidazole as compared with a seven-day course</TI>
<SO>J Reprod Med,</SO>
<YR>1982</YR>
<VL>27</VL>
<PG>743-745</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aure-1974" NAME="Aure 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aure MT</AU>
<TO>Estudio comparativo entre el tinidazole y el metronidazol en el tratamiento de la tricomoniasis vaginal</TO>
<SO>Rev Obstet Gynecol Venezuela,</SO>
<YR>1974</YR>
<VL>34</VL>
<PG>437-440</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azevedo-1985" NAME="Azevedo 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azevedo EMM, Fonseca AM, Souza AZ, Bagnoli VR, Salvatore CA</AU>
<TI>Vaginal trichomoniasis treatment by immunization with lactobacillus acidophilus vaccine</TI>
<SO>Archives of Gynecology</SO>
<YR>1985</YR>
<VL>237</VL>
<PG>65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bedoya-1974" NAME="Bedoya 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bedoya JM</AU>
<TI>Short treatment for human urogenital trichomoniasis with tinidazole: a preliminary report</TI>
<SO>Curr Med Res Opin,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>165-168</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bertini-de-Oliveira" NAME="Bertini de Oliveira" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertini de Oliveira AM, Delascio D, De Oliveira N</AU>
<TI>Treatment of vaginitis due to trichomonas. Results with a new imidazole derivative: Nitrimidazine</TI>
<SO>Minerva Ginecol,</SO>
<YR>1972</YR>
<VL>7</VL>
<PG>342-353</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bloch-1985" NAME="Bloch 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bloch B, Smyth E</AU>
<TI>The treatment of Trichomonas vaginalis vaginitis. An open controlled prospective study comparing a single dose of metronidazole tablets, benzoyl metronidazole suspension and tinidazole tablets</TI>
<SO>S Afr Med J,</SO>
<YR>1985</YR>
<VL>67</VL>
<PG>455-457</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Botero-1977" NAME="Botero 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Botero D, Perez A</AU>
<TI>Treatment of intestinal amoebiasis and vaginal trichomoniasis with panidazole and its comparison with metronidazole</TI>
<SO>Trans R Soc Trop Med Hyg,</SO>
<YR>1977</YR>
<VL>71</VL>
<PG>508-511</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bremond-1987" NAME="Bremond 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bremond A</AU>
<TI>Clinical evaluation of benzydamine for treatment of vaginitis: Results of a randomized study with emphasis on functional symptoms</TI>
<SO>Int J Tiss Reac,</SO>
<YR>1987</YR>
<VL>9</VL>
<PG>147-149</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burkett-1975" NAME="Burkett 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burkett G, Noel B</AU>
<TI>Single dose treatment of trichomonas vaginalis with tinidazole (Fasigyn)</TI>
<SO>W I Med J,</SO>
<YR>1975</YR>
<VL>24</VL>
<PG>179-181</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Catterall-1957" NAME="Catterall 1957" YEAR="1957">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catterall RD, Nicol CS</AU>
<TI>Systemic treatment of trichomonal infections</TI>
<SO>Br Med J,</SO>
<YR>1957</YR>
<VL>2</VL>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1975" NAME="Cohen 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J, Merger R</AU>
<TO>Un traitement-minute de la trichomonase vaginale</TO>
<SO>Gynecologie,</SO>
<YR>1975</YR>
<VL>26</VL>
<PG>27-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Csonka-1971" NAME="Csonka 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Csonka GW</AU>
<TI>Trichomonal vaginitis treated with one dose of metronidazole</TI>
<SO>Br J Vener Dis,</SO>
<YR>1971</YR>
<VL>47</VL>
<PG>456-458</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1973" NAME="Davidson 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson F</AU>
<TI>Short-term high-dose metronidazole for vaginal trichomoniasis</TI>
<SO>J Obstet Gynecol,</SO>
<YR>1973</YR>
<VL>80</VL>
<PG>368-370</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dellenbach-1972" NAME="Dellenbach 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dellenbach P, Muller P</AU>
<TO>Traitement des trichomonases urogenitales par le Fasigyn</TO>
<SO>J Gynecol Obstet Biol Reprod,</SO>
<YR>1972</YR>
<VL>1</VL>
<NO>Suppl. 2</NO>
<PG>369-371</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dellenbach-1974" NAME="Dellenbach 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dellenbach P, Muller P</AU>
<TI>Single dose therapy of urogenital trichomoniasis with 2 grams tinidazole</TI>
<SO>Curr Med Res Opin,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>142-146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Djahangiri-1976" NAME="Djahangiri 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Djahangiri MH</AU>
<TO>Eindosis-Therapie der Trichomonaden -Kolpitis mit tinidazol</TO>
<SO>Muench Med Wschr,</SO>
<YR>1976</YR>
<VL>118</VL>
<PG>47-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubois-1970" NAME="Dubois 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubois P, Lambotte R, Plomteux G</AU>
<TO>Essais therapeutiques cliniques avec le fasigyn dans la trichomoniase vaginale</TO>
<SO>Rev Med Liege,</SO>
<YR>1970</YR>
<VL>25</VL>
<PG>586-590</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunlop-1958" NAME="Dunlop 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunlop EMC, Philipp E, Watt JD</AU>
<TI>Oral treatment of trichomonal vaginitis with 2-Acetylamino-5-Nitrothiazole</TI>
<SO>Br J Vener Dis,</SO>
<YR>1958</YR>
<VL>34</VL>
<PG>57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dykers-1978" NAME="Dykers 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dykers JR</AU>
<TI>Single-dose metronidazole for trichomonal vaginitis: patient and consort</TI>
<SO>Am J Obstet Gynecol,</SO>
<YR>1978</YR>
<VL>132</VL>
<PG>579-580</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erb-1975" NAME="Erb 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erb H</AU>
<TO>Eindosis-therapie bei trichomoniasis</TO>
<SO>Geburtsh Frauenheilk,</SO>
<YR>1975</YR>
<VL>35</VL>
<PG>44-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feo-1961" NAME="Feo 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feo LG</AU>
<TI>Flagyl in the oral treatment of trichomonal vaginitis</TI>
<SO>Br J Vener Dis,</SO>
<YR>1961</YR>
<VL>37</VL>
<PG>219-222</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Figueroa-1997" NAME="Figueroa 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Figueroa RBG, Lopez FGB, Rechy GO, Romero-Cabello R</AU>
<TO>Estudio Comparativo para evaluar la eficacia y seguridad de metronidazol y secnidazol en presentacion de ovulos, para el tratamiento de tricomoniases vaginal</TO>
<SO>Ginecologia y Obstet De Mexico,</SO>
<YR>1997</YR>
<VL>65</VL>
<PG>487-491</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganju-1966" NAME="Ganju 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganju D, Anjaneyulu R</AU>
<TI>Leucorrhoea due to Trichomonas vaginalis - Clinical trial with Hamycin</TI>
<SO>Hindustan Antibiotics Bulletin,</SO>
<YR>1966</YR>
<VL>9</VL>
<PG>69-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giordano-1974" NAME="Giordano 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giordano C, Casanova R, Montagnoli JR, de Sousa MJ, Martinez A, dos Santos JF, da Silva SMM</AU>
<TO>Tratamento da tricomoniase vaginal com dose unica de tinidazol</TO>
<SO>Ginecologia,</SO>
<YR>1974</YR>
<VL>68</VL>
<PG>557-565</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldman-1974" NAME="Goldman 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldman JA</AU>
<TI>A comparative study of nitrimidazine and metronidazole in the treatment of trichomonas infections</TI>
<SO>Harefuah,</SO>
<YR>1974</YR>
<VL>86</VL>
<PG>463-465</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goncalves-1987" NAME="Goncalves 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goncalves NMC</AU>
<TI>Clinical evaluation of a salicylic acid/boric acid/ammonium alum combination as coadjuvants in the treatment of Trichomonas vaginalis and Candida albicans vulvovaginitis</TI>
<SO>J Bras Ginecol,</SO>
<YR>1987</YR>
<VL>97</VL>
<PG>359-362</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodwin-1972" NAME="Goodwin 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin DW, Reinhard J</AU>
<TI>Disulfiramlike effects of trichomonocidal drugs. A review and double-blind study</TI>
<SO>Quart J Stud Alc,</SO>
<YR>1972</YR>
<VL>33</VL>
<PG>734-740</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gyorik-1971" NAME="Gyorik 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gyorik W, Wenner R</AU>
<TO>Therapie der Trichomonadeninfektion mit Tinidazol im Vergleich zu Metronidazol</TO>
<SO>Schweiz Rundsch Med Prax,</SO>
<YR>1971</YR>
<VL>60</VL>
<PG>1612-1614</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heiss-1971" NAME="Heiss 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heiss VH</AU>
<TO>Klinische auswertung aktiver Arzneimittel gegen Trichomoniasis vaginalis im Doppel-blindversuch</TO>
<SO>Wien Med Wochen,</SO>
<YR>1971</YR>
<VL>46</VL>
<PG>832-834</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Helmy-1974" NAME="Helmy 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helmy NI</AU>
<TI>A new anti-trichomonal agent</TI>
<SO>Br J Clin Pract,</SO>
<YR>1974</YR>
<VL>28</VL>
<PG>411-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-1975" NAME="Henderson 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson JN, Tait IB</AU>
<TI>The use of povidone-iodine ('Betadine') pessaries in the treatment of candidal and trichomonal vaginitis</TI>
<SO>Curr Med Res Opin,</SO>
<YR>1975</YR>
<VL>3</VL>
<PG>157-162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1977" NAME="Jones 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones R, Enders P</AU>
<TI>An evaluation of tinidazole as single-dose therapy for the treatment of Trichomonas vaginalis</TI>
<SO>Med J Aust,</SO>
<YR>1977</YR>
<VL>2</VL>
<PG>679-680</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karagiosov-1979" NAME="Karagiosov 1979" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karagiosov I, Stoilov L, Trayanova E</AU>
<TI>One day treatment of genital trichomoniasis with Fasigyn</TI>
<SO>Akush Ginekol,</SO>
<YR>1979</YR>
<VL>18</VL>
<PG>98-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawamura-1978" NAME="Kawamura 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawamura N</AU>
<TI>Metronidazole and tinidazole in a single large dose for treating urogenital infections with trichomonas vaginalis in men</TI>
<SO>Br J Vener Dis,</SO>
<YR>1978</YR>
<VL>54</VL>
<PG>81-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kholodovskaya-1979" NAME="Kholodovskaya 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kholodovskaya IV, Minasova GS, Khokhlov AP</AU>
<TI>Clinicolaboratory evaluation of tinidazole (Facizhine) "Polfa" in treatment of vaginal trichomoniasis</TI>
<SO>Vestn Dermatol Venerol,</SO>
<YR>1979</YR>
<VL>4</VL>
<PG>58-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-1993" NAME="Kim 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim HJ, Kim JH, Kim YT</AU>
<TI>Tetracycline versus combination of tetracycline and metronidazole in the treatment of male patients with nongonococcal urethritis</TI>
<SO>Korean J Dermatol,</SO>
<YR>1993</YR>
<VL>31</VL>
<PG>937-943</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kulseng_x002d_Hanssen-1975" NAME="Kulseng-Hanssen 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kulseng-Hanssen S, Ladehaug B</AU>
<TO>Vaginal trichomoniasis behandlet med tinidazol (Fasigyn) i engangsdose</TO>
<SO>Tidsskrift for Den Norske Laegeforening,</SO>
<YR>1975</YR>
<VL>95</VL>
<PG>1003-1004</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanceley-1953" NAME="Lanceley 1953" YEAR="1953">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanceley F, McEntegart MG</AU>
<TI>Trichomonas vaginalis in the male. The experimental infection of a few volunteers</TI>
<SO>Lancet,</SO>
<YR>1953</YR>
<VL>1</VL>
<PG>668-669 (April 4)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liechti-1971" NAME="Liechti 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liechti R</AU>
<TO>Perorale behandlung der Trichomonadenkolpitis mit Fasigyn</TO>
<SO>Schweiz Z Gynaekol Geburtsh,</SO>
<YR>1971</YR>
<VL>2</VL>
<PG>229-235</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lotvin-1973" NAME="Lotvin 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lotvin BR, Moreno JAR, De Larios NM, Arista RB</AU>
<TO>Estudio doble ciego de un nuevo tricomonicida de uso oral exclusivamente</TO>
<SO>Ginec Obstet Mex,</SO>
<YR>1973</YR>
<VL>34</VL>
<PG>397-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyon-1963" NAME="Lyon 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyon FA, Sinykin MB, Barr MM</AU>
<TI>Trichomonal vaginitis treated with metronidazole</TI>
<SO>Am J Obstet Gynecol,</SO>
<YR>1963</YR>
<VL>85</VL>
<PG>955-958</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magnier-1976" NAME="Magnier 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magnier PA, Cohen A</AU>
<TO>La trichomonase uro-genitale et son traitement minute par la tinidazole 500</TO>
<SO>Lyon Med,</SO>
<YR>1976</YR>
<VL>236</VL>
<PG>279-284</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marianowski-1976" NAME="Marianowski 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marianowski J</AU>
<TO>Leczenie rzesistkowego zapalenia pochwy jednorazowa dawka tinidazolu</TO>
<SO>Gynecol Pol,</SO>
<YR>1976</YR>
<VL>47</VL>
<PG>317-319</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massa-1976" NAME="Massa 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massa M, Arias B, Subiabre V, Rojo M</AU>
<TI>Therapeutic trial of Trichomonas vaginalis in male by using a single dose of tinidazole</TI>
<TO>Ensayo terapéutico de la infeccion por Trichomonas vaginalis en el hombre mediante una dosis unica de tinidazol</TO>
<SO>Bol Chile Parasit,</SO>
<YR>1976</YR>
<VL>31</VL>
<PG>46-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCann-1972" NAME="McCann 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCann JS, Mahony JDH, Harris JRW</AU>
<TI>Comparison of nitrimidazine and metronidazole in the treatment of trichomonal vaginitis</TI>
<SO>Br J Vener Dis,</SO>
<YR>1972</YR>
<VL>48</VL>
<PG>387-390</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milek-1974" NAME="Milek 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milek E, Nedelkova E</AU>
<TI>Single-dose therapy with tinidazole in trichomoniasis</TI>
<SO>Curr Med Res Opin,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>169-177</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1969" NAME="Miller 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller MW, Howes HL, English AR</AU>
<TI>Tinidazole, a potent new antiprotozoal agent</TI>
<SO>Antimicrob Agents and Chemother,</SO>
<YR>1970</YR>
<VL>9</VL>
<PG>261-266</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mischer-1976" NAME="Mischer 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mischer P, Soeltz-Szoets J, Thurner J</AU>
<TO>Kurzzeitbehandlung der trichomoniasis</TO>
<SO>Z Hautkr,</SO>
<YR>1976</YR>
<VL>51</VL>
<PG>465-468</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-1979" NAME="Moore 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore JR</AU>
<TI>One-gram, single-dose metronidazole (flagyl) for trichomonal vaginitis</TI>
<SO>J Am Coll Health Assoc,</SO>
<YR>1979</YR>
<VL>28</VL>
<PG>128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mukherjee-1979" NAME="Mukherjee 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mukherjee K</AU>
<TI>Clinical experience with Flagyl suspension in vaginal trichomoniasis</TI>
<SO>Indian Practitioner,</SO>
<YR>1979</YR>
<VL>32</VL>
<PG>291-294</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naguib-1975" NAME="Naguib 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Naguib YA, Nagui A, Bassaly M, Gaber A.  Treatment of trichomonas vaginitis with a single dose of tinidazole.  .  1975;58:633-644.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naguib YA, Nagui A, Bassaly M, Gaber A</AU>
<TI>Treatment of trichomonas vaginitis with a single dose of tinidazole</TI>
<SO>J Egypt Med Assoc,</SO>
<YR>1975</YR>
<VL>58</VL>
<PG>633-644</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Obel-1975" NAME="Obel 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Obel E</AU>
<TO>Behandling af Trichomonas vaginalis med "enkeltdosis" metronidazol (Flagyl, Trichomol), tinidazol (Fasigyn)</TO>
<SO>Ugeskr Laeg,</SO>
<YR>1975</YR>
<VL>137</VL>
<PG>693-694</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ongom-1974" NAME="Ongom 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ongom VL, Wamboka JW, Odong EAI, Mafigiri J</AU>
<TI>A single dose treatment of Trichomonas infection with tinidazole (Fasigyn) in Uganda</TI>
<SO>East Afr Med J,</SO>
<YR>1974</YR>
<VL>51</VL>
<PG>878-882</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozbilgin-1974" NAME="Ozbilgin 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozbilgin A, Ozbel Y, Alkan MZ, Guruz Y, Atambay M, Tasci S, Ozcel MA</AU>
<TI>Trichomoniasis in non-gonococcic urethritis among male patients</TI>
<SO>J Egypt Soc Parasitol,</SO>
<YR>1994</YR>
<VL>24</VL>
<PG>621-625</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peeters-1974" NAME="Peeters 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peeters R, Snauwaert R, Cutsem JV, Amery W</AU>
<TI>A controlled trial with miconazole (R 14889) in the prevention of yeast infections after treatment of vaginal trichomoniasis</TI>
<SO>Eur J Obstet Gynecol Reprod Biol,</SO>
<YR>1974</YR>
<VL>4</VL>
<PG>95-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pereyra-1972" NAME="Pereyra 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pereyra AJ, Nelson RM, Ludders DJ</AU>
<TI>Flunidazole - A new drug for systemic treatment of urogenital trichomoniasis</TI>
<SO>Am J Obstet Gynecol,</SO>
<YR>1972</YR>
<VL>112</VL>
<PG>963-966</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-1976" NAME="Phillips 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillips C, Shrivastava M</AU>
<TI>Single-dose therapy of trichomonal vaginitis with tinidazole</TI>
<SO>J Obstet Gynaecol India,</SO>
<YR>1976</YR>
<VL>26</VL>
<PG>893-895</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plotho-1971" NAME="Plotho 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plotho B, Koelbl H</AU>
<TO>Die behandlung der trichomoniasis urogenitalis mit tinidazol*) einer neuen, trichomonaziden substanz</TO>
<SO>Wien Med Wochen,</SO>
<YR>1971</YR>
<VL>40</VL>
<PG>707-709</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porapakkham-1967" NAME="Porapakkham 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porapakkham S</AU>
<TI>Metronidazole treatment of vaginal trichomoniasis II. Oral vs Vaginal Therapy</TI>
<SO>J Obstet Gynecol,</SO>
<YR>1967</YR>
<VL>29</VL>
<PG>213-216</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Psaroudakis-1977" NAME="Psaroudakis 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Psaroudakis A, Kalogeropoulos G, Michalopoulos A, Antoniu K, Tsatsiadis K, Golemati E, Kaskarelis D</AU>
<TI>Treatment of vaginal trichomoniasis with a single oral dose of tinidazole</TI>
<SO>Curr Ther Res,</SO>
<YR>1977</YR>
<VL>21</VL>
<PG>473-478</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quartararo-1974" NAME="Quartararo 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quartararo P, Florino S</AU>
<TI>Treatment of vaginal trichomoniasis with a single dose of tinidazole</TI>
<SO>Curr Med Res Opin,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>153-157</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rainer-1974" NAME="Rainer 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rainer VA</AU>
<TO>Uber die behandlung der trichomoniasis urogenitalis beider geschiechter mit tinidazol (Fasigyn)</TO>
<SO>Wien Med Wochen,</SO>
<YR>1974</YR>
<VL>42-43</VL>
<PG>625-626</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1965" NAME="Robinson 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson SC, Gopi M</AU>
<TI>Trichomonas vaginalis. V. Further observations on metronidazole (Flagyl) (including infant follow-up)</TI>
<SO>Am J Obstet Gynecol,</SO>
<YR>1965</YR>
<VL>93</VL>
<PG>502-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ross-1973a" NAME="Ross 1973a" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ross SM</AU>
<TI>Vaginal and oral nitrimidazine in the treatment of vaginal trichomoniasis</TI>
<SO>Br J Vener Dis,</SO>
<YR>1973</YR>
<VL>49</VL>
<PG>310-313</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ross-1973b" NAME="Ross 1973b" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ross SM</AU>
<TI>Single and triple dose treatment of trichomonas infection of the vagina</TI>
<SO>Br J Vener Dis,</SO>
<YR>1973</YR>
<VL>49</VL>
<PG>475-477</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rzempoluch-1976" NAME="Rzempoluch 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rzempoluch E, Cwik F, Szymanska A, Lubelska K</AU>
<TO>Porownanie skutecznosci leczenia rzesistkowicy metronidazolem, fasigynem i pimafucina</TO>
<SO>Polski Tygodnik Lekarski,</SO>
<YR>1976</YR>
<VL>31</VL>
<PG>2021-2023</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-R_x00f6_semann-197" NAME="Rösemann 197" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rösemann GWE, Vaughan J</AU>
<TI>Treatment of trichomoniasis in the female with a single dose of tinidazole</TI>
<SO>S Afr Med J,</SO>
<YR>1973</YR>
<VL>47</VL>
<PG>1222-1224</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salinas-1971" NAME="Salinas 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salinas PL</AU>
<TO>Tinidazol (CP, 12-574) en el tratamiento de la tricomoniasis vaginal</TO>
<SO>Rev Clin Espanol,</SO>
<YR>1971</YR>
<VL>123</VL>
<PG>173-176</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandront_x002d_Degee-1975" NAME="Sandront-Degee 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandront-Degee M, Werbrouck-Navette J, Lambotte R</AU>
<TO>Acquisitions nouvelles dans la therapeutique des vaginites a trichomonas vaginalis</TO>
<SO>Rev Med Liege,</SO>
<YR>1975</YR>
<VL>30</VL>
<PG>560-562</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schellen-1974" NAME="Schellen 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schellen TMCM, Meinhardt G</AU>
<TI>Treatment of trichomoniasis with a single oral dose of tinidazole</TI>
<SO>Curr Med Res Opin,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>158-164</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmoer-1974" NAME="Schmoer 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmoer J</AU>
<TI>Single-dose treatment with tinidazole: progress in the therapy of trichomoniasis</TI>
<SO>Curr Med Res Opin,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>138-141</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shutsky-1978" NAME="Shutsky 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shutsky IV, Bratus FF, Melnichenko AI, Borosvky AV, Arabadzhi TM, Kunina EM</AU>
<TI>Comparative evaluation of some methods for treatment of trichomonosis in women</TI>
<SO>Vestn Dermatol Venerol,</SO>
<YR>1978</YR>
<VL>9</VL>
<PG>71-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szczucki IV, Bratus FF, Melitczenko AI, Borowski AV, Vinogradova MP, Elenieva LV, Kunina EM</AU>
<TI>Results of treatment with metronidazole according to various schedules in trichomonadosis alone or coexistent with gonorrhoea, syphilis and bacterial infections</TI>
<SO>Przegl Dermatol,</SO>
<YR>1987</YR>
<VL>2</VL>
<PG>133-138</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sternadel-1974" NAME="Sternadel 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Sternadel Z, Peksa A, Karwan-Plonska.  Treatment of&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sternadel Z, Peksa A, Karwan-Plonska</AU>
<TI>Treatment of trichomonas vaginitis with tinidasol</TI>
<TO>Leczenie rzesistkowego zapalenia pochwy tinidazolem</TO>
<SO>Gin Pol,</SO>
<YR>1974</YR>
<VL>9</VL>
<PG>110-1111</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sternadel-1975" NAME="Sternadel 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sternadel Z, Karwan-Plonska A, Peksa A</AU>
<TO>Ocena skutecznosci leczniczej jednorazowej dawki doustnej tinidazolu (2000 mg) w leczeniu rzesistkowego zapalenia pochwy</TO>
<SO>Gynecol Pol,</SO>
<YR>1975</YR>
<VL>46</VL>
<PG>787-789</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swarz-1974a" NAME="Swarz 1974a" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swarz H, Lahon HFJ</AU>
<TI>Introduction</TI>
<SO>Curr Med Res Opinion,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>127-129</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swarz-1974b" NAME="Swarz 1974b" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swarz H</AU>
<TI>International experience with a new single 2 gram dose of tinidazole ('Fasigyn')</TI>
<SO>Curr Med Res Opinion,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>181-187</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thavabalan-1974" NAME="Thavabalan 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thavabalan PB, Oriel JD</AU>
<TI>Single-dose treatment of vaginal trichomoniasis with tinidazole ('Fasigyn')</TI>
<SO>Curr Med Res Opinion,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>178-180</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-Dinh-De-1963" NAME="Tran Dinh De 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tran Dinh De, Nguyen Van Tu</AU>
<TI>Clinical and statistical study of trichomonad infestation in Vietnamese women with special reference to treatment by a new imidazole derivative</TI>
<SO>Am J Obstet Gynecol,</SO>
<YR>1963</YR>
<VL>87</VL>
<PG>92-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turanova-1977" NAME="Turanova 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turanova EN, Delektorsky VV, Nyunikova OI, Yashkova GN, Voskresenskaya GA</AU>
<TI>Fasigyn in the treatment of Trichomonas vaginitis</TI>
<SO>Akush Ginekol,</SO>
<YR>1977</YR>
<VL>4</VL>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Underhill-1974" NAME="Underhill 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Underhill RA, Peck JE</AU>
<TI>Causes of therapeutic failure after treatment of trichomonal vaginitis with metronidazole: Comparison of single-dose treatment with a standard regimen</TI>
<SO>Br J Clin Pract,</SO>
<YR>1974</YR>
<VL>28</VL>
<PG>134-136</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vartiainen-1966" NAME="Vartiainen 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vartiainen E, Widholm O</AU>
<TI>Treatment of trichomonas colpitis with thyadione</TI>
<TO>Uusi Isske trikomonaskolpiitin hoitoon</TO>
<SO>Duodecim</SO>
<YR>1966</YR>
<VL>82</VL>
<PG>755-757</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wacha-1976" NAME="Wacha 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wacha DSO, Zeigler O</AU>
<TI>The treatment of trichomonal vaginitis using single dose tinidazole (fasign-pfizer)</TI>
<SO>Med J Zambia,</SO>
<YR>1976</YR>
<VL>10</VL>
<PG>157-159</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallin-1974" NAME="Wallin 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallin J, Forsgren A</AU>
<TI>Tinidazole-a new preparation for T.vaginalis infections</TI>
<SO>Br J Vener Dis,</SO>
<YR>1974</YR>
<VL>50</VL>
<PG>148-150</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-1976" NAME="Ward 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward JP</AU>
<TI>Tinidazole (Fasigyn)-single dose therapy for Trichomonas vaginalis</TI>
<SO>Med J Aust,</SO>
<YR>1976</YR>
<VL>2</VL>
<PG>651-652</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watt-1960" NAME="Watt 1960" YEAR="1960">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watt L, Jennison RF</AU>
<TI>Clinical evaluation of metronidazole. A new systemic trichomonacid</TI>
<SO>Br Med J,</SO>
<YR>1960</YR>
<VL>2</VL>
<PG>902-905</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weidenbach-1974" NAME="Weidenbach 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weidenbach A, Leix H</AU>
<TI>Treatment of trichomonal vaginitis with a single dose of tinidazole</TI>
<SO>Curr Med Res Opin,</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>147-151</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weitgasser-1976" NAME="Weitgasser 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weitgasser H</AU>
<TI>Treatment of vaginal trichomoniasis with Tiberal Roche under particular consideration of single day therapy</TI>
<TO>Die behandlung der trichomoniasis vaginalis mit Tiberal Roche unter besonderer berucksichtigung der ein-tages-therapie</TO>
<SO>Wien Med Wochenschr</SO>
<YR>1976</YR>
<VL>126</VL>
<NO>11-12</NO>
<PG>162-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wladeck--1981" NAME="Wladeck  1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wladeck WG</AU>
<TI>A comparative study with Tinidazole and Nimorazole in the treatment of Trichomoniasis</TI>
<TO>Estudo comparativo entre o Tinidazol e o Nimorazol no Tratamento da Tricomoniase</TO>
<SO>Rev Bras Med</SO>
<YR>1981</YR>
<VL>38</VL>
<NO>7</NO>
<PG>439-442</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woodcock-1972" NAME="Woodcock 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woodcock KR</AU>
<TI>Treatment of trichomonal vaginitis with a single oral dose of metronidazole</TI>
<SO>Br J Vener Dis,</SO>
<YR>1972</YR>
<VL>48</VL>
<PG>65-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woodcock KR</AU>
<TI>Two-day treatment with metronidazole in vaginal trichomoniasis</TI>
<SO>Br J Vener Dis,</SO>
<YR>1972</YR>
<VL>48</VL>
<PG>383-386</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zaremba-1980" NAME="Zaremba 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zaremba A, Szarmach H, Trybula J</AU>
<TO>Badania porownawcze nad skutecznoscia leczenia rzesistkowicy jednorazowa dawka metronidazolu i fasyginu</TO>
<SO>Przeg Derm,</SO>
<YR>1980</YR>
<VL>67</VL>
<PG>229-231</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwierz-1969" NAME="Zwierz 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwierz C, Weryk-Wojciechowicz Z, Spiralska I</AU>
<TI>Clinical evaluation of metronidazol "polfa" in the treatment of trichomonas vaginalis</TI>
<SO>Wiad Parazytol,</SO>
<YR>1969</YR>
<VL>15</VL>
<PG>387-388</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-08 14:50:50 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-08 14:50:50 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-WHO-1994" NAME="WHO 1994" TYPE="BOOK">
<AU>Khanna J, Van Look PFA, Griffin PD</AU>
<SO>Challenges in reproductive health research. Biennial Report 1992-1993, WHO</SO>
<YR>1994</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-G_x00fc_lmezoglu-1998" NAME="Gülmezoglu 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gülmezoglu AM, Garner P</AU>
<TI>Trichomoniasis treatment in women: a systematic review</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>7</NO>
<PG>553-558</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-08 14:53:54 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-08 14:53:54 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-08-21 14:46:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aimakhu-1975">
<CHAR_METHODS MODIFIED="2008-08-21 14:05:44 +0100" MODIFIED_BY="[Empty name]">
<P>Cards labelled with either drug in sealed envelopes were picked up by nurses from a basket. </P>
<P>No placebos were used. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:06:14 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant (4) and non-pregnant (53) women with vaginal discharge in Ibadan, Nigeria were included in this study. However, only the data for non-pregnant women have been extracted. </P>
<P>Partners were treated if available. </P>
<P>Abstinence from sexual intercourse was advised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 200 mg 3 times daily by mouth for 7 days versus tinidazole 5 x 400 mg capsules taken as single dose in clinic.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:46:14 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:06:37 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear and confirmation by culture.</P>
<P>Follow up on days 3, 5, and 15. </P>
<P>Excluded 1 tinidazole and 3 metronidazole group women because wetmount diagnosis was not confirmed and 2 tinidazole and 1 metronidazole participants were lost to follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:46:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anjaneyulu-1977">
<CHAR_METHODS MODIFIED="2008-08-21 14:06:44 +0100" MODIFIED_BY="[Empty name]">
<P>Consecutive women allocated in a balanced randomisation schedule.</P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:06:50 +0100" MODIFIED_BY="[Empty name]">
<P>100 women with vaginal discharge in Poona, India were included. </P>
<P>Most partners were treated. </P>
<P>Those receiving antitrichomonal treatment in the past 4 weeks were ineligible.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 2 g (5 x 400 mg tabs) by mouth single dose versus tinidazole 2 g (4 x 500 mg tabs) by mouth single dose.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:46:24 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:07:01 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount.</P>
<P>Follow up on days 4, 8, and 12. </P>
<P>No exclusions or loss to follow up reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:53:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antonelli-2000">
<CHAR_METHODS MODIFIED="2008-08-21 14:07:05 +0100" MODIFIED_BY="[Empty name]">
<P>Sequentially numbered opaque envelopes containing medications. </P>
<P>No placebo use. </P>
<P>Outcome assessment was blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>46 women with motile trichopmonads on wet mount at gynecology clinic in North Carolina, USA.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:53:20 +0100" MODIFIED_BY="[Empty name]">
<P>Metronidazole 2 g (5 x 400 mg tabs) versus Nonoxynol-9 450 mg per vagina (3 x 150mg suppositories) suppositories per vagina.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological cure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:07:55 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wet mount. </P>
<P>Follow up 6-22 days after treatment. </P>
<P>Study terminated after results of first 46 patients because of poor clinical response with nonoxynol 9 suppositories. </P>
<P>26% (12 patients) loss to follow up. Data from 1 patient missing.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 14:41:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Austin-1982">
<CHAR_METHODS MODIFIED="2008-08-21 14:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>Series of random numbers prepared by the pharmacy. </P>
<P>Laboratory assessments were blinded. </P>
<P>Method of allocation concealment not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-08 14:41:25 +0100" MODIFIED_BY="[Empty name]">
<P>186 women with vaginal discharge attending sexually transmitted disease (STD) clinics and family planning clinics in Ontario, Canada.</P>
<P>Partners were treated if seen.</P>
<P>Abstinence from intercourse was advised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 1g versus 2 g, both given as single, oral dose.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:46:31 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:08:44 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount confirmed by culture.</P>
<P>Follow up weekly.</P>
<P>Loss to follow up 23/186 (12.4%).</P>
<P>No post- randomisation exclusions reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:08:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barnes-1957">
<CHAR_METHODS>
<P>Alternate allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women with trichomoniasis in England.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:08:32 +0100" MODIFIED_BY="[Empty name]">
<P>Aminitrozole, 100 mg three times daily by mouth for 10 days + aci-gel versus aci-gel only. </P>
<P>Aci-gel is a buffered vaginal jelly with a pH of 4.0 given twice daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological cure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:08:46 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount and culture.</P>
<P>Loss to follow up rate was 23% (14/60).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:46:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Begum-1980">
<CHAR_METHODS MODIFIED="2008-08-21 14:08:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation table. </P>
<P>No mention of blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:08:57 +0100" MODIFIED_BY="[Empty name]">
<P>69 women with trichomoniasis in Dacca and Sylhet, Bangladesh. </P>
<P>Most partners were treated.</P>
<P>Exclusion criteria: pregnancy, overt hepatic dysfunction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tinidazole 2 g by mouth single dose versus metronidazole 1 g by mouth twice a day for 2 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:46:05 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:09:04 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear and symptomology.</P>
<P>Follow up on post-treatment days 7, 14, and 21. </P>
<P>No mention of dropouts.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:45:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Block-1972">
<CHAR_METHODS MODIFIED="2008-08-21 14:09:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation done, description not given. </P>
<P>Double blind trial. </P>
<P>Preparations in neutral packaging.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:09:35 +0100" MODIFIED_BY="[Empty name]">
<P>100 women with trichomoniasis in Sweden. </P>
<P>Most partners were treated.</P>
<P>Exclusion criteria: concurrent infection with other pathogen found.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nifuratel 200 mg by mouth 3 times a day for 7 days plus 250 mg intravaginally daily for 10 days, versus metronidazole 200 mg by mouth 3 times a day for 7 days plus 500 mg intravaginally daily for 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:45:57 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure. <BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:09:51 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear and symptomology.</P>
<P>Follow up 14 days after treatment (patients found positive receive another treatment with the same regimen and are examined again after 14 days).</P>
<P>12% loss to follow up in nifuratel group, 3% in metronidazole group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:46:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaisilwattana-1980">
<CHAR_METHODS MODIFIED="2008-08-21 14:10:03 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind. </P>
<P>Sealed pre-numbered treatment packs were provided by the drug company. </P>
<P>The method of randomisation is not stated. </P>
<P>Code was broken after all trial procedures were finished implying blinded outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women at reproductive age with trichomoniasis attending a venereal disease clinic in Bangkok, Thailand.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:10:17 +0100" MODIFIED_BY="[Empty name]">
<P>Tinidazole 2 g versus ornidazole 1.5 g, both given as a single oral dose.</P>
<P>The male partners also received similarly coded corresponding medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:46:45 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:10:27 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount.</P>
<P>Loss to follow up rate was 11% (13/120).</P>
<P>More than half of patients had chronic or recurrent vaginitis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:46:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaudhuri-1980">
<CHAR_METHODS MODIFIED="2008-08-21 14:10:33 +0100" MODIFIED_BY="[Empty name]">
<P>Random allocation, double blind, coded treatment packs were used. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women with trichomoniasis in Rotterdam, Holland.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:10:36 +0100" MODIFIED_BY="[Empty name]">
<P>Carnidazole versus tinidazole, both 2 g, single oral dose.</P>
<P>Partners received same treatment and an instruction leaflet was given to all patients recommending condom use for 2 weeks and alcohol abstinence.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:46:53 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure after 1 and 2 weeks.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:10:56 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount.</P>
<P>Side effects reported for all (patients and partners).</P>
<P>Five patients did not attend the first follow up, all were seen at 2 weeks, no exclusions reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:47:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chung-1978">
<CHAR_METHODS MODIFIED="2008-08-21 14:11:01 +0100" MODIFIED_BY="[Empty name]">
<P>Patients allocated at random to 3 groups. </P>
<P>No further details provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:11:05 +0100" MODIFIED_BY="[Empty name]">
<P>109 patients with trichomoniasis seen at gynaecology outpatient clinics in two hospitals in Seoul and Hong Kong. </P>
<P>No partner treatment was employed although instructions for using a condom were given.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ornidazole 2 g single dose by mouth versus ornidazole 1 g by mouth plus 0.5 g vaginal tablet short course (24 h) versus ornidazole 1 g by mouth, short course (24 h).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:47:02 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical and parasitological cure. <BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount.</P>
<P>Follow up on day 3 and after the first menstruation after treatment.</P>
<P>Loss to follow up 37.7% after 3 days and 88.1% after menses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 15:01:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chunge-1992">
<CHAR_METHODS MODIFIED="2008-08-21 14:11:18 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised into 5 groups. </P>
<P>No details of the procedure given, placebos were not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:11:22 +0100" MODIFIED_BY="[Empty name]">
<P>Symptomatic women attending a family planning clinic and a female outpatient clinic in Kenya who agreed to take the medications in the clinic and to come back for follow up were enrolled.</P>
<P>Women with obvious clinical problems were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 15:01:14 +0100" MODIFIED_BY="[Empty name]">
<P>The women were divided into 5 groups:<BR/>Group 1: Nimorazole 2 g, oral single dose.<BR/>Group 2: Nimorazole 3 g, oral single dose.<BR/>Group 3: Nimorazole 4 g, oral in two doses 24 hours apart<BR/>Group 4: Tinidazole 2 g, oral single dose<BR/>Group 5: Ornidazole 1.5 g, oral single dose.</P>
<P>Advice on coital abstinence was withheld on purpose to find out those who had sex between the treatment and follow up visit.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:47:17 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure on day 3.<BR/>Clinical cure (defined as absence of any 3 of the initial symptoms that were present).<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:11:59 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount smear.</P>
<P>121 out of 153 women came for follow up on day 3 (21% loss to follow up). </P>
<P>A further 49 women were excluded from analysis because they had sexual intercourse during the study period. </P>
<P>Results reported for 47% of all women enrolled.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 14:53:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Csonka-1963">
<CHAR_METHODS MODIFIED="2008-08-21 14:12:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomly allocated tablets put in identical, numbered packets, with key to code kept by hospital pharmacy. </P>
<P>Double blind, placebo used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:12:04 +0100" MODIFIED_BY="[Empty name]">
<P>67 women with trichomoniasis in England.</P>
<P>Exclusion criteria: prostitutes and women thought to be promiscuous.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 200 mg three times a day for 10 days versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological cure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-08 14:53:54 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear.</P>
<P>Follow up to three months after treatment.</P>
<P>Loss to follow up - 10 women: 7 in placebo group, 3 in metronidazole group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:47:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diwald-1971">
<CHAR_METHODS MODIFIED="2008-08-21 14:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised following a list of random numbers. </P>
<P>Double blind. </P>
<P>Unclear whether lab assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:12:23 +0100" MODIFIED_BY="[Empty name]">
<P>50 women with trichomoniasis, in Steyr, Austria. </P>
<P>Partners received active treatment in both groups.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tinidazole 150 mg by mouth twice daily + tinidazole 150 mg vaginal tablet once daily, for 5 days versus tinidazole 150 mg by mouth twice daily + placebo vaginal tablets for 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:47:34 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:12:30 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount and culture (in 37/50 cases).</P>
<P>Follow up on day 7. </P>
<P>No loss to follow up reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 14:42:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DuBouchet-1997">
<CHAR_METHODS MODIFIED="2008-08-21 14:12:35 +0100" MODIFIED_BY="[Empty name]">
<P>Random allocation in order of study entry, based on table of random numbers. </P>
<P>Open label study. </P>
<P>No placebos were used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-08 14:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>168 women with trichomoniasis from Brooklyn, Charlottesville, and Baltimore, USA.</P>
<P>Patients were advised to use condoms to prevent reinfection and to refer partners for treatment.</P>
<P>Exclusion criteria: pregnancy or suspected pregnancy, hypersensitivity to imidazoles, central nervous system (CNS) disease, severe hepatic disease, blood dyscrasias, using oral anticoagulants, treatment for trichomoniasis in preceding 4 weeks, inability to complete treatment between menstrual periods.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 2 g by mouth single dose versus two 100 mg clotrimazole vaginal tablets once a day for 7 days versus AVC vaginal suppository (containing 1.05 g sulfanilamide, 14 mg aminacrine hydrochloride, and 140 mg allantoin) twice a day for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:47:44 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:13:13 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear, culture, and symptomatic score.</P>
<P>Follow up 2-3 and 4-6 weeks after treatment.</P>
<P>Patients dropped from the study were replaced with patients who received the same treatment.</P>
<P>Exclusion from analysis (35 women): failure to return for first follow up visit (19), invalid spacing of visits (5), discontinuance of drug because of adverse reactions (2), other protocol violations (9).</P>
<P>168 women enrolled, 133 (79%) evaluable for efficacy.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 14:43:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DuBouchet-1998">
<CHAR_METHODS MODIFIED="2008-08-21 14:13:18 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, open label pilot study. </P>
<P>Randomised based on table of random numbers.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-08 14:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>56 women with trichomoniasis in USA.</P>
<P>Patients were urged to abstain from intercourse during treatment and their partners were to use condoms until completion of the study.</P>
<P>Male partners were offered treatment.</P>
<P>Exclusion criteria: women under 18, pregnant women, women with candidiasis at diagnosis, lactation, intrauterine device (IUD) in situ, menstruation at time of diagnosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.75% metronidazole gel, 5 g intravaginally, two times a day for 7 days, versus 250 mg oral metronidazole three times a day for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological cure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:13:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear and culture</P>
<P>Follow up 5-7 days and 21-28 days after completion of treatment.</P>
<P>Exclusion from analysis: 8 patients dropped for not meeting entry criteria, 2 lost to follow up, 3 did not return for follow up within the allotted time period.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:47:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eriksson-1976">
<CHAR_METHODS MODIFIED="2008-08-21 14:13:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised in groups of 10. </P>
<P>The investigator did not know the group allocation but no further details reported. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Women attending a venereal disease clinic in Stockholm, Sweden.</P>
<P>Pregnant women were excluded. </P>
<P>Partner treatment was usually not possible.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 200 mg 3 times a day for 7 days versus nimorazole 300 mg twice daily for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:47:54 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis was by culture and wetmount in the first half and by culture only in the second half of the study.</P>
<P>Loss to follow up was 3/53 (5.6%) in the metronidazole group and 6/59 (10.2%) in the nimorazole group. </P>
<P>No post-randomisation exclusions reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:47:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1970">
<CHAR_METHODS MODIFIED="2008-08-21 14:14:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomly allocated consecutive women in a double blind way. </P>
<P>No placebos were used and because one treatment was oral and intravaginal and the other oral only, blinding was until the time of allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:14:22 +0100" MODIFIED_BY="[Empty name]">
<P>Women attending sexually transmitted disease clinic in London, England. </P>
<P>No mention of any partner treatment attempt.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 200 mg by mouth three times daily for 7 days versus nifuratel 200 mg by mouth three times daily for 7 days + one 250 mg vaginal pessary for 10 nights.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:47:59 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount in most cases and with culture and smear in some.</P>
<P>Loss to follow up 17% (19/115).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:48:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1971">
<CHAR_METHODS MODIFIED="2008-08-21 14:14:32 +0100" MODIFIED_BY="[Empty name]">
<P>Consecutive women randomly allocated to two treatment groups in a double blind way. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women attending a sexually transmitted disease clinic in London, England.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 200 mg by mouth three times daily for 7 days versus nitrimidazine 250 mg tablets by mouth, twice daily for 6 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:48:02 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:14:36 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount</P>
<P>Loss to follow up 26/142 (18%) and an additional 2 women were excluded because the diagnosis was based on cervical smears rather than wetmount technique.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 13:14:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Forster-1963">
<CHAR_METHODS MODIFIED="2008-08-21 14:14:53 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation from a table of random numbers, drugs numbered consecutively and placed in sealed envelopes. </P>
<P>Placebos were used for similar route schedules (i.e. oral and intravaginal) separately. </P>
<P>Combined oral and vaginal treatment and placebos had two envelopes, containing each treatment stapled together. </P>
<P>Outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-08 13:14:58 +0100" MODIFIED_BY="[Empty name]">
<P>Women attending a cancer detection clinic in Puerto Rico who had <I>Trichomonas </I>identified in their cervical and vaginal smears were eligible.</P>
<P>Mean age of women was 40, and 70% were between 30-49.</P>
<P>Eligible women were sent reminders and responders were included if they were wetmount positive.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:15:16 +0100" MODIFIED_BY="[Empty name]">
<P>There were 4 study groups. </P>
<P>All groups received metronidazole or placebo according to the following regimes:<BR/>Oral drug 250 mg three times daily for 10 days.<BR/>Vaginal drug 500 mg once daily for 10 days in addition to oral drug as above.<BR/>Oral placebo.<BR/>Oral and vaginal placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:20:35 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure after 2 weeks, 6 weeks, and 3 months.<BR/>Clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:15:28 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis and enrolment by wetmount smear.</P>
<P>Loss to follow up was 35/450 at 2 weeks, 21/450 at 6 weeks, and 42/450 at 3 months. Three in the drug and 4 in the placebo group had no follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:20:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fugere-1983">
<CHAR_METHODS MODIFIED="2008-08-21 14:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised from a table of random numbers. </P>
<P>Placebos were not used but the trial was conducted in a double blind fashion. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:15:40 +0100" MODIFIED_BY="[Empty name]">
<P>Symptomatic and asymptomatic women with trichomoniasis in Montreal, Canada.</P>
<P>Women with serious medical disorders, gonorrhoea or syphilis or who had been treated with metronidazole in the last 3 months were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:15:51 +0100" MODIFIED_BY="[Empty name]">
<P>Ornidazole was given as a single, oral dose of 0.5 g or 1.0 g or 1.5 g to three groups, respectively.</P>
<P>Women were given information about the nature of the disease, advised to either refrain from coitus or use a condom and were given a bottle of metronidazole tablets with instructions for the partner. </P>
<P>They were also advised to abstain from using douches, creams, and vaginal jellies.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:20:42 +0100" MODIFIED_BY="[Empty name]">
<P>Presence of infection at days 7-12 and around day 30.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Trial enrolment was according to wetmount smear results but samples were also collected for culture, urine microscopy, and Papanicolaou smears.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:48:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gabriel-1982">
<CHAR_METHODS MODIFIED="2008-08-21 14:16:03 +0100" MODIFIED_BY="[Empty name]">
<P>Random allocation to two groups. </P>
<P>Placebos were not used, however investigators were blind to the group allocation during the course of the study and for outcome assessments. </P>
<P>Follow up at 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:16:10 +0100" MODIFIED_BY="[Empty name]">
<P>Non-pregnant women with vaginal discharge who could attend a follow up visit after 2 weeks were eligible. </P>
<P>Trial conducted in a venereal disease clinic in London, England.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 2 g (400 g tabs x 5) versus tinidazole 2 g (500g x 4) as single dose by mouth.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:16:18 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount and culture.</P>
<P>Loss to follow up 6/46 and 7/49 in the metronidazole and tinidazole groups, respectively.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:48:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garud-1978">
<CHAR_METHODS MODIFIED="2008-08-21 14:16:25 +0100" MODIFIED_BY="[Empty name]">
<P>Women randomly allocated to two groups. </P>
<P>No further details given. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:16:30 +0100" MODIFIED_BY="[Empty name]">
<P>Women with vaginal discharge attending gynaecological outpatient departments in Bombay, India. </P>
<P>Partners treated in most cases. </P>
<P>Abstinence from sexual intercourse was advised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 2 g by mouth single dose versus tinidazole 2 g by mouth single dose.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:48:23 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:16:37 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount and culture.</P>
<P>Follow up on days 6, 14 and 21. </P>
<P>Loss to follow up 24/90 (27%) in whole group.</P>
<P>No exclusions reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:20:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gjonnaess-1969">
<CHAR_METHODS MODIFIED="2008-08-21 14:16:43 +0100" MODIFIED_BY="[Empty name]">
<P>Random division into groups.</P>
<P>No mention of blinding. </P>
<P>Method of allocation concealment not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:17:17 +0100" MODIFIED_BY="[Empty name]">
<P>95 women with trichomoniasis in Norway. </P>
<P>Most partners were treated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nifuratel 200 mg by mouth three times a day for 7 days plus a 250 mg vaginal tablet once a day for 10 days versus nifuratel 200 mg by mouth three times a day for 10 days plus a 250 mg vaginal tablet once a day for 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:20:52 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure during follow up and during first 4 months following therapy. <BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:17:29 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear.</P>
<P>Patients were re-treated (with 200 mg nifuratel three times a day for 10 days plus a 250 mg vaginal tablet twice daily for 10 days) if trichomonads were found during follow up.</P>
<P>Follow up 10 days after end of therapy.</P>
<P>5 patients lost to follow up, no breakdown into treatment groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 13:15:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gorlero-1992">
<CHAR_METHODS MODIFIED="2008-08-21 14:17:37 +0100" MODIFIED_BY="[Empty name]">
<P>Random allocation to three groups. </P>
<P>No details of randomisation procedure given. </P>
<P>Placebos were used for the no-treatment group. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:17:41 +0100" MODIFIED_BY="[Empty name]">
<P>Women with trichomoniasis, &gt;18 years, in Italy.</P>
<P>Exclusion criteria: patients with serious metabolic or systemic disorders and women who were treated for vaginal infections in the last 4 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:17:47 +0100" MODIFIED_BY="[Empty name]">
<P>Three groups: Fenticonazole, 600 mg single intravaginal ovule versus fenticonazole 1000 mg single intravaginal ovule versus placebo.</P>
<P>No mention of any partner treatment or notification.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:17:49 +0100" MODIFIED_BY="[Empty name]">
<P>Presence of infection on day 4.</P>
<P>Clinical cure was assessed by the women (w) and physicians (p) separately using a semi-quantitative scale (symptoms (w)/vaginal erythema and oedema (p): none, mild, moderate, severe).<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-08 13:15:05 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis was made by wetmount smear.</P>
<P>All women were asked to come for a second follow up visit on day 8; those who were <I>Trichomonas </I>positive on day 4 were given an additional 600 mg ovule regardless of their allocated group.</P>
<P>No mention of exclusions or loss to follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 14:39:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gorlero-1994">
<CHAR_METHODS MODIFIED="2008-08-21 14:18:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, ran parallel in two centres. </P>
<P>Placebos were used. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:18:41 +0100" MODIFIED_BY="[Empty name]">
<P>Women with trichomoniasis, aged 18-70 years, in Italy.</P>
<P>Women with serious systemic disorders and who received vaginitis treatment in the last 2 weeks were excluded. </P>
<P>Presence of another infectious agent was also a reason for exclusion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-08 14:39:15 +0100" MODIFIED_BY="[Empty name]">
<P>Three groups:<BR/>Group 1: Fenticonazole 600 mg intravaginal ovule on days 1 &amp; 2 followed by placebo on days 3 &amp; 4.<BR/>Group 2: Fenticonazole 1000 mg intravaginal ovule on days 1 &amp; 2 followed by placebo on days 3 &amp; 4.<BR/>Group 3: Placebo ovules for four days.</P>
<P>No mention of any partner treatment or notification measures.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:48:42 +0100" MODIFIED_BY="[Empty name]">
<P>Presence of infection on day 7.<BR/>Clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:18:47 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis was made by wetmount smear.</P>
<P>Of the 61 women enrolled, 2 withdrew and 1 stopped because of side effects resulting in 3 exclusions.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:48:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gummerus-1983">
<CHAR_METHODS MODIFIED="2008-08-21 14:18:50 +0100" MODIFIED_BY="[Empty name]">
<P>Random allocation of participants. </P>
<P>No further information is given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:18:51 +0100" MODIFIED_BY="[Empty name]">
<P>45 women with trichomoniasis. </P>
<P>All husbands were treated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tinidazole 2 g orally as a single dose versus tinidazole 2 g single dose + 500 mg vaginally every night for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:48:51 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure on day 14.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis made by culture and wet smear.</P>
<P>Follow up 2 weeks after treatment.</P>
<P>No mention of losses to follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 14:53:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hager-1980">
<CHAR_METHODS MODIFIED="2008-08-21 14:19:01 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not specified. </P>
<P>Placebos were used, the trial was conducted in a double blind fashion.</P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:19:03 +0100" MODIFIED_BY="[Empty name]">
<P>Symptomatic women attending a venereal disease clinic in Georgia, USA.</P>
<P>Women younger than 18 years, who had missed a period and who were treated for trichomoniasis in the last month were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:19:15 +0100" MODIFIED_BY="[Empty name]">
<P>Single dose versus 7 day regimen.</P>
<P>Single dose regimen: Metronidazole 2 g (8 x 250 mg tabs) followed by one placebo tablet three times daily for 7 days.<BR/>Seven day regimen: Eight placebo tablets followed by one metronidazole tablet three times daily for 7 days.</P>
<P>Each women was given 2 g metronidazole for partner treatment and were asked to abstain from coitus and alcohol during the treatment period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:19:23 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure 7-21 days after completing therapy.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-08 14:53:23 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis was based on wetmount and culture.</P>
<P>Participants were given standard treatments for any other sexually transmitted disease identified.</P>
<P>Neisseria gonorrhoea was identified in 14% and 18% of single dose and 7 day groups respectively.</P>
<P>Overall loss to follow up was 62% (292/468).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:49:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayward-1976">
<CHAR_METHODS>
<P>Alternate allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:21:16 +0100" MODIFIED_BY="[Empty name]">
<P>105 women attending a venereal disease clinic in Bournemouth, England. </P>
<P>Abstinence from sexual intercourse advised. </P>
<P>Partners treated when they were available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 400 mg immediately followed by 4, 12 hourly doses of 400 mg (2 g) versus nimorazole 750 mg stat followed by 3, 12 hourly doses of 750 mg (3 g), oral.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:49:05 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:21:27 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount confirmed by culture.</P>
<P>Follow up at days 7, 14, and 28.</P>
<P>Loss to follow up and exclusion because of not taking drugs appropriately (1 in each group) accounted for 15/53 (28%) and 18/52 (35%) with metronidazole and nimorazole respectively.</P>
<P>Excluded: those with less than 3 visits or attended follow ups for less than 28 days.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 14:41:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hillstroem-1977">
<CHAR_METHODS MODIFIED="2008-08-21 15:01:46 +0100" MODIFIED_BY="[Empty name]">
<P>Random numbers used to generate two groups.</P>
<P>Each treatment was separately packed, numbered and women were enrolled consecutively.</P>
<P>Placebos were used and outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-08 14:41:47 +0100" MODIFIED_BY="[Empty name]">
<P>Women with trichomoniasis attending two gynaecology outpatient and one venereal disease clinic in Sweden.</P>
<P>Women who had recently been treated for other sexually transmitted diseases (STDs) were also included.</P>
<P>Age range was 14-71 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:22:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ornidazole 1.5 g versus tinidazole 2 g, both given as a single oral dose.</P>
<P>Of the sexual partners, 27/45 and 25/43 received treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:49:17 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure on day 7 and 30.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:22:17 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolment was by wetmount smear but all women also had cultures.</P>
<P>No exclusions or loss to follow up reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:22:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iannino-1975">
<CHAR_METHODS MODIFIED="2008-08-21 14:22:20 +0100" MODIFIED_BY="[Empty name]">
<P>No description of how groups were randomised. </P>
<P>No mention of blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>29 women with trichomoniasis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 500 mg, intravaginally, 1 tablet per day versus Methyl-Patricin 25,000 units, intravaginally, 1 tablet per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological cure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:22:27 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear.</P>
<P>Follow up on post-treatment day 2 to 4.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:49:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korner-1978">
<CHAR_METHODS MODIFIED="2008-08-21 14:22:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation from a list of random numbers. </P>
<P>Double blind, placebos were used. </P>
<P>Outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:22:33 +0100" MODIFIED_BY="[Empty name]">
<P>Women with trichomoniasis, attending general practice clinics in Copenhagen, Denmark.</P>
<P>Women with liver, blood diseases, who could not attend follow up visits and who were known to be promiscuous were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:22:45 +0100" MODIFIED_BY="[Empty name]">
<P>Ornidazole, 1 g (500 mg tabs x 2) + 2 placebo tabs versus ornidazole 2 g (500 mg tabs x 4). </P>
<P>Women were given an extra pack of tablets to take to their partners with written instructions.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:49:32 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure on day 7.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:22:52 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis was made by wetmount and culture.</P>
<P>Culture negative patients (18 and 16 in the 1 g and 2 g groups, respectively) were excluded from further analysis except for side effects. </P>
<P>Loss to follow up was 6 and 1 in the 1 g and 2g groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:49:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lean-1972">
<CHAR_METHODS MODIFIED="2008-08-21 14:22:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind. Identical capsules were used for the two treatment groups and the placebo group. </P>
<P>Outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:23:01 +0100" MODIFIED_BY="[Empty name]">
<P>50 non-pregnant women with vaginal discharge in Singapore were included. </P>
<P>Women with neurological diseases were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole versus tinidazole versus placebo all administered 200 mg 3 times daily for 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:49:40 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:23:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by dark ground microscopy.</P>
<P>Follow up examinations on day 5, day 10, 3rd week and 4th week. </P>
<P>No losses to follow up. </P>
<P>45/50 remained in hospital for the first 5 days, the remainder were hospitalised for the whole course.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:49:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lyng-1981">
<CHAR_METHODS MODIFIED="2008-08-21 14:23:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation on a random basis.</P>
<P>Active or placebo treatments were given in coded boxes. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:23:23 +0100" MODIFIED_BY="[Empty name]">
<P>Partners of women who had trichomoniasis were randomised to treatment and control groups.</P>
<P>The trial was conducted in Copenhagen, Denmark.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>To the partners: Tinidazole 2 g oral, single dose versus placebo.</P>
<P>All women received standard treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:49:57 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure on days 7-14 and around day 30.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:23:48 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis was made by culture.</P>
<P>Loss to follow up rate was 8% (12/149) in the first and 11% (14/132) in the second follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:50:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahony-1975">
<CHAR_METHODS MODIFIED="2008-08-21 14:24:05 +0100" MODIFIED_BY="[Empty name]">
<P>Containers only identifiable by numbers were given to women and their partners (separately marked) where possible. </P>
<P>Neither the nurse administering the treatment nor the women could identify the treatment arms. </P>
<P>Outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients attending "special clinics" (venereal disease) in south east England.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:24:12 +0100" MODIFIED_BY="[Empty name]">
<P>Single dose, 2 g metronidazole versus nimorazole. </P>
<P>Partners offered concomitantly coded treatment if they were available.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:50:04 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:24:14 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount.</P>
<P>12/93 (13%) lost to follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:50:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manth-1989">
<CHAR_METHODS MODIFIED="2008-08-21 14:24:28 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned to two groups, method of randomisation not mentioned, double blind trial. </P>
<P>Placebos not used. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:24:34 +0100" MODIFIED_BY="[Empty name]">
<P>Symptomatic women with trichomoniasis.</P>
<P>Patients with serious medical disorders, poor general health, immunodeficient, and those considered unsuitable or unreliable were excluded.</P>
<P>Trial conducted in Europe.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>Fenticonazole intravaginal ovule 600 mg versus 1000 mg.</P>
<P>No mention of partner treatment, notification, and other precautions.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:24:46 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure on day 1or 2.<BR/>Clinical cure was assessed semi- quantitatively (symptoms cleared, improved, unchanged, worsened).<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:24:53 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis was made by wetmount smear.</P>
<P>No loss to follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:25:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mati-1974">
<CHAR_METHODS MODIFIED="2008-08-21 14:25:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double blind. </P>
<P>Paired (for partner treatment) numbered envelopes containing either active or placebo were given to the women. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:25:23 +0100" MODIFIED_BY="[Empty name]">
<P>31 non-pregnant women attending gynaecology outpatient clinics in Nairobi, Kenya. </P>
<P>No advice on sexual intercourse was given during the course of the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tinidazole 2 g single dose (4 tablets) by mouth versus 4 yeast tablets as single dose.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:25:32 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical and parasitological cure. <BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:25:40 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount.</P>
<P>Follow up on day 7. </P>
<P>No report of losses to follow up or post-randomisation exclusions.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:26:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McClean-1972">
<CHAR_METHODS MODIFIED="2008-08-21 14:26:20 +0100" MODIFIED_BY="[Empty name]">
<P>Random, both the patient and prescriber blind to allocation. </P>
<P>No further details given. </P>
<P>No mention of blind outcome assessment. </P>
<P>Follow up intended until 3 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women with trichomoniasis in London, England.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 400 mg twice daily for 5 days versus nitrimidazine 250 mg twice daily for 6 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:26:32 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure. <BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:26:36 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount smear.</P>
<P>Loss to follow up was 16% (5 v 11 in metronidazole and nitrimidazine groups, respectively) and one patient who did not complete the treatment was excluded.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:26:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Notowicz-1977">
<CHAR_METHODS>
<P>Alternate allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:26:47 +0100" MODIFIED_BY="[Empty name]">
<P>Women with trichomoniasis, attending a venereal disease clinic in Rotterdam, Holland. </P>
<P>Thirty women (20%) were commercial sex workers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Carnidazole 2 g versus 1.5 g, oral single dose.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological cure after 1-3 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:26:57 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount and culture.</P>
<P>Concomitant treatment was given to 49 women with gonorrhoea and one woman with syphilis.</P>
<P>Loss to follow up was 6.6% and 13.1% in the 2 g and 1.5 g groups,<BR/>respectively.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:50:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nygaard-1977">
<CHAR_METHODS MODIFIED="2008-08-21 14:27:02 +0100" MODIFIED_BY="[Empty name]">
<P>Random allocation to two groups. </P>
<P>Blinding could not be maintained after allocation, however no details are given about how allocation concealment was done.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:27:12 +0100" MODIFIED_BY="[Empty name]">
<P>119 Women attending general practices in Copenhagen, Denmark, who required a gynaecological examination were recruited. </P>
<P>Pregnancy, presumed promiscuity, and systemic disorders were reasons for exclusion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:27:24 +0100" MODIFIED_BY="[Empty name]">
<P>Metronidazole 200 mg 3 times daily for 7 days versus ornidazole 500 mg 4 tablets by mouth as single dose. </P>
<P>Partner treatments were given to the women to take to their partners.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:50:58 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:27:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount and culture. Only those verified by culture results were analysed.</P>
<P>Excluded wetmount positive culture negatives (10/53 in the metronidazole and 12/66 in the ornidazole groups). </P>
<P>Only 1 woman in the ornidazole group was lost to follow up at 1 week, 8 in the ornidazole, and 3 in the metronidazole group were lost at 5 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:51:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x002d_Prasertsawat-1992">
<CHAR_METHODS MODIFIED="2008-08-21 14:27:38 +0100" MODIFIED_BY="[Empty name]">
<P>Double blind randomised controlled trial. </P>
<P>Patients were asked to choose a box that contained one of the drugs.</P>
<P>Outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Symptomatic women with trichomoniasis attending a gynaecology outpatient clinic in Bangkok, Thailand.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:51:06 +0100" MODIFIED_BY="[Empty name]">
<P>Metronidazole 1.6 g split into two doses versus tinidazole 2 g as a single oral dose. </P>
<P>Same treatments were given to the partners. They were also asked to refrain from coitus or to use condoms.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:27:53 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure between 6-16 days after treatment. <BR/>Clinical improvement (self-assessed by the women).<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:27:56 +0100" MODIFIED_BY="[Empty name]">
<P>Both wetmount smear and culture were used for diagnosis.</P>
<P>Dropout rate was 16.3% (13/67) in the metronidazole and 18.8% (15/65) in the tinidazole groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:28:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rao-1978">
<CHAR_METHODS MODIFIED="2008-08-21 14:28:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation according to a randomisation schedule. </P>
<P>No further details reported. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:28:15 +0100" MODIFIED_BY="[Empty name]">
<P>60 non-pregnant women with vaginal discharge, without gonorrhoea or candidiasis, and no history of antitrichomonal treatment in the past 2 weeks. </P>
<P>Sexual intercourse abstinence was advised. </P>
<P>Partners were treated when possible. </P>
<P>Trial conducted in Mangalore, India.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 2 g (400 mg x 5 tabs) versus tinidazole 2 g (500 mg x 4 tabs) both given as single oral dose.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount. </P>
<P>Follow up on days 4, 8, and 12. </P>
<P>One patient in tinidazole group was lost to follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:51:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rees-1974">
<CHAR_METHODS MODIFIED="2008-08-21 14:28:31 +0100" MODIFIED_BY="[Empty name]">
<P>Random allocation to one of two treatment groups. </P>
<P>Outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:28:33 +0100" MODIFIED_BY="[Empty name]">
<P>29 prison women in Nairobi, Kenya. </P>
<P>Pregnancy, coexistent disease, and unwillingness to participate were reasons for exclusion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tinidazole 2 g (5 x 400 mg tablets) single dose by mouth versus placebo (ascorbic acid 5 x 25 mg tablets) single dose by mouth.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:51:20 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:28:41 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount.</P>
<P>Follow up at days 4, 5, 7, and at 2 months. </P>
<P>Excluded 9/29 because transfer to another prison, discharge or reluctance to carry on with examinations. Only 6 women in each group were examined at 2 months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:29:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roncuzzi-1972">
<CHAR_METHODS MODIFIED="2008-08-21 14:28:59 +0100" MODIFIED_BY="[Empty name]">
<P>Simple randomisation using numbered sealed envelopes containing the instructions for therapy. </P>
<P>No mention of blinding. </P>
<P>Follow up less than one month and greater than one month after treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:29:03 +0100" MODIFIED_BY="[Empty name]">
<P>68 women with trichomoniasis in Italy. </P>
<P>Partners were not treated.</P>
<P>Exclusion criteria: women who were pregnant or suspected to be pregnant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 600 mg every 24 hours for 7 days versus nimorazole 750 mg every 12 hours for 4 days versus nimorazole 1000 mg every 12 hours for 3 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological cure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:29:08 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear.</P>
<P>Loss to follow up at less than 1 month after treatment: none; greater than one month after treatment: 11 in metronidazole group, 9 in nimorazole 750 mg group, 7 in nimorazole 1000 mg group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:51:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roy-1975">
<CHAR_METHODS>
<P>Alternate allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>218 consecutive women attending a venereal disease clinic in Bournemouth, England. </P>
<P>Abstinence from sexual intercourse was advised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:29:20 +0100" MODIFIED_BY="[Empty name]">
<P>Metronidazole 200 mg 3 times daily by mouth for 7 days versus nimorazole 250 mg 12 hourly for 6 days. </P>
<P>Contact slips were issued for male partners of all women requesting them to attend the clinic within 24 hours and they were given the same treatment if they attended.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:29:27 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount and culture.</P>
<P>Follow up on days 7, 14, 28, and 42.</P>
<P>Loss to follow up 21/218 (9.6%) in total with 9/109 in metronidazole and 12/109 in nimorazole groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:30:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saeed-1976">
<CHAR_METHODS>
<P>Consecutive women attending the clinic were enrolled by alternate allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women attending veneral disease clinic in Bournemouth, England.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:29:36 +0100" MODIFIED_BY="[Empty name]">
<P>Metronidazole 400 mg tablets 12 hourly for 48 hours versus nimorazole 250 mg tablets 12 hourly for 48 hours. </P>
<P>Women were advised against sexual intercourse and asked to bring their partners to the clinic the next day. Additional female contacts of male partners were sent contact slips. Reminders and social worker contact were attempted for women who did not attend follow up visits.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:29:55 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure around days 7-9, 14-21, and 21-35. <BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis was made by wetmount and/or culture. </P>
<P>Diagnostic tests for candida, syphilis, and gonorrhoea were also carried out.</P>
<P>Of the 333 cases followed up, 208 had other sexually transmitted diseases as well. </P>
<P>Loss to follow up rate was 11.4% (43/376).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:51:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sandvei-1979">
<CHAR_METHODS MODIFIED="2008-08-21 14:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised by a table of random numbers. </P>
<P>Placebos were not used but it was a double blind trial. </P>
<P>No mention of blind outcome assessment. </P>
<P>Method of allocation concealment not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:30:46 +0100" MODIFIED_BY="[Empty name]">
<P>Symptomatic women with trichomoniasis, between 13-57 years, in Norway.</P>
<P>Those living too far to attend follow up were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:30:52 +0100" MODIFIED_BY="[Empty name]">
<P>Metronidazole 2 g versus tinidazole 2 g versus ornidazole 2 g. All were given oral as a single dose.</P>
<P>Same medication with written instructions for the partner.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:51:51 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure on day 3 and around 4 weeks.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:31:04 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount and culture. </P>
<P>Cultures for candida and gonorrhoea were also taken.</P>
<P>Side effects were reported in all persons who took the drug (including the partners).</P>
<P>Loss to follow up was 2/25, 1/25, and 0/25 in the metronidazole, tinidazole, and ornidazole groups, respectively on day 3 and 7/25, 6/25, and 6/25 after 4 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:31:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schnell-1974">
<CHAR_METHODS MODIFIED="2008-08-21 14:31:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind. </P>
<P>No other details given. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women with trichomoniasis in Germany.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:31:13 +0100" MODIFIED_BY="[Empty name]">
<P>Intravaginal, metronidazole (250 mg) versus clotrimazole (100 mg), both for 6 days to be inserted in the evenings. </P>
<P>Partners were treated with metronidazole.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:31:14 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure after 2 and 4 weeks. <BR/>Clinical cure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:31:22 +0100" MODIFIED_BY="[Empty name]">
<P>Both wetmount and culture were used for initial diagnosis and follow ups.</P>
<P>Loss to follow up was 8% v 4% (metronidazole and clotrimazole) at 2 weeks, and 23% and 36% after 4 weeks.</P>
<P>Treatment failures after 2 weeks were given oral and vaginal metronidazole. It is not clear whether they were included in 4 weeks follow up results.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:52:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serup-1978">
<CHAR_METHODS MODIFIED="2008-08-21 14:31:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, random number tables used, no placebos.</P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:31:34 +0100" MODIFIED_BY="[Empty name]">
<P>Women with trichomoniasis, most (33/47) were admitted to the hospital for various gynaecological problems. </P>
<P>The trial took place in Copenhagen, Denmark. </P>
<P>Patients with known liver disorders, neurological and haematological disorders were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:31:37 +0100" MODIFIED_BY="[Empty name]">
<P>Single, oral 2 g dose of tinidazole versus ornidazole.</P>
<P>Partners were given corresponding treatments.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:52:02 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:31:47 +0100" MODIFIED_BY="[Empty name]">
<P>Both wetmount and culture methods were used.</P>
<P>Of the 47 patients enrolled in the trial, 7 were excluded because of negative culture results and 4 were lost to follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:32:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sesti-1990">
<CHAR_METHODS MODIFIED="2008-08-21 14:31:55 +0100" MODIFIED_BY="[Empty name]">
<P>Patients randomly divided into two treatment groups, no further details given. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women with trichomoniasis in Rome, Italy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:32:10 +0100" MODIFIED_BY="[Empty name]">
<P>Tinidazole 2 g oral single dose + tinidazole 150 mg and nystatine 100.000 IU ovule for 7 days versus ornidazole 2 g oral single dose + ornidazole 500 mg ovule single dose.</P>
<P>Corresponding oral treatments given to the partners.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:32:05 +0100" MODIFIED_BY="[Empty name]">
<P>No parasitological cure (2 weeks). <BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:32:08 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount.</P>
<P>No mention of exclusions or loss to follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 14:41:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spence-1997">
<CHAR_METHODS MODIFIED="2008-08-21 14:32:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised by table of random numbers, identical packs numbered consecutively. </P>
<P>Double blind, placebos were used. </P>
<P>Outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-08 14:41:54 +0100" MODIFIED_BY="[Empty name]">
<P>167 women attending an inner city sexually transmitted disease (STD) clinic in Philadelphia, USA.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:32:23 +0100" MODIFIED_BY="[Empty name]">
<P>Metronidazole 0.5 g v 1 g v 1.5 g v 2 g, all administered as single, oral dose. </P>
<P>All women received 4 tablets (active and placebo according to the dose).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:52:32 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:32:33 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by wetmount.</P>
<P>Follow up 7-10 days after treatment.</P>
<P>Loss to follow up was 18/41 (44%), 15/44 (34%), 15/42 (36%), and 18/37 (49%) in the 0.5, 1, 1.5, and 2 g groups,respectively (overall 66/164, 40%). Women lost to follow up were similar in baseline demographic characteristics to those attending follow up examinations.</P>
<P>Excluded 3 women (2 with 2 g and 1 with 0.5 g dose) who vomited after ingestion of the medication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:56:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thin-1979">
<CHAR_METHODS MODIFIED="2008-08-21 14:32:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebos used. </P>
<P>Individual, numbered treatment packs were randomly arranged to be given to patients. </P>
<P>Outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women with trichomoniasis who could attend follow up visits after 2 weeks in London, England.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:56:34 +0100" MODIFIED_BY="[Empty name]">
<P>Single dose versus five day regimen:<BR/>Single dose regimen: Metronidazole 2 g (5 x 400 mg tabs) followed by placebo for 5 days (1 tablet twice daily).<BR/>Five day regimen: 5 placebo tablets as a single dose followed by metronidazole 400 mg tabs twice daily for 5 days.</P>
<P>No partner treatment or notification measures are mentioned. It is not clear whether the women were advised against coitus during the treatment period or not.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:52:44 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure on day 7 and day 14.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>Both wetmount smear and culture were used for diagnosis.</P>
<P>Loss to follow up on day 14 was 46% and 31% in the single dose and 5 day groups, respectively.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-08 14:53:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tidwell-1994">
<CHAR_METHODS MODIFIED="2008-08-21 14:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>Random number table used to prepare consecutively numbered, sealed envelopes containing the medication. </P>
<P>Placebos were used. </P>
<P>Outcome assessments were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Women, 15-65 years old, seen in the emergency department (Jackson, USA) with a diagnosis of trichomoniasis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 14:42:40 +0100" MODIFIED_BY="[Empty name]">
<P>Metronidazole 2 g vaginal cream + oral placebo versus metronidazole 2 g oral + vaginal placebo. </P>
<P>Partners were offered treatment with a single 2 g dose of metronidazole. </P>
<P>Women were asked to abstain from coitus and alcohol until follow up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:52:51 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological cure on day 3-5.<BR/>Clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-08 14:53:37 +0100" MODIFIED_BY="[Empty name]">
<P>Both wetmount smear and culture were done but patients were enrolled according to culture results.</P>
<P>All patients had cultures for <I>N. gonorrhea</I>, 20% and 14% were positive in the oral and vaginal groups, respectively.</P>
<P>Of the 305 patients tested for possible enrolment, 302 could be evaluated. 94 were positive and 61 of these could be enrolled (they needed to be called back).</P>
<P>Loss to follow up was 7/61 (11.4%) and one was excluded because of bacterial overgrowth in culture.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:57:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tinkler-1974">
<CHAR_METHODS MODIFIED="2008-08-21 14:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind but no placebos used. </P>
<P>No mention of blind outcome assessment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:44:12 +0100" MODIFIED_BY="[Empty name]">
<P>100 women attending Bristol Royal Infirmary, England. </P>
<P>Exclusion criteria: women with more than one partner, who were thought insufficiently intelligent to understand the study, not reliable to take medications as prescribed, and those with partners unwilling to take concurrent medication. </P>
<P>Abstinence from sexual intercourse was advised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Metronidazole 200 mg 3 times daily for 7 days versus nimorazole 250 mg twice daily for 6 days, both by mouth.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 14:57:37 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological and clinical cure.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by dark field microscopy and culture.</P>
<P>Follow up on days 8 and 14.</P>
<P>Loss to follow up 4/100 and 7 others excluded for not taking drugs as prescribed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 14:44:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wigfield-1975">
<CHAR_METHODS MODIFIED="2008-08-21 14:44:33 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation. </P>
<P>No mention of blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 14:44:39 +0100" MODIFIED_BY="[Empty name]">
<P>199 women with trichomoniasis in England. </P>
<P>Some partners were treated. </P>
<P>Patients were advised to avoid sexual intercourse.<BR/>
</P>
<P>Exclusion criteria: pregnancy or suspected pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nimorazole 3 g (two 500 mg tablets 12 hourly for three doses) versus metronidazole 4.2 g (one 200 mg tablet three times daily for 7 days).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological cure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 14:44:45 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis by smear.</P>
<P>Follow up on completion of treatment and 3 more times at weekly intervals.</P>
<P>Loss to follow up: 23 in metronidazole group and 20 in nimorazole group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-10-08 13:15:45 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Akinla-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ali-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Andersen-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Apte-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arnold-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arya-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women with both trichomoniasis and candidiasis were included in this trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aubert-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women attending family planning clinics were offered either a single, 2 g or 250 mg three times daily for 7 days metronidazole treatment. There was no randomised comparison between the two groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aure-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double blind trial comparing metronidazole with tinidazol. The trial is excluded because the data were reported per couple rather than individuals.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Azevedo-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bedoya-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bertini-de-Oliveira">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 13:15:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bloch-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 13:15:13 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was excluded because the data were not in a suitable form for analysis. Correspondence with the author revealed that the data were destroyed during a move. Women with trichomoniasis were randomly allocated to metronidazole 2 g oral tablets, benzoyl metronidazole suspension (2 g) or tinidazole (2 g) oral treatment. On day 7, 1.7%, 4.5%, and 1.7 % were <I>Trichomonas </I>positive respectively, on day 14, none of the metronidazole and 5.1 % of tinidazole groups were positive. The side effects were highest with metronidazole tablets (22.4 %) and lowest with metronidazole suspension (7.5 %).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Botero-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>This clinical trial was excluded as there was no randomised or quasi-randomised comparison between women treated with metronidazole or panidazole for trichomoniasis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 13:15:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bremond-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 13:15:20 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of this randomised trial was symptomatic treatment of vaginitis. Women with trichomoniasis and candidiasis were randomised to benzydamine versus placebo in addition to standard treatment with tinidazole 2 g for <I>Trichomonas </I>and econazole for candida. Self assessment by the women showed that benzydamine + specific treatment was more effective than specific treatment alone in providing symptomatic relief.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burkett-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Catterall-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>There were no randomised comparisons between groups treated with trichomycin and acetarsol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Csonka-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fifty-four women attending sexually transmitted disease clinics were treated with a single 2 g dose of metronidazole. Subsequently, a group of 58 women treated with the 7 day regime were taken as a control group. There was no randomised comparison between the two groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davidson-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>There was no randomised comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dellenbach-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study was conducted in two parts. In the first part, all women received tinidazole; in the second, women were randomly allocated to tinidazole oral or oral + vaginal suppository. The results, however, are reported together and it is not possible to separate the randomised part from the first part.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dellenbach-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Djahangiri-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dubois-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dunlop-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>The data in this study were not available in a suitable form to be extracted. Eight patients were treated with 2-acetylamino-5-nitrothiazole and 5 control patients were given calcium lactate tablets. Outcomes were reported as number of vaginal smears positive or negative for trichomonads, and not as number of patients cured.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dykers-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Erb-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feo-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>There was no comparison group in this study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Figueroa-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>The data from this study was not in a suitable form for analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ganju-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>There was no indication that any randomised or quasi-randomised comparison were made between study groups. Women with trichomoniasis (pregnant and non-pregnant) were divided into four groups (metronidazole, hamycin, stovarsol vaginal compound, and placebo)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giordano-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goldman-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 13:15:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goncalves-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 13:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>This RCT was excluded because outcome of interest was symptomatic relief from <I>Trichomonas </I>and candida infections. Vinegar was compared to salicylic acid/boric acid/ammonium alum combination in hip bath in addition to specific therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goodwin-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised crossover study to investigate the disulfiram-like effects of flunidazole, a nitroimidazole structurally similar to metronidazole but lacking the metallic taste effect. The study was excluded because the objective was not the treatment of trichomoniasis. However, investigators could not substantiate the reported disulfiram-like effects of nitroimidazoles in this small study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gyorik-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heiss-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Helmy-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation was not randomised in this study. Initially, consecutive women were given tinidazole and the third given metronidazole and later this was changed to alternation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henderson-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karagiosov-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 13:15:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kawamura-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 13:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>No randomised or quasi-randomised comparisons were made. In the first recruitment period patients (male <I>Trichomonas </I>positive) were treated with tinidazole, in the second, with metronidazole.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kholodovskaya-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study examined the pharmacokinetics of tinidazole versus metronidazole.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kim-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study involved treatment of nongonococcal urethritis in males, and included diseases other than trichomoniasis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kulseng_x002d_Hanssen-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 13:15:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lanceley-1953">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 13:15:45 +0100" MODIFIED_BY="[Empty name]">
<P>There were no randomised comparisons. Cultured <I>Trichomonas vaginalis </I>were inoculated in the urethra of 5 and culture media only to 5 other men.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liechti-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>It was not possible to clarify whether the study was a true randomised controlled trial or not. The study involves several groups of patients with trichomoniasis treated with different doses of tinidazole, metronidazole, and vaginal and oral route combinations. For groups concerning tinidazole oral versus oral + vaginal with two different doses (4 groups compared altogether) it is stated that the study was double blind. However there is no mention of randomisation and one group has significantly fewer number of participants compared to other three.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lotvin-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lyon-1963">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women with trichomoniasis were given metronidazole in three different regimes (oral or intravaginal alone and in combination) but there were no randomised comparisons between the three groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Magnier-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marianowski-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Massa-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCann-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pregnant women were included in this trial and it was not possible to look at them separately. The trial was a randomised comparison of metronidazole and nitrimidazine, both given by mouth as "long'"treatments.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Milek-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made. Tinidazole, single, oral dose was tested in doses of 1.5 g, 1.6 g, 1.8 g and 2.0 g.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mischer-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moore-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>There was no comparison group in this study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mukherjee-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>There was no randomised comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Naguib-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Obel-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ongom-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ozbilgin-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peeters-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>The main reasons for excluding this trial was inclusion of pregnant women (n=1), and the aim was to investigate the effect of miconazole on the incidence of yeast infections occurring after trichomoniasis treatment. It was a randomised controlled trial in which the experiment group received metronidazole 250 mg tablets twice daily for 10 days + miconazole vaginal cream for once in the evening for 15 days while the control group received only metronidazole in the same way. In the metronidazole + miconazole group the number of + yeast cultures were 6 and 0, before and after the treatment, and in the metronidazole only group, all 3 of the yeast positive women remained positive. The parasitological cure rates were 100% in the combined treatment group and 90% (18/20) in the metronidazole only group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pereyra-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial was excluded because three pregnant women were included in the study. The three pregnant women were treated with flunidazole, but their treatment outcomes were not noted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Phillips-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Plotho-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Porapakkham-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Although the allocation was reported as "random", this study was excluded because there was a large unexplained imbalance in the numbers of women allocated to metronidazole oral + vaginal and metronidazole oral only. Also pregnant women were included in the trial and data for them were not reported separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Psaroudakis-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Quartararo-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rainer-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial was excluded because it was not clear whether the comparisons had been made between randomised groups. The authors extended a series of metronidazole treated pregnant and non-pregnant women to include a group of women randomly allocated to a treatment and placebo. Consequently, there is an imbalance in the sample sizes of two groups and it is not possible to identify randomised groups in the tables presented.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ross-1973a">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was excluded because it was not possible to separate pregnant from non-pregnant women. Alternate women with trichomoniasis were given 2 g metronidazole or 2 g nimorazole as single dose. Eleven of 75 in the metronidazole group and 6 of 73 were regarded as treatment failures.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ross-1973b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rzempoluch-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial examined the treatment of mixed infections.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-R_x00f6_semann-197">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salinas-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sandront_x002d_Degee-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schellen-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmoer-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shutsky-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sternadel-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sternadel-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Swarz-1974a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Swarz-1974b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thavabalan-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tran-Dinh-De-1963">
<CHAR_REASON_FOR_EXCLUSION>
<P>There was no randomised comparison between groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turanova-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Underhill-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vartiainen-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wacha-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wallin-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ward-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Watt-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>There was no comparison group in this study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weidenbach-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weitgasser-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial is reported as double blind, but no mention of random allocation is made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wladeck--1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Woodcock-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Metronidazole was given 400 mg/day for 2 days when the researcher was on duty, 200 mg/day for 7 days when the researcher was off duty. There was thus no randomised comparison between the two groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zaremba-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zwierz-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomised or quasi-randomised comparisons were made.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-21 14:45:07 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-21 14:45:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-10-08 14:46:28 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Treatment versus no treatment</NAME>
<DICH_OUTCOME CHI2="125.50093645627875" CI_END="0.23435945908370578" CI_START="0.1493009861024147" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1870564041769909" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="182" I2="96.01596598305714" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.6301175130421998" LOG_CI_START="-0.8259373238394554" LOG_EFFECT_SIZE="-0.7280274184408276" METHOD="MH" NO="1" P_CHI2="-4.440892098500626E-16" P_Q="0.0" P_Z="4.1303574812962996E-48" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="451" TOTAL_2="221" WEIGHT="100.0" Z="14.573678874391929">
<NAME>No parasitological cure (day 4 to 2 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favourd Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.093778983031486" CI_START="0.03060278397580952" EFFECT_SIZE="0.05357142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="108" LOG_CI_END="-1.0278944811963233" LOG_CI_START="-1.5142390633767526" LOG_EFFECT_SIZE="-1.271066772286538" ORDER="116" O_E="0.0" SE="0.28568121501729266" STUDY_ID="STD-Forster-1963" TOTAL_1="280" TOTAL_2="135" VAR="0.08161375661375661" WEIGHT="60.092888510987876"/>
<DICH_DATA CI_END="0.8434745958269045" CI_START="0.488668179747893" EFFECT_SIZE="0.6420118343195266" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="26" LOG_CI_END="-0.07392799316772851" LOG_CI_START="-0.3109859396905221" LOG_EFFECT_SIZE="-0.19245696642912524" ORDER="117" O_E="0.0" SE="0.13924901124324945" STUDY_ID="STD-Gorlero-1992" TOTAL_1="65" TOTAL_2="31" VAR="0.019390287132222614" WEIGHT="14.517935459787447"/>
<DICH_DATA CI_END="0.7494678952253533" CI_START="0.33356999224740497" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="-0.12524696618475098" LOG_CI_START="-0.47681302514321133" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="118" O_E="0.0" SE="0.20651164331225833" STUDY_ID="STD-Gorlero-1994" TOTAL_1="40" TOTAL_2="20" VAR="0.04264705882352941" WEIGHT="9.34645785813535"/>
<DICH_DATA CI_END="0.18534338730438882" CI_START="0.00792582503640981" EFFECT_SIZE="0.03832752613240418" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.7320229041499018" LOG_CI_START="-2.1009555190016327" LOG_EFFECT_SIZE="-1.4164892115757672" ORDER="119" O_E="0.0" SE="0.8041177942896376" STUDY_ID="STD-Lean-1972" TOTAL_1="40" TOTAL_2="10" VAR="0.6466054270932319" WEIGHT="6.827460590374323"/>
<DICH_DATA CI_END="0.6387583493313903" CI_START="0.00262149999121764" EFFECT_SIZE="0.04092071611253197" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.19466341007468405" LOG_CI_START="-2.5814501394052" LOG_EFFECT_SIZE="-1.388056774739942" ORDER="120" O_E="0.0" SE="1.4020103395936014" STUDY_ID="STD-Mati-1974" TOTAL_1="16" TOTAL_2="15" VAR="1.9656329923273659" WEIGHT="4.885648425843478"/>
<DICH_DATA CI_END="0.7133237566884246" CI_START="0.0794721076819395" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.1467133119012532" LOG_CI_START="-1.099785268894548" LOG_EFFECT_SIZE="-0.6232492903979004" ORDER="121" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Rees-1974" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="4.329609154871522"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.12653973049221057" CI_START="0.05087272986360848" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0802335436481778" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="111" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.8977730948481868" LOG_CI_START="-1.293514957220388" LOG_EFFECT_SIZE="-1.0956440260342872" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.9373790713161523E-27" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="142" WEIGHT="100.0" Z="10.85264428701751">
<NAME>No parasitological cure (6 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12653973049221057" CI_START="0.05087272986360848" EFFECT_SIZE="0.0802335436481778" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="111" LOG_CI_END="-0.8977730948481868" LOG_CI_START="-1.293514957220388" LOG_EFFECT_SIZE="-1.0956440260342872" ORDER="122" O_E="0.0" SE="0.23246072891124325" STUDY_ID="STD-Forster-1963" TOTAL_1="287" TOTAL_2="142" VAR="0.05403799048594652" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.581888182478659" CI_END="0.22114377071697006" CI_START="0.12584471303584938" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1668225834997851" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="144" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.6553252895358355" LOG_CI_START="-0.9001650252295446" LOG_EFFECT_SIZE="-0.77774515738269" METHOD="MH" NO="3" P_CHI2="0.4455732999248214" P_Q="0.0" P_Z="1.36659364689135E-35" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="302" TOTAL_2="163" WEIGHT="100.00000000000001" Z="12.451839104478127">
<NAME>No parasitological cure (3 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.33678629065563853" CI_START="0.039322444631842" EFFECT_SIZE="0.11507936507936507" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="27" LOG_CI_END="-0.4726455953605879" LOG_CI_START="-1.405359490404588" LOG_EFFECT_SIZE="-0.939002542882588" ORDER="123" O_E="0.0" SE="0.5478807589570882" STUDY_ID="STD-Csonka-1963" TOTAL_1="28" TOTAL_2="29" VAR="0.300173326035395" WEIGHT="14.442112715228442"/>
<DICH_DATA CI_END="0.23360581116384657" CI_START="0.1319324679008173" EFFECT_SIZE="0.17555680329402956" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="117" LOG_CI_END="-0.6315163579423378" LOG_CI_START="-0.8796483136653453" LOG_EFFECT_SIZE="-0.7555823358038416" ORDER="124" O_E="0.0" SE="0.1457539390646847" STUDY_ID="STD-Forster-1963" TOTAL_1="274" TOTAL_2="134" VAR="0.021244210752871823" WEIGHT="85.55788728477157"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.267940335489122" CI_END="1.5797686593208713" CI_START="1.0131186623851935" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2651059682924635" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="89" I2="41.620105837622134" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.19859349370352528" LOG_CI_START="0.005660315450087793" LOG_EFFECT_SIZE="0.10212690457680654" METHOD="MH" NO="4" P_CHI2="0.051346812339034154" P_Q="0.0" P_Z="0.03798953010877805" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1946" TOTAL_2="1002" WEIGHT="600.0" Z="2.0749676819210676">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7845126660833337" CI_END="1.7810009186584395" CI_START="0.9574488710213879" DF="1.0" EFFECT_SIZE="1.3058396987599885" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="39" I2="43.962291834284926" ID="CMP-001.04.01" LOG_CI_END="0.25066414347682475" LOG_CI_START="-0.01888440861380905" LOG_EFFECT_SIZE="0.11588986743150784" NO="1" P_CHI2="0.18159630565691942" P_Z="0.09192372511718522" STUDIES="3" TAU2="0.0" TOTAL_1="353" TOTAL_2="171" WEIGHT="100.0" Z="1.6853362006745451">
<NAME>Any side effect</NAME>
<DICH_DATA CI_END="1.6905447796653863" CI_START="0.9025869942242717" EFFECT_SIZE="1.235258568591902" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="39" LOG_CI_END="0.22802667897875317" LOG_CI_START="-0.04451092871231233" LOG_EFFECT_SIZE="0.09175787513322041" ORDER="125" O_E="0.0" SE="0.16008993984064765" STUDY_ID="STD-Forster-1963" TOTAL_1="297" TOTAL_2="146" VAR="0.025628788838182183" WEIGHT="99.02449323777313"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="126" O_E="0.0" SE="0.0" STUDY_ID="STD-Lean-1972" TOTAL_1="40" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="145.1061123452629" CI_START="0.49447169310952516" EFFECT_SIZE="8.470588235294118" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1616857067306996" LOG_CI_START="-0.30585856529674815" LOG_EFFECT_SIZE="0.9279135707169758" ORDER="127" O_E="0.0" SE="1.4494477199300628" STUDY_ID="STD-Mati-1974" TOTAL_1="16" TOTAL_2="15" VAR="2.100898692810458" WEIGHT="0.9755067622268652"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.762211659401099E-31" CI_END="8.663949713500346" CI_START="1.089524309519654" DF="0.0" EFFECT_SIZE="3.0723905723905727" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="4" I2="100.0" ID="CMP-001.04.02" LOG_CI_END="0.9377159229325118" LOG_CI_START="0.03723692469008809" LOG_EFFECT_SIZE="0.48747642381129996" NO="2" P_CHI2="0.0" P_Z="0.03383251290051123" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="146" WEIGHT="100.0" Z="2.122062226542484">
<NAME>Unpleasant taste</NAME>
<DICH_DATA CI_END="8.663949713500346" CI_START="1.0895243095196534" EFFECT_SIZE="3.0723905723905722" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="4" LOG_CI_END="0.9377159229325118" LOG_CI_START="0.037236924690087825" LOG_EFFECT_SIZE="0.48747642381129996" ORDER="128" O_E="0.0" SE="0.5289458210105299" STUDY_ID="STD-Forster-1963" TOTAL_1="297" TOTAL_2="146" VAR="0.2797836815645035" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.347223932384999" CI_END="5.6618675427399445" CI_START="1.1391730619471507" DF="2.0" EFFECT_SIZE="2.5396548948631295" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="7" I2="40.248993183586045" ID="CMP-001.04.03" LOG_CI_END="0.7529597049919916" LOG_CI_START="0.056589706642124205" LOG_EFFECT_SIZE="0.40477470581705793" NO="3" P_CHI2="0.18756856679992595" P_Z="0.02269606533729414" STUDIES="3" TAU2="0.0" TOTAL_1="328" TOTAL_2="175" WEIGHT="99.99999999999997" Z="2.2785124205067793">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="9.626585300216961" CI_START="1.2300326217672637" EFFECT_SIZE="3.441077441077441" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" LOG_CI_END="0.9834722634214165" LOG_CI_START="0.08991662954154668" LOG_EFFECT_SIZE="0.5366944464814816" ORDER="129" O_E="0.0" SE="0.5248790025127593" STUDY_ID="STD-Forster-1963" TOTAL_1="297" TOTAL_2="146" VAR="0.27549796727878917" WEIGHT="59.71289996352358"/>
<DICH_DATA CI_END="90.68889381830684" CI_START="0.24419008532721606" EFFECT_SIZE="4.705882352941177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9575541046041152" LOG_CI_START="-0.6122719733767759" LOG_EFFECT_SIZE="0.6726410656136697" ORDER="130" O_E="0.0" SE="1.5095285590502205" STUDY_ID="STD-Mati-1974" TOTAL_1="16" TOTAL_2="15" VAR="2.2786764705882354" WEIGHT="5.735356719024795"/>
<DICH_DATA CI_END="3.1892264350131265" CI_START="0.12139636420189365" EFFECT_SIZE="0.6222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5036853552371823" LOG_CI_START="-0.9157943201034313" LOG_EFFECT_SIZE="-0.20605448243312444" ORDER="131" O_E="0.0" SE="0.8338093878327919" STUDY_ID="STD-Rees-1974" TOTAL_1="15" TOTAL_2="14" VAR="0.6952380952380952" WEIGHT="34.5517433174516"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.158474975623939" CI_END="2.831871488484605" CI_START="0.44902310261180023" DF="2.0" EFFECT_SIZE="1.1276416638087003" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.4520735409992426" LOG_CI_START="-0.3477313136098033" LOG_EFFECT_SIZE="0.05217111369471959" NO="4" P_CHI2="0.5603256468372728" P_Z="0.798185482308352" STUDIES="3" TAU2="0.0" TOTAL_1="328" TOTAL_2="175" WEIGHT="100.0" Z="0.25569613208956465">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="3.3813664408524584" CI_START="0.19851716939610997" EFFECT_SIZE="0.819304152637486" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5290922380880486" LOG_CI_START="-0.7022019259208864" LOG_EFFECT_SIZE="-0.08655484391641886" ORDER="132" O_E="0.0" SE="0.7232682869432593" STUDY_ID="STD-Forster-1963" TOTAL_1="297" TOTAL_2="146" VAR="0.5231170148978368" WEIGHT="52.64340019688326"/>
<DICH_DATA CI_END="90.68889381830684" CI_START="0.24419008532721606" EFFECT_SIZE="4.705882352941177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9575541046041152" LOG_CI_START="-0.6122719733767759" LOG_EFFECT_SIZE="0.6726410656136697" ORDER="133" O_E="0.0" SE="1.5095285590502205" STUDY_ID="STD-Mati-1974" TOTAL_1="16" TOTAL_2="15" VAR="2.2786764705882354" WEIGHT="6.741785649129814"/>
<DICH_DATA CI_END="3.880477204887019" CI_START="0.2244855632740339" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5888851366007624" LOG_CI_START="-0.6488115833556488" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="134" O_E="0.0" SE="0.7270291799999699" STUDY_ID="STD-Rees-1974" TOTAL_1="15" TOTAL_2="14" VAR="0.5285714285714286" WEIGHT="40.61481415398691"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.368994545989441" CI_END="1.9284042474834289" CI_START="0.46346116143477695" DF="2.0" EFFECT_SIZE="0.9453784809558693" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" I2="54.222877164359964" ID="CMP-001.04.05" LOG_CI_END="0.285198079384597" LOG_CI_START="-0.3339866543593851" LOG_EFFECT_SIZE="-0.024394287487394063" NO="5" P_CHI2="0.11253437846012793" P_Z="0.8772666881069202" STUDIES="3" TAU2="0.0" TOTAL_1="328" TOTAL_2="175" WEIGHT="99.99999999999999" Z="0.15443508955625357">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.3148414865390399" CI_START="0.22689994747611408" EFFECT_SIZE="0.5462027684249906" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.1188733987034175" LOG_CI_START="-0.6441656046476179" LOG_EFFECT_SIZE="-0.26264610297210017" ORDER="135" O_E="0.0" SE="0.44821288767238116" STUDY_ID="STD-Forster-1963" TOTAL_1="297" TOTAL_2="146" VAR="0.20089479267561458" WEIGHT="88.62015166571945"/>
<DICH_DATA CI_END="64.38881850957007" CI_START="0.12381526053184887" EFFECT_SIZE="2.823529411764706" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8088104561608964" LOG_CI_START="-0.9072258241662695" LOG_EFFECT_SIZE="0.4507923159973133" ORDER="136" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Mati-1974" TOTAL_1="16" TOTAL_2="15" VAR="2.545343137254902" WEIGHT="3.78305140175341"/>
<DICH_DATA CI_END="35.16895341922818" CI_START="0.6192330354042057" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5461594444893334" LOG_CI_START="-0.20814588257218206" LOG_EFFECT_SIZE="0.6690067809585756" ORDER="137" O_E="0.0" SE="1.030487633067356" STUDY_ID="STD-Rees-1974" TOTAL_1="15" TOTAL_2="14" VAR="1.061904761904762" WEIGHT="7.596796932527133"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.056777421116116764" CI_END="1.124279987501298" CI_START="0.41037881491951167" DF="1.0" EFFECT_SIZE="0.6792500930500533" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="0.05087448016940273" LOG_CI_START="-0.3868150670020688" LOG_EFFECT_SIZE="-0.16797029341633302" NO="6" P_CHI2="0.811663832333431" P_Z="0.13249528069867297" STUDIES="2" TAU2="0.0" TOTAL_1="312" TOTAL_2="160" WEIGHT="100.0" Z="1.5043344201211313">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="1.1199330997489014" CI_START="0.4012341412285408" EFFECT_SIZE="0.6703397612488522" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.04919208045797719" LOG_CI_START="-0.39660211972861525" LOG_EFFECT_SIZE="-0.17370501963531904" ORDER="138" O_E="0.0" SE="0.26186171990648477" STUDY_ID="STD-Forster-1963" TOTAL_1="297" TOTAL_2="146" VAR="0.06857156035238228" WEIGHT="96.61195833397066"/>
<DICH_DATA CI_END="13.53677361466875" CI_START="0.06435145743791972" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.131515165950651" LOG_CI_START="-1.1914416127055376" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="139" O_E="0.0" SE="1.3645163106041502" STUDY_ID="STD-Rees-1974" TOTAL_1="15" TOTAL_2="14" VAR="1.861904761904762" WEIGHT="3.3880416660293378"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Short versus long treatment</NAME>
<DICH_OUTCOME CHI2="2.8266177880129035" CI_END="2.1570135656462255" CI_START="0.577907897972243" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1164923535878886" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="29.244059508802966" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.33385287642696465" LOG_CI_START="-0.23814137021206494" LOG_EFFECT_SIZE="0.047855753107449835" METHOD="MH" NO="1" P_CHI2="0.24333708407464283" P_Q="0.0" P_Z="0.7429420765627788" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="216" WEIGHT="99.99999999999999" Z="0.32795977615080574">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="140" O_E="0.0" SE="0.0" STUDY_ID="STD-Aimakhu-1975" TOTAL_1="21" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.955703597548578" CI_START="0.6944758850999538" EFFECT_SIZE="1.6574500768049154" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.5972237422851776" LOG_CI_START="-0.1583428300557402" LOG_EFFECT_SIZE="0.2194404561147187" ORDER="141" O_E="0.0" SE="0.443823544707908" STUDY_ID="STD-Hager-1980" TOTAL_1="93" TOTAL_2="83" VAR="0.19697933883709243" WEIGHT="47.96715659551718"/>
<DICH_DATA CI_END="2.510608187199283" CI_START="0.007103072165534455" EFFECT_SIZE="0.13354037267080746" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39977894074374754" LOG_CI_START="-2.148553772976236" LOG_EFFECT_SIZE="-0.8743874161162444" ORDER="142" O_E="0.0" SE="1.4969032504894946" STUDY_ID="STD-Nygaard-1977" TOTAL_1="45" TOTAL_2="42" VAR="2.2407193413260145" WEIGHT="23.45910956852163"/>
<DICH_DATA CI_END="3.592417169944924" CI_START="0.28699504216420657" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5553867634310201" LOG_CI_START="-0.542125605632994" LOG_EFFECT_SIZE="0.006630578899013076" ORDER="143" O_E="0.0" SE="0.6446841983620474" STUDY_ID="STD-Thin-1979" TOTAL_1="52" TOTAL_2="66" VAR="0.41561771561771566" WEIGHT="28.573733835961182"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.687557969263516" CI_END="2.8024505113382103" CI_START="1.5184585558315133" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.062863290728667" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="48" I2="36.6756167120997" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.447537952099303" LOG_CI_START="0.18140294296531018" LOG_EFFECT_SIZE="0.3144704475323066" METHOD="MH" NO="2" P_CHI2="0.07059288663878649" P_Q="0.0" P_Z="3.6238598032557884E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1218" TOTAL_2="1122" WEIGHT="700.0" Z="4.631865257946543">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.412711965987789" CI_END="4.491712494243259" CI_START="1.617108846714673" DF="2.0" EFFECT_SIZE="2.6951044527698" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="16" I2="17.10572881495287" ID="CMP-002.02.01" LOG_CI_END="0.6524119501362424" LOG_CI_START="0.20873925301500332" LOG_EFFECT_SIZE="0.4305756015756228" NO="1" P_CHI2="0.2992859632341508" P_Z="1.4225586455386048E-4" STUDIES="4" TAU2="0.0" TOTAL_1="231" TOTAL_2="227" WEIGHT="100.00000000000001" Z="3.804212777507375">
<NAME>Any side effect</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="144" O_E="0.0" SE="0.0" STUDY_ID="STD-Aimakhu-1975" TOTAL_1="21" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.5909226176943587" CI_START="0.8872463727587393" EFFECT_SIZE="1.7849462365591398" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.5552060464319943" LOG_CI_START="-0.05195576745975431" LOG_EFFECT_SIZE="0.25162513948612" ORDER="145" O_E="0.0" SE="0.35664985497946394" STUDY_ID="STD-Hager-1980" TOTAL_1="93" TOTAL_2="83" VAR="0.12719911905687267" WEIGHT="59.97826921829671"/>
<DICH_DATA CI_END="9.054708843246624" CI_START="1.8356528147831919" EFFECT_SIZE="4.076923076923077" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="6" LOG_CI_END="0.9568744900112788" LOG_CI_START="0.2637905445766257" LOG_EFFECT_SIZE="0.6103325172939522" ORDER="146" O_E="0.0" SE="0.4071209403691767" STUDY_ID="STD-Nygaard-1977" TOTAL_1="65" TOTAL_2="53" VAR="0.16574746008708272" WEIGHT="37.51511207530423"/>
<DICH_DATA CI_END="91.22019324758946" CI_START="0.15767011620079177" EFFECT_SIZE="3.792452830188679" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9600909879473756" LOG_CI_START="-0.8022506123079763" LOG_EFFECT_SIZE="0.5789201878196999" ORDER="147" O_E="0.0" SE="1.6226131298014435" STUDY_ID="STD-Thin-1979" TOTAL_1="52" TOTAL_2="66" VAR="2.6328733690040362" WEIGHT="2.5066187063990664"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3221866670264015" CI_END="5.448048737807411" CI_START="1.2155701380196053" DF="2.0" EFFECT_SIZE="2.5734190012809983" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.7362409840857385" LOG_CI_START="0.0847800225591053" LOG_EFFECT_SIZE="0.4105105033224219" NO="2" P_CHI2="0.5162865891387401" P_Z="0.013507651421469966" STUDIES="3" TAU2="0.0" TOTAL_1="210" TOTAL_2="202" WEIGHT="100.0" Z="2.470096749625308">
<NAME>Nausea/vomiting</NAME>
<DICH_DATA CI_END="4.4607191412755345" CI_START="0.8199206906738732" EFFECT_SIZE="1.912442396313364" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6494048797683827" LOG_CI_START="-0.08622815404125626" LOG_EFFECT_SIZE="0.2815883628635632" ORDER="148" O_E="0.0" SE="0.43211448550202775" STUDY_ID="STD-Hager-1980" TOTAL_1="93" TOTAL_2="83" VAR="0.18672292858068215" WEIGHT="82.73855000201053"/>
<DICH_DATA CI_END="50.51701169929241" CI_START="0.8423010608320425" EFFECT_SIZE="6.523076923076923" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7034376522377637" LOG_CI_START="-0.07453265233800961" LOG_EFFECT_SIZE="0.814452499949877" ORDER="149" O_E="0.0" SE="1.0443885580027592" STUDY_ID="STD-Nygaard-1977" TOTAL_1="65" TOTAL_2="53" VAR="1.0907474600870828" WEIGHT="12.321708610260622"/>
<DICH_DATA CI_END="91.22019324758946" CI_START="0.15767011620079177" EFFECT_SIZE="3.792452830188679" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9600909879473756" LOG_CI_START="-0.8022506123079763" LOG_EFFECT_SIZE="0.5789201878196999" ORDER="150" O_E="0.0" SE="1.6226131298014435" STUDY_ID="STD-Thin-1979" TOTAL_1="52" TOTAL_2="66" VAR="2.6328733690040362" WEIGHT="4.939741387728842"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.14900538549560438" CI_END="2.7952315460530737" CI_START="0.1440947062398027" DF="1.0" EFFECT_SIZE="0.6346479878647273" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.44641778896951795" LOG_CI_START="-0.8413519740303759" LOG_EFFECT_SIZE="-0.19746709253042904" NO="3" P_CHI2="0.6994878163388154" P_Z="0.5477845709370597" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="136" WEIGHT="100.0" Z="0.6010832069699888">
<NAME>Abdominal pain</NAME>
<DICH_DATA CI_END="4.831880553740137" CI_START="0.04121109048500374" EFFECT_SIZE="0.44623655913978494" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6841161897909062" LOG_CI_START="-1.3849858934745911" LOG_EFFECT_SIZE="-0.3504348518418424" ORDER="151" O_E="0.0" SE="1.2154008059306496" STUDY_ID="STD-Hager-1980" TOTAL_1="93" TOTAL_2="83" VAR="1.4771991190568727" WEIGHT="48.96047113411261"/>
<DICH_DATA CI_END="5.595760668211801" CI_START="0.11881352874557077" EFFECT_SIZE="0.8153846153846154" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7478591313562974" LOG_CI_START="-0.9251341054404305" LOG_EFFECT_SIZE="-0.08863748704206653" ORDER="152" O_E="0.0" SE="0.9827245087444817" STUDY_ID="STD-Nygaard-1977" TOTAL_1="65" TOTAL_2="53" VAR="0.9657474600870828" WEIGHT="51.03952886588739"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8428983382847035" CI_END="6.126532820772175" CI_START="0.11894345399265259" DF="1.0" EFFECT_SIZE="0.8536456962358514" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="0.7872147644357026" LOG_CI_START="-0.924659454199198" LOG_EFFECT_SIZE="-0.06872234488174764" NO="4" P_CHI2="0.35856923356242665" P_Z="0.8749583211327898" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="136" WEIGHT="100.0" Z="0.15736357196707404">
<NAME>Skin rash</NAME>
<DICH_DATA CI_END="7.213544177717633" CI_START="0.012300185457331947" EFFECT_SIZE="0.2978723404255319" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8581486958758309" LOG_CI_START="-1.9100883403907898" LOG_EFFECT_SIZE="-0.5259698222574795" ORDER="153" O_E="0.0" SE="1.6260761380973414" STUDY_ID="STD-Hager-1980" TOTAL_1="93" TOTAL_2="83" VAR="2.6441236068895644" WEIGHT="74.23006054224795"/>
<DICH_DATA CI_END="59.043787711513794" CI_START="0.10203941213708569" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7711742100860695" LOG_CI_START="-0.991232052084545" LOG_EFFECT_SIZE="0.3899710790007623" ORDER="154" O_E="0.0" SE="1.6226511125305503" STUDY_ID="STD-Nygaard-1977" TOTAL_1="65" TOTAL_2="53" VAR="2.632996632996633" WEIGHT="25.769939457752038"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2610242559128217" CI_END="43.541671744504185" CI_START="2.3731841562925653" DF="2.0" EFFECT_SIZE="10.1652548183776" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="1" I2="0.0" ID="CMP-002.02.05" LOG_CI_END="1.6389050993829697" LOG_CI_START="0.37533144026474186" LOG_EFFECT_SIZE="1.0071182698238557" NO="5" P_CHI2="0.5323194700946818" P_Z="0.0017820568083118133" STUDIES="3" TAU2="0.0" TOTAL_1="210" TOTAL_2="202" WEIGHT="100.00000000000001" Z="3.1243379011311885">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="64.92189759945867" CI_START="0.11070166911598754" EFFECT_SIZE="2.6808510638297873" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8123912053151556" LOG_CI_START="-0.9558458309514648" LOG_EFFECT_SIZE="0.4282726871818454" ORDER="155" O_E="0.0" SE="1.6260761380973414" STUDY_ID="STD-Hager-1980" TOTAL_1="93" TOTAL_2="83" VAR="2.6441236068895644" WEIGHT="25.493712761336223"/>
<DICH_DATA CI_END="117.56282225232039" CI_START="2.262116741562981" EFFECT_SIZE="16.307692307692307" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" LOG_CI_END="2.0702700033438974" LOG_CI_START="0.35451501389993173" LOG_EFFECT_SIZE="1.2123925086219147" ORDER="156" O_E="0.0" SE="1.0078429739235586" STUDY_ID="STD-Nygaard-1977" TOTAL_1="65" TOTAL_2="53" VAR="1.0157474600870828" WEIGHT="53.184683852985955"/>
<DICH_DATA CI_END="91.22019324758946" CI_START="0.15767011620079177" EFFECT_SIZE="3.792452830188679" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9600909879473756" LOG_CI_START="-0.8022506123079763" LOG_EFFECT_SIZE="0.5789201878196999" ORDER="157" O_E="0.0" SE="1.6226131298014435" STUDY_ID="STD-Thin-1979" TOTAL_1="52" TOTAL_2="66" VAR="2.6328733690040362" WEIGHT="21.321603385677832"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.873538592780945" CI_END="4.9561403678078895" CI_START="0.2645194583739699" DF="1.0" EFFECT_SIZE="1.144987146529563" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="65.19970177145862" ID="CMP-002.02.06" LOG_CI_END="0.6951435979665616" LOG_CI_START="-0.5775423752219382" LOG_EFFECT_SIZE="0.05880061137231162" NO="6" P_CHI2="0.09004681210053866" P_Z="0.8562824662976483" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="136" WEIGHT="100.0" Z="0.18110843206660796">
<NAME>Headache</NAME>
<DICH_DATA CI_END="119.33929191908899" CI_START="0.3278804241739315" EFFECT_SIZE="6.25531914893617" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.07678345669775" LOG_CI_START="-0.4842845117448703" LOG_EFFECT_SIZE="0.7962494724764398" ORDER="158" O_E="0.0" SE="1.5043840021540988" STUDY_ID="STD-Hager-1980" TOTAL_1="93" TOTAL_2="83" VAR="2.2631712259371835" WEIGHT="16.10968294772922"/>
<DICH_DATA CI_END="3.3363602491299407" CI_START="0.008025769852375837" EFFECT_SIZE="0.16363636363636364" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5232729381774025" LOG_CI_START="-2.0955132982872406" LOG_EFFECT_SIZE="-0.786120180054919" ORDER="159" O_E="0.0" SE="1.5382879985002698" STUDY_ID="STD-Nygaard-1977" TOTAL_1="65" TOTAL_2="53" VAR="2.366329966329966" WEIGHT="83.89031705227077"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5855331111847357" CI_START="0.4415272623285034" DF="0.0" EFFECT_SIZE="0.8366935483870968" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" I2="0.0" ID="CMP-002.02.07" LOG_CI_END="0.20017531596554702" LOG_CI_START="-0.3550424755217566" LOG_EFFECT_SIZE="-0.07743357977810476" NO="7" P_CHI2="1.0" P_Z="0.584589202405524" STUDIES="1" TAU2="0.0" TOTAL_1="93" TOTAL_2="83" WEIGHT="100.0" Z="0.5466936754765896">
<NAME>Candidiasis after treatment</NAME>
<DICH_DATA CI_END="1.5855331111847357" CI_START="0.4415272623285034" EFFECT_SIZE="0.8366935483870968" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.20017531596554702" LOG_CI_START="-0.3550424755217566" LOG_EFFECT_SIZE="-0.07743357977810476" ORDER="160" O_E="0.0" SE="0.32613767909203517" STUDY_ID="STD-Hager-1980" TOTAL_1="93" TOTAL_2="83" VAR="0.1063657857235393" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Oral versus intravaginal treatment</NAME>
<DICH_OUTCOME CHI2="0.4216038823336313" CI_END="0.5598605340232269" CI_START="0.07010114368022435" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1981082121883123" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.2519201459360522" LOG_CI_START="-1.1542748965845715" LOG_EFFECT_SIZE="-0.7030975212603119" METHOD="MH" NO="1" P_CHI2="0.5161378391824385" P_Q="0.0" P_Z="0.002255617684989126" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="46" WEIGHT="100.0" Z="3.054332718477294">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.534553565279208" CI_START="0.005042171891742195" EFFECT_SIZE="0.08796296296296297" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.1859820525587601" LOG_CI_START="-2.297382352954964" LOG_EFFECT_SIZE="-1.0557001501981018" ORDER="161" O_E="0.0" SE="1.4587405446508255" STUDY_ID="STD-DuBouchet-1998" TOTAL_1="23" TOTAL_2="18" VAR="2.127923976608187" WEIGHT="27.55367286030615"/>
<DICH_DATA CI_END="0.7387256771964272" CI_START="0.07797211032192689" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.13151680517434125" LOG_CI_START="-1.1080607114024468" LOG_EFFECT_SIZE="-0.619788758288394" ORDER="162" O_E="0.0" SE="0.5736267244886862" STUDY_ID="STD-Tidwell-1994" TOTAL_1="25" TOTAL_2="28" VAR="0.3290476190476191" WEIGHT="72.44632713969385"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.423078119824604" CI_END="5.53919051062046" CI_START="0.6806396140861328" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9416983523447402" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="81.56028775716138" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.743446302190985" LOG_CI_START="-0.16708277801665528" LOG_EFFECT_SIZE="0.28818176208716484" METHOD="MH" NO="2" P_CHI2="0.01987237516591167" P_Q="0.0" P_Z="0.2147335353010834" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="22" WEIGHT="100.0" Z="1.2406542239448928">
<NAME>Persistent itching</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.205531455980942" CI_START="0.03857095042274451" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3435132562026264" LOG_CI_START="-1.4137396595973248" LOG_EFFECT_SIZE="-0.5351132016973491" ORDER="163" O_E="0.0" SE="1.0322190612831128" STUDY_ID="STD-DuBouchet-1998" TOTAL_1="8" TOTAL_2="7" VAR="1.0654761904761905" WEIGHT="79.08745247148289"/>
<DICH_DATA CI_END="58.601901990225905" CI_START="1.1423204108886387" EFFECT_SIZE="8.181818181818182" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7679117117596408" LOG_CI_START="0.057787936802558976" LOG_EFFECT_SIZE="0.9128498242810998" ORDER="164" O_E="0.0" SE="1.0045351706590016" STUDY_ID="STD-Tidwell-1994" TOTAL_1="11" TOTAL_2="15" VAR="1.0090909090909093" WEIGHT="20.91254752851711"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6099393267300925" CI_START="0.4982782707566555" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3411764705882352" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.5574999026569722" LOG_CI_START="-0.3025280514126126" LOG_EFFECT_SIZE="0.12748592562217984" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5611939047411123" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="19" WEIGHT="100.0" Z="0.5810690724013554">
<NAME>Persistent discharge</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6099393267300934" CI_START="0.4982782707566554" EFFECT_SIZE="1.3411764705882352" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5574999026569725" LOG_CI_START="-0.30252805141261263" LOG_EFFECT_SIZE="0.12748592562217984" ORDER="165" O_E="0.0" SE="0.5051846774275063" STUDY_ID="STD-Tidwell-1994" TOTAL_1="17" TOTAL_2="19" VAR="0.25521155830753356" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="146.87309205952002" CI_START="0.5984120288308663" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="2.1669422379926337" LOG_CI_START="-0.22299968519312108" LOG_EFFECT_SIZE="0.9719712763997564" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.11089012439099032" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="14" WEIGHT="100.0" Z="1.594205011652815">
<NAME>Persistent dysuria</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="166" O_E="0.0" SE="0.0" STUDY_ID="STD-DuBouchet-1998" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="146.87309205952002" CI_START="0.5984120288308661" EFFECT_SIZE="9.375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.1669422379926337" LOG_CI_START="-0.22299968519312127" LOG_EFFECT_SIZE="0.9719712763997564" ORDER="167" O_E="0.0" SE="1.4038637160826308" STUDY_ID="STD-Tidwell-1994" TOTAL_1="15" TOTAL_2="9" VAR="1.9708333333333332" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Oral versus oral plus intravaginal</NAME>
<DICH_OUTCOME CHI2="2.19530829414354" CI_END="8.15947116674172" CI_START="1.1040039127578258" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.001347712964548" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.9116620120861596" LOG_CI_START="0.04297061260162349" LOG_EFFECT_SIZE="0.4773163123438915" METHOD="MH" NO="1" P_CHI2="0.5328731644799035" P_Q="0.0" P_Z="0.0312506194170655" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="209" WEIGHT="100.0" Z="2.1538667977664314">
<NAME>No parasitological cure (2 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="49.86373995788284" CI_START="0.09090329685875712" EFFECT_SIZE="2.129032258064516" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6977848490204932" LOG_CI_START="-1.0414203656053012" LOG_EFFECT_SIZE="0.32818224170759597" ORDER="168" O_E="0.0" SE="1.6090227023556853" STUDY_ID="STD-Chung-1978" TOTAL_1="30" TOTAL_2="21" VAR="2.588954056695992" WEIGHT="11.794927423961186"/>
<DICH_DATA CI_END="8.434974839029426" CI_START="0.015364598291429213" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9260837914554372" LOG_CI_START="-1.8134787899208629" LOG_EFFECT_SIZE="-0.44369749923271273" ORDER="169" O_E="0.0" SE="1.6092326213539263" STUDY_ID="STD-Diwald-1971" TOTAL_1="24" TOTAL_2="26" VAR="2.5896296296296293" WEIGHT="29.084886172609"/>
<DICH_DATA CI_END="21.468031197250095" CI_START="1.0688502184197008" EFFECT_SIZE="4.79020979020979" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3317922177303194" LOG_CI_START="0.02891685032440806" LOG_EFFECT_SIZE="0.6803545340273638" ORDER="170" O_E="0.0" SE="0.7653154401513146" STUDY_ID="STD-Forster-1963" TOTAL_1="143" TOTAL_2="137" VAR="0.5857077229340003" WEIGHT="41.19527877705153"/>
<DICH_DATA CI_END="33.355107053065396" CI_START="0.4215996062500309" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5231623388570166" LOG_CI_START="-0.3750998034015788" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="171" O_E="0.0" SE="1.1150485789118487" STUDY_ID="STD-Gummerus-1983" TOTAL_1="20" TOTAL_2="25" VAR="1.2433333333333332" WEIGHT="17.92490762637829"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.956756436639648" CI_START="0.9319241832159292" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.546206896551724" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.8424067985171904" LOG_CI_START="-0.03061941827939124" LOG_EFFECT_SIZE="0.40589369011889953" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.0683819757838875" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="145" TOTAL_2="142" WEIGHT="99.99999999999999" Z="1.8224813845893186">
<NAME>No parasitological cure (6 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.956756436639648" CI_START="0.9319241832159292" EFFECT_SIZE="2.546206896551724" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8424067985171904" LOG_CI_START="-0.03061941827939124" LOG_EFFECT_SIZE="0.40589369011889953" ORDER="172" O_E="0.0" SE="0.5128199212957822" STUDY_ID="STD-Forster-1963" TOTAL_1="145" TOTAL_2="142" VAR="0.26298427167781224" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.138158329381445" CI_START="0.9738859388257316" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7482014388489209" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.49667485124647015" LOG_CI_START="-0.011491904558035788" LOG_EFFECT_SIZE="0.24259147334421713" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.06130115219881826" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="139" TOTAL_2="135" WEIGHT="100.0" Z="1.8713170245008703">
<NAME>No parasitological cure (3 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.138158329381445" CI_START="0.9738859388257316" EFFECT_SIZE="1.7482014388489209" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" LOG_CI_END="0.49667485124647015" LOG_CI_START="-0.011491904558035788" LOG_EFFECT_SIZE="0.24259147334421713" ORDER="173" O_E="0.0" SE="0.2984996678255769" STUDY_ID="STD-Forster-1963" TOTAL_1="139" TOTAL_2="135" VAR="0.08910205169197975" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Partner treatment versus no partner treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9223977134258705" CI_START="0.11666651119570445" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6764705882352942" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.5935516270648564" LOG_CI_START="-0.9330537891141809" LOG_EFFECT_SIZE="-0.16975108102466221" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6629260595409394" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="69" WEIGHT="100.0" Z="0.43587688294439986">
<NAME>No parasitological cure (at average 10 days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9223977134258705" CI_START="0.11666651119570445" EFFECT_SIZE="0.6764705882352942" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5935516270648564" LOG_CI_START="-0.9330537891141809" LOG_EFFECT_SIZE="-0.16975108102466221" ORDER="174" O_E="0.0" SE="0.8967355782822514" STUDY_ID="STD-Lyng-1981" TOTAL_1="68" TOTAL_2="69" VAR="0.8041346973572038" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7069078403488223" CI_START="0.0649566530826429" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.15063720153102386" LOG_CI_START="-1.1873763603861276" LOG_EFFECT_SIZE="-0.6690067809585756" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.011421679457919423" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="2.5295257440452192">
<NAME>No parasitological cure (at average 2 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7069078403488223" CI_START="0.0649566530826429" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.15063720153102386" LOG_CI_START="-1.1873763603861276" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="175" O_E="0.0" SE="0.6089857138530911" STUDY_ID="STD-Lyng-1981" TOTAL_1="59" TOTAL_2="59" VAR="0.370863599677159" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.791960279391076" CI_START="0.07068907558604412" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23660714285714288" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.10129659981689852" LOG_CI_START="-1.1506476976498492" LOG_EFFECT_SIZE="-0.6259721487333737" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.019368328973453662" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="2.338364860676734">
<NAME>No parasitological cure with intercourse (at 2 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.791960279391076" CI_START="0.07068907558604412" EFFECT_SIZE="0.23660714285714285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.10129659981689852" LOG_CI_START="-1.1506476976498492" LOG_EFFECT_SIZE="-0.6259721487333738" ORDER="176" O_E="0.0" SE="0.6163940292387832" STUDY_ID="STD-Lyng-1981" TOTAL_1="56" TOTAL_2="53" VAR="0.3799415992812219" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Metronidazole versus ornidazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="107.20322514518227" CI_START="0.2736883870615186" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.416666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="2.0302078510441275" LOG_CI_START="-0.5627436298536661" LOG_EFFECT_SIZE="0.7337321105952308" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.2673314155616149" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="1.1092290169419468">
<NAME>No parasitological cure (day 3)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="107.20322514518227" CI_START="0.2736883870615186" EFFECT_SIZE="5.416666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0302078510441275" LOG_CI_START="-0.5627436298536661" LOG_EFFECT_SIZE="0.7337321105952308" ORDER="177" O_E="0.0" SE="1.5231125351961998" STUDY_ID="STD-Sandvei-1979" TOTAL_1="23" TOTAL_2="25" VAR="2.319871794871795" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.316560117637714" CI_START="0.20907642222110503" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="1.3287171233160748" LOG_CI_START="-0.6796949402890666" LOG_EFFECT_SIZE="0.3245110915135041" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5264946048841375" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.6333660940161479">
<NAME>No parasitological cure (4 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.316560117637714" CI_START="0.20907642222110503" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3287171233160748" LOG_CI_START="-0.6796949402890666" LOG_EFFECT_SIZE="0.3245110915135041" ORDER="178" O_E="0.0" SE="1.1797511879617142" STUDY_ID="STD-Sandvei-1979" TOTAL_1="18" TOTAL_2="19" VAR="1.391812865497076" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.493683713263621" CI_END="0.5898630078192799" CI_START="0.16745500038941946" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="34" I2="33.23962718726383" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.22924883896173728" LOG_CI_START="-0.7761018794223639" LOG_EFFECT_SIZE="-0.5026753591920505" METHOD="MH" NO="3" P_CHI2="0.21285467957118165" P_Q="0.0" P_Z="3.1425640649972245E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="172" TOTAL_2="172" WEIGHT="400.0" Z="3.603255452698139">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.713217161667703" CI_START="0.1398213574342073" DF="0.0" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="-0.14677821523320564" LOG_CI_START="-0.8544264859051649" LOG_EFFECT_SIZE="-0.5006023505691853" NO="1" P_CHI2="1.0" P_Z="0.005553814099939965" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="2.7730233178130095">
<NAME>Any side effect</NAME>
<DICH_DATA CI_END="0.713217161667703" CI_START="0.1398213574342073" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.14677821523320564" LOG_CI_START="-0.8544264859051649" LOG_EFFECT_SIZE="-0.5006023505691853" ORDER="179" O_E="0.0" SE="0.415676097108143" STUDY_ID="STD-Sandvei-1979" TOTAL_1="43" TOTAL_2="43" VAR="0.17278661770705833" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.18091723147054" CI_START="0.24708216414768958" DF="0.0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="2.0050986120834273" LOG_CI_START="-0.6071586034113897" LOG_EFFECT_SIZE="0.6989700043360189" NO="2" P_CHI2="1.0" P_Z="0.294239054635855" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.048867643390089">
<NAME>Nausea/vomiting</NAME>
<DICH_DATA CI_END="101.18091723147054" CI_START="0.24708216414768958" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0050986120834273" LOG_CI_START="-0.6071586034113897" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="180" O_E="0.0" SE="1.5344528192634188" STUDY_ID="STD-Sandvei-1979" TOTAL_1="43" TOTAL_2="43" VAR="2.354545454545454" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.110070290833572" CI_START="0.05630274093099782" DF="0.0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-006.03.03" LOG_CI_END="0.045350479646684205" LOG_CI_START="-1.249470462302609" LOG_EFFECT_SIZE="-0.6020599913279624" NO="3" P_CHI2="1.0" P_Z="0.06835332660335058" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.8226703960454087">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="1.1100702908335718" CI_START="0.05630274093099784" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.045350479646684115" LOG_CI_START="-1.2494704623026087" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="181" O_E="0.0" SE="0.7605842307680479" STUDY_ID="STD-Sandvei-1979" TOTAL_1="43" TOTAL_2="43" VAR="0.5784883720930232" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.132014281064236" CI_START="0.003926138140471255" DF="0.0" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-006.03.04" LOG_CI_END="0.05385190578182064" LOG_CI_START="-2.4060344238931832" LOG_EFFECT_SIZE="-1.1760912590556813" NO="4" P_CHI2="1.0" P_Z="0.06090991834176205" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.8741488031164824">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="1.1320142810642353" CI_START="0.003926138140471259" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.053851905781820385" LOG_CI_START="-2.406034423893183" LOG_EFFECT_SIZE="-1.1760912590556813" ORDER="182" O_E="0.0" SE="1.444949406684811" STUDY_ID="STD-Sandvei-1979" TOTAL_1="43" TOTAL_2="43" VAR="2.0878787878787874" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Metronidazole versus nimorazole</NAME>
<DICH_OUTCOME CHI2="6.5148862164181764" CI_END="1.0107840437328481" CI_START="0.40610614889509083" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6406915134173029" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="42" I2="7.903226538640242" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.004658377516306196" LOG_CI_START="-0.3913604347626323" LOG_EFFECT_SIZE="-0.19335102862316306" METHOD="MH" NO="1" P_CHI2="0.3680447475621559" P_Q="0.0" P_Z="0.05563884020580494" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="510" TOTAL_2="495" WEIGHT="100.00000000000001" Z="1.9138537904014972">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.08678677164774" CI_START="0.08614967395928418" EFFECT_SIZE="0.424" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31947807502244757" LOG_CI_START="-1.0647463618369823" LOG_EFFECT_SIZE="-0.3726341434072674" ORDER="183" O_E="0.0" SE="0.8131002862326996" STUDY_ID="STD-Eriksson-1976" TOTAL_1="50" TOTAL_2="53" VAR="0.661132075471698" WEIGHT="11.170313411691168"/>
<DICH_DATA CI_END="2.4505539606616558" CI_START="0.20907704089029" EFFECT_SIZE="0.7157894736842105" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3892642700233394" LOG_CI_START="-0.6796936551885623" LOG_EFFECT_SIZE="-0.14521469258261144" ORDER="184" O_E="0.0" SE="0.62791117669654" STUDY_ID="STD-Hayward-1976" TOTAL_1="38" TOTAL_2="34" VAR="0.3942724458204334" WEIGHT="12.144612970377565"/>
<DICH_DATA CI_END="2.4180728609147684" CI_START="0.13890108082071406" EFFECT_SIZE="0.5795454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.3834693828012186" LOG_CI_START="-0.8572943749056832" LOG_EFFECT_SIZE="-0.23691249605223225" ORDER="185" O_E="0.0" SE="0.7288307731566898" STUDY_ID="STD-Mahony-1975" TOTAL_1="44" TOTAL_2="34" VAR="0.5311942959001782" WEIGHT="10.384381616776283"/>
<DICH_DATA CI_END="22.403858834976788" CI_START="0.21094124701530734" EFFECT_SIZE="2.1739130434782608" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3503228275485795" LOG_CI_START="-0.6758384909117277" LOG_EFFECT_SIZE="0.3372421683184259" ORDER="186" O_E="0.0" SE="1.190177188123867" STUDY_ID="STD-Roncuzzi-1972" TOTAL_1="23" TOTAL_2="25" VAR="1.4165217391304348" WEIGHT="2.2052060393580315"/>
<DICH_DATA CI_END="0.743022479170902" CI_START="0.10954276061046704" EFFECT_SIZE="0.2852941176470588" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="-0.12899804703053913" LOG_CI_START="-0.9604163185214813" LOG_EFFECT_SIZE="-0.5447071827760103" ORDER="187" O_E="0.0" SE="0.4883792082605987" STUDY_ID="STD-Roy-1975" TOTAL_1="100" TOTAL_2="97" VAR="0.23851425106124927" WEIGHT="39.71414981496697"/>
<DICH_DATA CI_END="2.475098577359197" CI_START="0.4715656850192048" EFFECT_SIZE="1.0803571428571428" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.39359250054255146" LOG_CI_START="-0.3264578052500145" LOG_EFFECT_SIZE="0.033567347646268446" ORDER="188" O_E="0.0" SE="0.4229611139290513" STUDY_ID="STD-Saeed-1976" TOTAL_1="168" TOTAL_2="165" VAR="0.1788961038961039" WEIGHT="23.21815054365213"/>
<DICH_DATA CI_END="70.15799076657736" CI_START="0.12276504595119608" EFFECT_SIZE="2.9347826086956523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8460771429081089" LOG_CI_START="-0.9109252692812447" LOG_EFFECT_SIZE="0.46757593681343207" ORDER="189" O_E="0.0" SE="1.619476864302069" STUDY_ID="STD-Tinkler-1974" TOTAL_1="45" TOTAL_2="44" VAR="2.6227053140096617" WEIGHT="1.1631856031778627"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="190" O_E="0.0" SE="0.0" STUDY_ID="STD-Wigfield-1975" TOTAL_1="42" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9092899387763218" CI_END="4.818517900898649" CI_START="0.19962204315418236" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9807560289656089" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.6829134767363361" LOG_CI_START="-0.6997915036716592" LOG_EFFECT_SIZE="-0.008439013467661587" METHOD="MH" NO="2" P_CHI2="0.6346732866434918" P_Q="0.0" P_Z="0.9809129472939495" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="381" TOTAL_2="374" WEIGHT="200.0" Z="0.023924355080842584">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.26580879729295115" CI_END="12.187772270955508" CI_START="0.21883058846641634" DF="1.0" EFFECT_SIZE="1.6331127879445024" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="1.085924330815538" LOG_CI_START="-0.6598919717642263" LOG_EFFECT_SIZE="0.21301617952565577" NO="1" P_CHI2="0.6061572723263817" P_Z="0.6324431620115504" STUDIES="2" TAU2="0.0" TOTAL_1="213" TOTAL_2="209" WEIGHT="100.0" Z="0.47829091683662806">
<NAME>Nausea/vomiting</NAME>
<DICH_DATA CI_END="71.81798925525747" CI_START="0.12090716404035536" EFFECT_SIZE="2.9467455621301775" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8562332416760097" LOG_CI_START="-0.9175479653839217" LOG_EFFECT_SIZE="0.469342638146044" ORDER="191" O_E="0.0" SE="1.6293328114654202" STUDY_ID="STD-Saeed-1976" TOTAL_1="168" TOTAL_2="165" VAR="2.654725410517811" WEIGHT="33.28317585359917"/>
<DICH_DATA CI_END="15.150142679509194" CI_START="0.06310497550687236" EFFECT_SIZE="0.9777777777777777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180416722913026" LOG_CI_START="-1.1999363974913386" LOG_EFFECT_SIZE="-0.009759837289156264" ORDER="192" O_E="0.0" SE="1.3982312058635027" STUDY_ID="STD-Tinkler-1974" TOTAL_1="45" TOTAL_2="44" VAR="1.9550505050505051" WEIGHT="66.71682414640084"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.9797765839174986" CI_START="0.013434129337817265" DF="0.0" EFFECT_SIZE="0.32741617357001973" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-007.02.02" LOG_CI_END="0.9019907322366848" LOG_CI_START="-1.8717904748232466" LOG_EFFECT_SIZE="-0.4848998712932808" NO="2" P_CHI2="1.0" P_Z="0.4931773121000732" STUDIES="1" TAU2="0.0" TOTAL_1="168" TOTAL_2="165" WEIGHT="100.00000000000001" Z="0.6852640586243642">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="7.9797765839174986" CI_START="0.013434129337817265" EFFECT_SIZE="0.32741617357001973" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9019907322366848" LOG_CI_START="-1.8717904748232466" LOG_EFFECT_SIZE="-0.4848998712932808" ORDER="193" O_E="0.0" SE="1.6293328114654202" STUDY_ID="STD-Saeed-1976" TOTAL_1="168" TOTAL_2="165" VAR="2.654725410517811" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Metronidazole versus nifuratel</NAME>
<DICH_OUTCOME CHI2="4.6377406841845605" CI_END="1.048898460414397" CI_START="0.2975629844198335" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5586710626426579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="22" I2="78.43777675172396" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.020733447949390964" LOG_CI_START="-0.5264210941679653" LOG_EFFECT_SIZE="-0.25284382310928716" METHOD="MH" NO="1" P_CHI2="0.03127622009512587" P_Q="0.0" P_Z="0.07007504445119508" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="91" WEIGHT="100.0" Z="1.8114252879630781">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3177835881244224" CI_START="0.4668224513827869" EFFECT_SIZE="1.0401891252955082" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3650728833657081" LOG_CI_START="-0.3308482651434179" LOG_EFFECT_SIZE="0.01711230911114507" ORDER="194" O_E="0.0" SE="0.40878752749950376" STUDY_ID="STD-Block-1972" TOTAL_1="47" TOTAL_2="44" VAR="0.16710724263915752" WEIGHT="41.195029165609945"/>
<DICH_DATA CI_END="0.7275201181102587" CI_START="0.06734639500567495" EFFECT_SIZE="0.22135007849293564" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.13815499263282358" LOG_CI_START="-1.1716856467271173" LOG_EFFECT_SIZE="-0.6549203196799706" ORDER="195" O_E="0.0" SE="0.6071010222742367" STUDY_ID="STD-Evans-1970" TOTAL_1="49" TOTAL_2="47" VAR="0.36857165124642327" WEIGHT="58.804970834390055"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5200123535951593" CI_END="5.549558011040864" CI_START="0.5750891023183657" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7864742748870428" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="14.77302638054794" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.7442583955533468" LOG_CI_START="-0.24026486201076264" LOG_EFFECT_SIZE="0.25199676677129207" METHOD="MH" NO="2" P_CHI2="0.31817598146613335" P_Q="0.0" P_Z="0.3156980276661825" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="179" WEIGHT="300.0" Z="1.0033375713526211">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6506988283372745" CI_END="4.8703431945710225" CI_START="0.30565179030036116" DF="1.0" EFFECT_SIZE="1.220093896713615" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="62.274099595566724" ID="CMP-008.02.01" LOG_CI_END="0.6875595653741591" LOG_CI_START="-0.5147730560649724" LOG_EFFECT_SIZE="0.08639325465459334" NO="1" P_CHI2="0.10350444089910038" P_Z="0.7782001921166998" STUDIES="2" TAU2="0.0" TOTAL_1="96" TOTAL_2="91" WEIGHT="100.0" Z="0.2816652640224029">
<NAME>Any side effect</NAME>
<DICH_DATA CI_END="123.53413046377574" CI_START="0.3486194955865132" EFFECT_SIZE="6.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.091786962650444" LOG_CI_START="-0.45764832982241765" LOG_EFFECT_SIZE="0.8170693164140133" ORDER="196" O_E="0.0" SE="1.497550910706788" STUDY_ID="STD-Block-1972" TOTAL_1="47" TOTAL_2="44" VAR="2.24265873015873" WEIGHT="14.422535211267606"/>
<DICH_DATA CI_END="2.9660412744002165" CI_START="0.03446544229362776" EFFECT_SIZE="0.3197278911564626" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47217719022558524" LOG_CI_START="-1.4626161438505025" LOG_EFFECT_SIZE="-0.4952194768124586" ORDER="197" O_E="0.0" SE="1.1365071818177597" STUDY_ID="STD-Evans-1970" TOTAL_1="49" TOTAL_2="47" VAR="1.2916485743233463" WEIGHT="85.5774647887324"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="95.00251677800429" CI_START="0.23128499112654333" DF="0.0" EFFECT_SIZE="4.6875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="1.9777351106395982" LOG_CI_START="-0.6358525491680476" LOG_EFFECT_SIZE="0.6709412807357753" NO="2" P_CHI2="1.0" P_Z="0.31427345978703847" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="44" WEIGHT="100.0" Z="1.006295496574299">
<NAME>Allergic symptoms</NAME>
<DICH_DATA CI_END="95.0025167780042" CI_START="0.23128499112654344" EFFECT_SIZE="4.6875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.977735110639598" LOG_CI_START="-0.6358525491680473" LOG_EFFECT_SIZE="0.6709412807357753" ORDER="198" O_E="0.0" SE="1.5352343288385797" STUDY_ID="STD-Block-1972" TOTAL_1="47" TOTAL_2="44" VAR="2.3569444444444443" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.27160065944743" CI_START="0.1175853729130662" DF="0.0" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-008.02.03" LOG_CI_END="1.827831761402069" LOG_CI_START="-0.9296466991632314" LOG_EFFECT_SIZE="0.4490925311194189" NO="3" P_CHI2="1.0" P_Z="0.5232048091307779" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="44" WEIGHT="100.0" Z="0.6384131004523219">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="67.27160065944743" CI_START="0.1175853729130662" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.827831761402069" LOG_CI_START="-0.9296466991632314" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="199" O_E="0.0" SE="1.6197564974745775" STUDY_ID="STD-Block-1972" TOTAL_1="47" TOTAL_2="44" VAR="2.623611111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Metronidazole versus tinidazole</NAME>
<DICH_OUTCOME CHI2="7.190341136068955" CI_END="6.317357195468997" CI_START="1.6637091586997865" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2419508054379493" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="10" I2="30.46227007341185" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.8005354334299776" LOG_CI_START="0.2210774074044304" LOG_EFFECT_SIZE="0.510806420417204" METHOD="MH" NO="1" P_CHI2="0.20686503289834757" P_Q="0.0" P_Z="5.492479976444828E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="293" TOTAL_2="302" WEIGHT="100.0" Z="3.4555123654302653">
<NAME>No parasitological cure (3-21 days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.09540656769308" CI_START="1.8852701497807993" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" LOG_CI_END="1.2809289095397058" LOG_CI_START="0.2753735912275813" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="200" O_E="0.0" SE="0.590668171555645" STUDY_ID="STD-Anjaneyulu-1977" TOTAL_1="50" TOTAL_2="50" VAR="0.3488888888888888" WEIGHT="29.238440777588075"/>
<DICH_DATA CI_END="37.080730161632154" CI_START="0.5135099074654106" EFFECT_SIZE="4.363636363636363" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5691482773075631" LOG_CI_START="-0.2894511728728387" LOG_EFFECT_SIZE="0.6398485522173621" ORDER="201" O_E="0.0" SE="1.0917505172516255" STUDY_ID="STD-Begum-1980" TOTAL_1="33" TOTAL_2="36" VAR="1.191919191919192" WEIGHT="9.322401407346922"/>
<DICH_DATA CI_END="5.566245671643115" CI_START="0.04951721793455041" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.745562370428569" LOG_CI_START="-1.3052437636166552" LOG_EFFECT_SIZE="-0.2798406965940431" ORDER="202" O_E="0.0" SE="1.2046536747922518" STUDY_ID="STD-Gabriel-1982" TOTAL_1="40" TOTAL_2="42" VAR="1.4511904761904764" WEIGHT="19.016872050463785"/>
<DICH_DATA CI_END="56.53687250741505" CI_START="0.9169237296102815" EFFECT_SIZE="7.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7523317806243375" LOG_CI_START="-0.0376667877618007" LOG_EFFECT_SIZE="0.8573324964312685" ORDER="203" O_E="0.0" SE="1.0514540197058337" STUDY_ID="STD-Garud-1978" TOTAL_1="30" TOTAL_2="36" VAR="1.1055555555555556" WEIGHT="8.860133568966083"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="204" O_E="0.0" SE="0.0" STUDY_ID="STD-Lean-1972" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.20354663171422" CI_START="0.12076845272361303" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8463590529228993" LOG_CI_START="-0.91804649781231" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="205" O_E="0.0" SE="1.6238255045300312" STUDY_ID="STD-O_x002d_Prasertsawat-1992" TOTAL_1="67" TOTAL_2="65" VAR="2.6368092691622103" WEIGHT="4.9458059026765895"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="206" O_E="0.0" SE="0.0" STUDY_ID="STD-Rao-1978" TOTAL_1="30" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7902117712953483" CI_START="0.12767939531372255" EFFECT_SIZE="0.6956521739130435" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5786634760724488" LOG_CI_START="-0.893879182795785" LOG_EFFECT_SIZE="-0.1576078533616681" ORDER="207" O_E="0.0" SE="0.8649788470229208" STUDY_ID="STD-Sandvei-1979" TOTAL_1="23" TOTAL_2="24" VAR="0.7481884057971014" WEIGHT="28.61634629295854"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17122822945700783" CI_END="2.4927283593908456" CI_START="0.13401491906207277" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5779816513761468" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.3966749546187843" LOG_CI_START="-0.8728468515928682" LOG_EFFECT_SIZE="-0.23808594848704195" METHOD="MH" NO="2" P_CHI2="0.6790228203243165" P_Q="0.0" P_Z="0.46225255870583937" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.7351427631670998">
<NAME>No parasitological cure (4 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="208" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Lean-1972" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="33.944954128440365"/>
<DICH_DATA CI_END="3.7345210116896546" CI_START="0.13260037928726534" EFFECT_SIZE="0.7037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5722349072705821" LOG_CI_START="-0.8774552336828987" LOG_EFFECT_SIZE="-0.15261016320615833" ORDER="209" O_E="0.0" SE="0.8515551648780068" STUDY_ID="STD-Sandvei-1979" TOTAL_1="18" TOTAL_2="19" VAR="0.7251461988304093" WEIGHT="66.05504587155963"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.209549563524394" CI_END="7.901933509557831" CI_START="1.833176069843865" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.8059999231764" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" I2="23.217929856993294" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.8977333710106232" LOG_CI_START="0.263204179359028" LOG_EFFECT_SIZE="0.5804687751848256" METHOD="MH" NO="3" P_CHI2="0.26646428725767135" P_Q="0.0" P_Z="3.358414789424042E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="210" TOTAL_2="216" WEIGHT="100.00000000000003" Z="3.5859591914157933">
<NAME>No clinical improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="29.215727759651852" CI_START="1.6771788265247685" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4656167089952299" LOG_CI_START="0.22457937103328363" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="210" O_E="0.0" SE="0.728991475552747" STUDY_ID="STD-Anjaneyulu-1977" TOTAL_1="50" TOTAL_2="50" VAR="0.5314285714285714" WEIGHT="23.712372440813823"/>
<DICH_DATA CI_END="37.080730161632154" CI_START="0.5135099074654106" EFFECT_SIZE="4.363636363636363" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5691482773075631" LOG_CI_START="-0.2894511728728387" LOG_EFFECT_SIZE="0.6398485522173621" ORDER="211" O_E="0.0" SE="1.0917505172516255" STUDY_ID="STD-Begum-1980" TOTAL_1="33" TOTAL_2="36" VAR="1.191919191919192" WEIGHT="11.340699862997916"/>
<DICH_DATA CI_END="56.53687250741505" CI_START="0.9169237296102815" EFFECT_SIZE="7.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7523317806243375" LOG_CI_START="-0.0376667877618007" LOG_EFFECT_SIZE="0.8573324964312685" ORDER="212" O_E="0.0" SE="1.0514540197058337" STUDY_ID="STD-Garud-1978" TOTAL_1="30" TOTAL_2="36" VAR="1.1055555555555556" WEIGHT="10.778351109460829"/>
<DICH_DATA CI_END="3.717067588814234" CI_START="0.2532075492379538" EFFECT_SIZE="0.9701492537313433" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5702004581046541" LOG_CI_START="-0.5965233502205958" LOG_EFFECT_SIZE="-0.013161446057970849" ORDER="213" O_E="0.0" SE="0.6853393403862471" STUDY_ID="STD-O_x002d_Prasertsawat-1992" TOTAL_1="67" TOTAL_2="65" VAR="0.46969001148105627" WEIGHT="48.14330162225837"/>
<DICH_DATA CI_END="125.6476695477666" CI_START="0.3652252238038033" EFFECT_SIZE="6.774193548387097" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0991544379191938" LOG_CI_START="-0.43743923611990043" LOG_EFFECT_SIZE="0.8308576008996467" ORDER="214" O_E="0.0" SE="1.4900076804717564" STUDY_ID="STD-Rao-1978" TOTAL_1="30" TOTAL_2="29" VAR="2.2201228878648234" WEIGHT="6.025274964469086"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.69542299281002" CI_END="1.8347381552667996" CI_START="1.3314930158964629" CI_STUDY="95" CI_TOTAL="95" DF="23.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5629910555523034" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="157" I2="33.70883529863198" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.26357409265515275" LOG_CI_START="0.12433889276851455" LOG_EFFECT_SIZE="0.19395649271183366" METHOD="MH" NO="4" P_CHI2="0.05574916022613885" P_Q="0.0" P_Z="4.747633824473464E-8" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1119" TOTAL_2="1114" WEIGHT="900.0" Z="5.460512005475715">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.291155198972362" CI_END="2.0236007457208336" CI_START="1.3455857407254976" DF="4.0" EFFECT_SIZE="1.6501297853088517" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="67" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="0.3061248307792177" LOG_CI_START="0.1289113762265446" LOG_EFFECT_SIZE="0.21751810350288114" NO="1" P_CHI2="0.5103350397883332" P_Z="1.498323601534016E-6" STUDIES="6" TAU2="0.0" TOTAL_1="226" TOTAL_2="232" WEIGHT="100.00000000000001" Z="4.811459151645683">
<NAME>Any side effect</NAME>
<DICH_DATA CI_END="2.120728118614574" CI_START="1.1725625593897642" EFFECT_SIZE="1.5769230769230769" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="26" LOG_CI_END="0.3264849947051894" LOG_CI_START="0.06913602279264562" LOG_EFFECT_SIZE="0.1978105087489175" ORDER="215" O_E="0.0" SE="0.15116805999938437" STUDY_ID="STD-Anjaneyulu-1977" TOTAL_1="50" TOTAL_2="50" VAR="0.022851782363977478" WEIGHT="39.61799941250904"/>
<DICH_DATA CI_END="1.9306131915669826" CI_START="1.0189920396100876" EFFECT_SIZE="1.4025974025974026" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.285695269328021" LOG_CI_START="0.008170791300914696" LOG_EFFECT_SIZE="0.14693303031446783" ORDER="216" O_E="0.0" SE="0.16301925216144433" STUDY_ID="STD-Begum-1980" TOTAL_1="33" TOTAL_2="36" VAR="0.02657527657527657" WEIGHT="30.60788583374444"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="217" O_E="0.0" SE="0.0" STUDY_ID="STD-Gabriel-1982" TOTAL_1="40" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.064904320523248" CI_START="0.5946352020831954" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.48641692136099984" LOG_CI_START="-0.22574938437098754" LOG_EFFECT_SIZE="0.13033376849500614" ORDER="218" O_E="0.0" SE="0.4183300132670378" STUDY_ID="STD-Garud-1978" TOTAL_1="30" TOTAL_2="36" VAR="0.175" WEIGHT="11.081957877624907"/>
<DICH_DATA CI_END="3.9518999288381162" CI_START="1.361977807363776" EFFECT_SIZE="2.32" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" LOG_CI_END="0.5968059387233696" LOG_CI_START="0.13417003105842976" LOG_EFFECT_SIZE="0.3654879848908996" ORDER="219" O_E="0.0" SE="0.2717546222470626" STUDY_ID="STD-Rao-1978" TOTAL_1="30" TOTAL_2="29" VAR="0.07385057471264368" WEIGHT="15.495958049221267"/>
<DICH_DATA CI_END="12.69836034318998" CI_START="0.5830249835695758" EFFECT_SIZE="2.7209302325581395" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.103747646949905" LOG_CI_START="-0.23431283461675478" LOG_EFFECT_SIZE="0.4347174061665751" ORDER="220" O_E="0.0" SE="0.7859833503784622" STUDY_ID="STD-Sandvei-1979" TOTAL_1="43" TOTAL_2="39" VAR="0.6177698270721526" WEIGHT="3.1961988269003543"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.029710017807904276" CI_END="26.34183888779386" CI_START="0.7878374212276253" DF="1.0" EFFECT_SIZE="4.555555555555556" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-009.04.02" LOG_CI_END="1.4206460891886283" LOG_CI_START="-0.10356339462780692" LOG_EFFECT_SIZE="0.6585413472804107" NO="2" P_CHI2="0.8631498800654887" P_Z="0.09033714332921265" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="86" WEIGHT="100.0" Z="1.693621955124292">
<NAME>Side effect requiring treatment</NAME>
<DICH_DATA CI_END="41.28023140889969" CI_START="0.6056167600506762" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6157421231958629" LOG_CI_START="-0.2178021145238255" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="221" O_E="0.0" SE="1.0770329614269007" STUDY_ID="STD-Anjaneyulu-1977" TOTAL_1="50" TOTAL_2="50" VAR="1.16" WEIGHT="68.68686868686869"/>
<DICH_DATA CI_END="84.80656864778499" CI_START="0.1511795604456008" EFFECT_SIZE="3.5806451612903225" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9284294916081937" LOG_CI_START="-0.820506921703424" LOG_EFFECT_SIZE="0.5539612849523847" ORDER="222" O_E="0.0" SE="1.6147388566339482" STUDY_ID="STD-Garud-1978" TOTAL_1="30" TOTAL_2="36" VAR="2.6073815751235103" WEIGHT="31.313131313131315"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.034262771130339" CI_END="1.5126125676142679" CI_START="0.572666410076796" DF="1.0" EFFECT_SIZE="0.9307107009875344" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="83.42796729396191" ID="CMP-009.04.03" LOG_CI_END="0.17972770443167022" LOG_CI_START="-0.2420982898151082" LOG_EFFECT_SIZE="-0.031185292691718967" NO="3" P_CHI2="0.014030865747485133" P_Z="0.7719711927010793" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="94" WEIGHT="99.99999999999999" Z="0.28979745846270183">
<NAME>Bitter taste</NAME>
<DICH_DATA CI_END="1.101729066075605" CI_START="0.37968180239853166" EFFECT_SIZE="0.6467661691542289" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="0.042074807242567056" LOG_CI_START="-0.4205802174698712" LOG_EFFECT_SIZE="-0.18925270511365205" ORDER="223" O_E="0.0" SE="0.271765851695394" STUDY_ID="STD-O_x002d_Prasertsawat-1992" TOTAL_1="67" TOTAL_2="65" VAR="0.07385667814772291" WEIGHT="95.99320058280718"/>
<DICH_DATA CI_END="58.01862956349359" CI_START="1.0307800252158055" EFFECT_SIZE="7.733333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7635674662790952" LOG_CI_START="0.013165994063378955" LOG_EFFECT_SIZE="0.8883667301712372" ORDER="224" O_E="0.0" SE="1.0281944894065407" STUDY_ID="STD-Rao-1978" TOTAL_1="30" TOTAL_2="29" VAR="1.0571839080459768" WEIGHT="4.006799417192812"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9280733762835447" CI_END="3.2238100954273943" CI_START="0.8386288827429731" DF="1.0" EFFECT_SIZE="1.6442567495691764" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="65.84785039542795" ID="CMP-009.04.04" LOG_CI_END="0.5083694509565391" LOG_CI_START="-0.07643018438428797" LOG_EFFECT_SIZE="0.2159696332861256" NO="4" P_CHI2="0.08705147324782059" P_Z="0.14771485771255344" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="94" WEIGHT="100.0" Z="1.44765036574768">
<NAME>Anorexia</NAME>
<DICH_DATA CI_END="2.3716393988121394" CI_START="0.5542807369812701" EFFECT_SIZE="1.146540027137042" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.3750486564412595" LOG_CI_START="-0.2562702142599778" LOG_EFFECT_SIZE="0.05938922109064087" ORDER="225" O_E="0.0" SE="0.3708398297287174" STUDY_ID="STD-O_x002d_Prasertsawat-1992" TOTAL_1="67" TOTAL_2="65" VAR="0.1375221793132241" WEIGHT="95.64708635619003"/>
<DICH_DATA CI_END="213.67652495550573" CI_START="0.7407113753242429" EFFECT_SIZE="12.580645161290322" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.329756812092499" LOG_CI_START="-0.13035098570804618" LOG_EFFECT_SIZE="1.0997029131922265" ORDER="226" O_E="0.0" SE="1.4450794981580395" STUDY_ID="STD-Rao-1978" TOTAL_1="30" TOTAL_2="29" VAR="2.0882547559966915" WEIGHT="4.35291364380997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.355489022620704" CI_END="2.168072905657938" CI_START="1.0319068671767837" DF="3.0" EFFECT_SIZE="1.4957437346980094" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="33" I2="52.796708651021454" ID="CMP-009.04.05" LOG_CI_END="0.3360738821064688" LOG_CI_START="0.013640502624148596" LOG_EFFECT_SIZE="0.17485719236530867" NO="5" P_CHI2="0.09553935199484698" P_Z="0.0335202465062582" STUDIES="4" TAU2="0.0" TOTAL_1="173" TOTAL_2="169" WEIGHT="100.0" Z="2.125796032805524">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="2.232770393477789" CI_START="0.7096249399785362" EFFECT_SIZE="1.2587412587412588" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.3488440647764935" LOG_CI_START="-0.14897112950000493" LOG_EFFECT_SIZE="0.09993646763824425" ORDER="227" O_E="0.0" SE="0.2924191093429694" STUDY_ID="STD-Begum-1980" TOTAL_1="33" TOTAL_2="36" VAR="0.0855089355089355" WEIGHT="37.931475307842895"/>
<DICH_DATA CI_END="1.8151740665531566" CI_START="0.44180905968924367" EFFECT_SIZE="0.8955223880597015" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.25891827814279184" LOG_CI_START="-0.35476538277715736" LOG_EFFECT_SIZE="-0.04792355231718278" ORDER="228" O_E="0.0" SE="0.36048082020749245" STUDY_ID="STD-O_x002d_Prasertsawat-1992" TOTAL_1="67" TOTAL_2="65" VAR="0.1299464217374665" WEIGHT="40.25647620481123"/>
<DICH_DATA CI_END="6.8637095950221045" CI_START="1.5126974569134983" EFFECT_SIZE="3.2222222222222223" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" LOG_CI_END="0.8365589001396746" LOG_CI_START="0.17975207677958777" LOG_EFFECT_SIZE="0.5081554884596312" ORDER="229" O_E="0.0" SE="0.3858115792879261" STUDY_ID="STD-Rao-1978" TOTAL_1="30" TOTAL_2="29" VAR="0.14885057471264368" WEIGHT="18.61281353259092"/>
<DICH_DATA CI_END="19.230844901029585" CI_START="0.17110154415530238" EFFECT_SIZE="1.813953488372093" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2839983652470175" LOG_CI_START="-0.7667460710252298" LOG_EFFECT_SIZE="0.2586261471108939" ORDER="230" O_E="0.0" SE="1.2046174332149964" STUDY_ID="STD-Sandvei-1979" TOTAL_1="43" TOTAL_2="39" VAR="1.451103160405486" WEIGHT="3.199234954754957"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6996094838311648" CI_END="8.157790541951957" CI_START="1.4211817048875672" DF="3.0" EFFECT_SIZE="3.404952667883499" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" I2="0.0" ID="CMP-009.04.06" LOG_CI_END="0.9115725502526785" LOG_CI_START="0.15264960810696326" LOG_EFFECT_SIZE="0.5321110791798209" NO="6" P_CHI2="0.873295818425715" P_Z="0.0059883701414472496" STUDIES="4" TAU2="0.0" TOTAL_1="173" TOTAL_2="169" WEIGHT="100.00000000000001" Z="2.748417508682843">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="12.08078470643126" CI_START="1.0945597340898208" EFFECT_SIZE="3.6363636363636362" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.082095144765631" LOG_CI_START="0.03923946757384385" LOG_EFFECT_SIZE="0.5606673061697374" ORDER="231" O_E="0.0" SE="0.6125785870013131" STUDY_ID="STD-Begum-1980" TOTAL_1="33" TOTAL_2="36" VAR="0.3752525252525253" WEIGHT="48.375352864712696"/>
<DICH_DATA CI_END="10.232494274529142" CI_START="0.3679218572770878" EFFECT_SIZE="1.9402985074626866" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0099815103130467" LOG_CI_START="-0.43424441110102596" LOG_EFFECT_SIZE="0.2878685496060103" ORDER="232" O_E="0.0" SE="0.8483454552722354" STUDY_ID="STD-O_x002d_Prasertsawat-1992" TOTAL_1="67" TOTAL_2="65" VAR="0.7196900114810563" WEIGHT="34.227005860662196"/>
<DICH_DATA CI_END="125.6476695477666" CI_START="0.3652252238038033" EFFECT_SIZE="6.774193548387097" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0991544379191938" LOG_CI_START="-0.43743923611990043" LOG_EFFECT_SIZE="0.8308576008996467" ORDER="233" O_E="0.0" SE="1.4900076804717564" STUDY_ID="STD-Rao-1978" TOTAL_1="30" TOTAL_2="29" VAR="2.2201228878648234" WEIGHT="8.567219719955329"/>
<DICH_DATA CI_END="91.8492054567256" CI_START="0.22494649705519573" EFFECT_SIZE="4.545454545454546" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9630754037855158" LOG_CI_START="-0.6479207654299282" LOG_EFFECT_SIZE="0.6575773191777938" ORDER="234" O_E="0.0" SE="1.5337120744366353" STUDY_ID="STD-Sandvei-1979" TOTAL_1="43" TOTAL_2="39" VAR="2.352272727272727" WEIGHT="8.83042155466978"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.060237358793312" CI_START="0.48775448324263604" DF="0.0" EFFECT_SIZE="2.425373134328358" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-009.04.07" LOG_CI_END="1.081355855283383" LOG_CI_START="-0.31179873005524933" LOG_EFFECT_SIZE="0.38477856261406673" NO="7" P_CHI2="1.0" P_Z="0.27896208856441984" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="65" WEIGHT="100.0" Z="1.0826539031393279">
<NAME>Ataxia</NAME>
<DICH_DATA CI_END="12.060237358793312" CI_START="0.48775448324263604" EFFECT_SIZE="2.425373134328358" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.081355855283383" LOG_CI_START="-0.31179873005524933" LOG_EFFECT_SIZE="0.38477856261406673" ORDER="235" O_E="0.0" SE="0.8183458996543309" STUDY_ID="STD-O_x002d_Prasertsawat-1992" TOTAL_1="67" TOTAL_2="65" VAR="0.6696900114810562" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5576953304759735" CI_END="2.7170374530938624" CI_START="0.5949802441331532" DF="2.0" EFFECT_SIZE="1.2714494119549968" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="43.78383154769956" ID="CMP-009.04.08" LOG_CI_END="0.43409562500599774" LOG_CI_START="-0.22549745445027253" LOG_EFFECT_SIZE="0.10429908527786266" NO="8" P_CHI2="0.16883264226279893" P_Z="0.535360412144876" STUDIES="4" TAU2="0.0" TOTAL_1="173" TOTAL_2="169" WEIGHT="100.00000000000001" Z="0.6198441346097702">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="2.9009031839436403" CI_START="0.008331367644240426" EFFECT_SIZE="0.15546218487394958" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.462533234703846" LOG_CI_START="-2.07928370068288" LOG_EFFECT_SIZE="-0.808375232989517" ORDER="236" O_E="0.0" SE="1.493075850042916" STUDY_ID="STD-Begum-1980" TOTAL_1="33" TOTAL_2="36" VAR="2.229275493981376" WEIGHT="32.030541221213376"/>
<DICH_DATA CI_END="4.632962355631103" CI_START="0.20315070623691117" EFFECT_SIZE="0.9701492537313433" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6658587714295515" LOG_CI_START="-0.6921816635454933" LOG_EFFECT_SIZE="-0.013161446057970849" ORDER="237" O_E="0.0" SE="0.7977196739129121" STUDY_ID="STD-O_x002d_Prasertsawat-1992" TOTAL_1="67" TOTAL_2="65" VAR="0.6363566781477228" WEIGHT="29.10032173210696"/>
<DICH_DATA CI_END="6.845156764584485" CI_START="0.8531985429456113" EFFECT_SIZE="2.4166666666666665" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8353833985933693" LOG_CI_START="-0.06894989489070684" LOG_EFFECT_SIZE="0.3832167518513312" ORDER="238" O_E="0.0" SE="0.5312098531145455" STUDY_ID="STD-Rao-1978" TOTAL_1="30" TOTAL_2="29" VAR="0.282183908045977" WEIGHT="38.869137046679676"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="239" O_E="0.0" SE="0.0" STUDY_ID="STD-Sandvei-1979" TOTAL_1="43" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.084762960430641" CI_START="0.12948746964228935" DF="0.0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-009.04.09" LOG_CI_END="0.6111668594084917" LOG_CI_START="-0.8877722557410546" LOG_EFFECT_SIZE="-0.13830269816628143" NO="9" P_CHI2="1.0" P_Z="0.7175910177376401" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="36" WEIGHT="100.0" Z="0.3616802105315418">
<NAME>Abdominal discomfort</NAME>
<DICH_DATA CI_END="4.084762960430641" CI_START="0.1294874696422894" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6111668594084917" LOG_CI_START="-0.8877722557410545" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="240" O_E="0.0" SE="0.8804842561071294" STUDY_ID="STD-Begum-1980" TOTAL_1="33" TOTAL_2="36" VAR="0.7752525252525252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Metronidazole versus nitrimidazine</NAME>
<DICH_OUTCOME CHI2="4.062627433302774" CI_END="1.094768604245608" CI_START="0.23002014877288965" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5018155410312274" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="75.38538750064426" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.03932233422730966" LOG_CI_START="-0.63823411999276" LOG_EFFECT_SIZE="-0.29945589288272517" METHOD="MH" NO="1" P_CHI2="0.043842327482451204" P_Q="0.0" P_Z="0.08319009789405506" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="95" WEIGHT="100.00000000000001" Z="1.7324689665425097">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8486371166920625" CI_START="0.014547653843457145" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.07127797749276538" LOG_CI_START="-1.8372070413858845" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="241" O_E="0.0" SE="1.0373154736206653" STUDY_ID="STD-Evans-1971" TOTAL_1="57" TOTAL_2="57" VAR="1.0760233918128654" WEIGHT="54.2483660130719"/>
<DICH_DATA CI_END="2.416538145568932" CI_START="0.3854183649489686" EFFECT_SIZE="0.9650793650793651" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3831936549598335" LOG_CI_START="-0.414067595321527" LOG_EFFECT_SIZE="-0.01543697018084676" ORDER="242" O_E="0.0" SE="0.46831520492210843" STUDY_ID="STD-McClean-1972" TOTAL_1="45" TOTAL_2="38" VAR="0.2193191311612364" WEIGHT="45.75163398692811"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.11266385611417915" CI_END="5.088862973420433" CI_START="0.45814965378106265" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5269121813031161" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.7066207568885085" LOG_CI_START="-0.3389926372906762" LOG_EFFECT_SIZE="0.18381405979891613" METHOD="MH" NO="2" P_CHI2="0.9452253415147606" P_Q="0.0" P_Z="0.4907569239858802" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="147" TOTAL_2="133" WEIGHT="200.0" Z="0.6891054362224991">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.719883756968056" CI_START="0.32710822282843355" DF="0.0" EFFECT_SIZE="1.6888888888888889" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="0.940510695478" LOG_CI_START="-0.48530853846710476" LOG_EFFECT_SIZE="0.22760107850544767" NO="1" P_CHI2="1.0" P_Z="0.5314911522611836" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="38" WEIGHT="100.0" Z="0.6257313775728259">
<NAME>Any side effect</NAME>
<DICH_DATA CI_END="8.719883756968056" CI_START="0.32710822282843355" EFFECT_SIZE="1.6888888888888889" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.940510695478" LOG_CI_START="-0.48530853846710476" LOG_EFFECT_SIZE="0.22760107850544767" ORDER="243" O_E="0.0" SE="0.8375332759383913" STUDY_ID="STD-McClean-1972" TOTAL_1="45" TOTAL_2="38" VAR="0.7014619883040936" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0804208119651533" CI_END="8.025187711611819" CI_START="0.2299261243103766" DF="1.0" EFFECT_SIZE="1.3583815028901731" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-010.02.02" LOG_CI_END="0.9044551994773808" LOG_CI_START="-0.6384116811914993" LOG_EFFECT_SIZE="0.13302175914294076" NO="2" P_CHI2="0.7767279572151767" P_Z="0.7353892177785668" STUDIES="2" TAU2="0.0" TOTAL_1="102" TOTAL_2="95" WEIGHT="100.0" Z="0.3379654594274477">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="15.601794815114387" CI_START="0.06409518980670356" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1931745620380056" LOG_CI_START="-1.1931745620380056" LOG_EFFECT_SIZE="0.0" ORDER="244" O_E="0.0" SE="1.4017532881009247" STUDY_ID="STD-Evans-1971" TOTAL_1="57" TOTAL_2="57" VAR="1.9649122807017543" WEIGHT="47.97687861271676"/>
<DICH_DATA CI_END="17.910184739093324" CI_START="0.15925830585021325" EFFECT_SIZE="1.6888888888888889" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2531000655115128" LOG_CI_START="-0.7978979085006173" LOG_EFFECT_SIZE="0.22760107850544767" ORDER="245" O_E="0.0" SE="1.2047663625384357" STUDY_ID="STD-McClean-1972" TOTAL_1="45" TOTAL_2="38" VAR="1.4514619883040936" WEIGHT="52.02312138728323"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2008-10-08 14:45:05 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Intravaginal: metronidazole versus methyl patricin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8626204381683618" CI_START="0.8942855175162543" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.45676376767339244" LOG_CI_START="-0.0485238023615429" LOG_EFFECT_SIZE="0.2041199826559248" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.11330179467416467" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="1.5835252567281342">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8626204381683618" CI_START="0.8942855175162543" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.45676376767339244" LOG_CI_START="-0.0485238023615429" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="246" O_E="0.0" SE="0.2968084198523318" STUDY_ID="STD-Iannino-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.08809523809523809" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2008-10-08 14:45:13 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Intravaginal: metronidazole versus lotrimazole</NAME>
<DICH_OUTCOME CHI2="2.0587494390658465" CI_END="0.8683892794423822" CI_START="0.45361734453289093" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6276276276276276" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="63" I2="51.42682343832244" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-0.0612855466959172" LOG_CI_START="-0.3433103480946146" LOG_EFFECT_SIZE="-0.20229794739526588" METHOD="MH" NO="1" P_CHI2="0.15133436877827777" P_Q="0.0" P_Z="0.004926727289389962" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="148" TOTAL_2="154" WEIGHT="200.00000000000003" Z="2.811785978216674">
<NAME>No parasitological cure (2 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8431652250476983" CI_START="0.22293735333871403" DF="0.0" EFFECT_SIZE="0.43355855855855857" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="-0.07408731351830403" LOG_CI_START="-0.6518171590218966" LOG_EFFECT_SIZE="-0.3629522362701003" NO="1" P_CHI2="1.0" P_Z="0.013791432553444621" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="77" WEIGHT="100.00000000000001" Z="2.4626503779723645">
<NAME>Wetmount</NAME>
<DICH_DATA CI_END="0.8431652250476982" CI_START="0.22293735333871406" EFFECT_SIZE="0.43355855855855857" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="-0.07408731351830407" LOG_CI_START="-0.6518171590218966" LOG_EFFECT_SIZE="-0.3629522362701003" ORDER="247" O_E="0.0" SE="0.3393613710576679" STUDY_ID="STD-Schnell-1974" TOTAL_1="74" TOTAL_2="77" VAR="0.11516614016614016" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0771271155056872" CI_START="0.5181289998766959" DF="0.0" EFFECT_SIZE="0.7470547470547471" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="0.032266958920132184" LOG_CI_START="-0.28556209940568084" LOG_EFFECT_SIZE="-0.1266475702427743" NO="2" P_CHI2="1.0" P_Z="0.11828771927235655" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="77" WEIGHT="100.00000000000001" Z="1.5620011443439772">
<NAME>Culture</NAME>
<DICH_DATA CI_END="1.0771271155056872" CI_START="0.5181289998766959" EFFECT_SIZE="0.7470547470547471" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" LOG_CI_END="0.032266958920132184" LOG_CI_START="-0.28556209940568084" LOG_EFFECT_SIZE="-0.1266475702427743" ORDER="248" O_E="0.0" SE="0.18669436213979482" STUDY_ID="STD-Schnell-1974" TOTAL_1="74" TOTAL_2="77" VAR="0.034854784854784854" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2008-10-08 14:45:18 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Intravaginal: clotrimazole versus AVC suppositories</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4658406512369044" CI_START="0.9359850836187426" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1713261648745519" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.1660867615398241" LOG_CI_START="-0.0287310723662635" LOG_EFFECT_SIZE="0.06867784458678029" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.167012749979283" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="43" WEIGHT="100.0" Z="1.3818663232937463">
<NAME>No parasitological cure (2-3 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4658406512369042" CI_START="0.9359850836187427" EFFECT_SIZE="1.1713261648745519" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="31" LOG_CI_END="0.16608676153982405" LOG_CI_START="-0.028731072366263443" LOG_EFFECT_SIZE="0.06867784458678029" ORDER="249" O_E="0.0" SE="0.11443696000026671" STUDY_ID="STD-DuBouchet-1997" TOTAL_1="45" TOTAL_2="43" VAR="0.013095817814102642" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3026410940315265" CI_START="0.9155266758911609" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.092063492063492" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.11482477461314625" LOG_CI_START="-0.03832899704928712" LOG_EFFECT_SIZE="0.03824788878192956" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.32760765250255086" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="43" WEIGHT="100.0" Z="0.978944020556084">
<NAME>No parasitological cure (4-6 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3026410940315265" CI_START="0.9155266758911609" EFFECT_SIZE="1.092063492063492" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="35" LOG_CI_END="0.11482477461314625" LOG_CI_START="-0.03832899704928712" LOG_EFFECT_SIZE="0.03824788878192956" ORDER="250" O_E="0.0" SE="0.08996328359790998" STUDY_ID="STD-DuBouchet-1997" TOTAL_1="45" TOTAL_2="43" VAR="0.008093392395717977" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Any side effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.050924314140067" CI_START="0.006257944143209875" EFFECT_SIZE="0.11328976034858387" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3119496337677694" LOG_CI_START="-2.2035683175726937" LOG_EFFECT_SIZE="-0.9458093419024621" ORDER="251" O_E="0.0" SE="1.4776276966320705" STUDY_ID="STD-DuBouchet-1997" TOTAL_1="50" TOTAL_2="51" VAR="2.1833836098541983" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>Tinidazole versus ornidazole</NAME>
<DICH_OUTCOME CHI2="4.660950228753606" CI_END="2.0121057348109685" CI_START="0.6077988945650745" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1058732483273812" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.3036507988681809" LOG_CI_START="-0.21624009412893677" LOG_EFFECT_SIZE="0.043705352369622086" METHOD="MH" NO="1" P_CHI2="0.4586418190722992" P_Q="0.0" P_Z="0.7417519435216929" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="175" WEIGHT="100.0" Z="0.32953420700357033">
<NAME>No parasitological cure (days 3-14)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.456536051503893" CI_START="0.014668621440720757" EFFECT_SIZE="0.3522012578616352" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9271925046720503" LOG_CI_START="-1.8336106993005525" LOG_EFFECT_SIZE="-0.4532090973142511" ORDER="252" O_E="0.0" SE="1.6217094682097721" STUDY_ID="STD-Chaisilwattana-1980" TOTAL_1="52" TOTAL_2="55" VAR="2.6299415992812216" WEIGHT="9.57227149578254"/>
<DICH_DATA CI_END="2.3795105211958902" CI_START="0.4932153485588623" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.3764876294067731" LOG_CI_START="-0.3069634168883492" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="253" O_E="0.0" SE="0.40146252773099655" STUDY_ID="STD-Chunge-1992" TOTAL_1="14" TOTAL_2="13" VAR="0.16117216117216118" WEIGHT="40.83098896593754"/>
<DICH_DATA CI_END="105.84681951096839" CI_START="0.2581502239890899" EFFECT_SIZE="5.2272727272727275" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0246778128553062" LOG_CI_START="-0.5881274937924954" LOG_EFFECT_SIZE="0.7182751595314054" ORDER="254" O_E="0.0" SE="1.534774770719777" STUDY_ID="STD-Hillstroem-1977" TOTAL_1="43" TOTAL_2="45" VAR="2.3555335968379443" WEIGHT="3.2081491330379497"/>
<DICH_DATA CI_END="133.88955234184917" CI_START="0.39583671072918036" EFFECT_SIZE="7.28" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1267466895041034" LOG_CI_START="-0.4024839308780289" LOG_EFFECT_SIZE="0.8621313793130372" ORDER="255" O_E="0.0" SE="1.4856825863059535" STUDY_ID="STD-Sandvei-1979" TOTAL_1="24" TOTAL_2="25" VAR="2.2072527472527472" WEIGHT="3.2167270718963397"/>
<DICH_DATA CI_END="6.907791933318855" CI_START="0.013028765323097881" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8393392478918953" LOG_CI_START="-1.8850967384525705" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="256" O_E="0.0" SE="1.600347184554374" STUDY_ID="STD-Serup-1978" TOTAL_1="19" TOTAL_2="17" VAR="2.5611111111111113" WEIGHT="10.361247200002948"/>
<DICH_DATA CI_END="2.180121527093581" CI_START="0.16512840936896409" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3384807032720784" LOG_CI_START="-0.7821782025047912" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="257" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Sesti-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.43333333333333335" WEIGHT="32.81061613334267"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.478915392180662E-4" CI_END="14.530771024738218" CI_START="0.6503392969861088" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.074074074074074" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="1.1622886592329968" LOG_CI_START="-0.18686000279882373" LOG_EFFECT_SIZE="0.4877143282170866" METHOD="MH" NO="2" P_CHI2="0.9754387337753777" P_Q="0.0" P_Z="0.1564696260022405" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="1.417045496839534">
<NAME>No parasitological cure (4 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="29.042596403078964" CI_START="0.34165333781755347" EFFECT_SIZE="3.15" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4630354396149952" LOG_CI_START="-0.4664143320357941" LOG_EFFECT_SIZE="0.4983105537896005" ORDER="258" O_E="0.0" SE="1.1333683467980786" STUDY_ID="STD-Hillstroem-1977" TOTAL_1="40" TOTAL_2="42" VAR="1.2845238095238096" WEIGHT="49.382716049382715"/>
<DICH_DATA CI_END="26.327436276978744" CI_START="0.34184870510425597" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4204085702731564" LOG_CI_START="-0.4661660608338316" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="259" O_E="0.0" SE="1.1081832770072813" STUDY_ID="STD-Sandvei-1979" TOTAL_1="19" TOTAL_2="19" VAR="1.2280701754385965" WEIGHT="50.617283950617285"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.666891815105831" CI_START="0.15215481891868105" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.7533449217378363" LOG_CI_START="-0.817714288480639" LOG_EFFECT_SIZE="-0.03218468337140124" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.9359958304495718" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.08030355552671938">
<NAME>No clinical cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.666891815105831" CI_START="0.15215481891868105" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7533449217378363" LOG_CI_START="-0.817714288480639" LOG_EFFECT_SIZE="-0.03218468337140124" ORDER="260" O_E="0.0" SE="0.9228479569508466" STUDY_ID="STD-Chunge-1992" TOTAL_1="14" TOTAL_2="13" VAR="0.8516483516483517" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.311212110786144" CI_END="0.7280644586076261" CI_START="0.20359841839961762" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38501009371896544" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="32" I2="3.3423372497940926" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="-0.13783016906834664" LOG_CI_START="-0.6912256000238179" LOG_EFFECT_SIZE="-0.4145278845460823" METHOD="MH" NO="4" P_CHI2="0.4090567385187246" P_Q="0.0" P_Z="0.003321830283612998" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="421" TOTAL_2="446" WEIGHT="300.0" Z="2.9362718911326646">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3869784130402316" CI_END="4.228896305283548" CI_START="0.4944588181261784" DF="2.0" EFFECT_SIZE="1.4460342558489636" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-014.04.01" LOG_CI_END="0.6262270361529818" LOG_CI_START="-0.3058698735416832" LOG_EFFECT_SIZE="0.16017858130564927" NO="1" P_CHI2="0.49982907114215214" P_Z="0.5005465390715156" STUDIES="3" TAU2="0.0" TOTAL_1="134" TOTAL_2="143" WEIGHT="100.0" Z="0.673630063974002">
<NAME>Nausea/vomiting</NAME>
<DICH_DATA CI_END="3.375539620476798" CI_START="0.1864223630106055" EFFECT_SIZE="0.7932692307692307" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5283432098965943" LOG_CI_START="-0.7295019913943048" LOG_EFFECT_SIZE="-0.10057939074885529" ORDER="261" O_E="0.0" SE="0.7388644976724391" STUDY_ID="STD-Chaisilwattana-1980" TOTAL_1="52" TOTAL_2="55" VAR="0.5459207459207458" WEIGHT="72.78828218942027"/>
<DICH_DATA CI_END="29.02955803126674" CI_START="0.33953941963168377" EFFECT_SIZE="3.13953488372093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4628404238425872" LOG_CI_START="-0.46910979801174824" LOG_EFFECT_SIZE="0.4968653129154196" ORDER="262" O_E="0.0" SE="1.13483712362507" STUDY_ID="STD-Hillstroem-1977" TOTAL_1="43" TOTAL_2="45" VAR="1.2878552971576227" WEIGHT="18.296486361097173"/>
<DICH_DATA CI_END="78.70912807961442" CI_START="0.1383575230179751" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8960251014152905" LOG_CI_START="-0.8589972216595154" LOG_EFFECT_SIZE="0.5185139398778874" ORDER="263" O_E="0.0" SE="1.6183137501545841" STUDY_ID="STD-Sandvei-1979" TOTAL_1="39" TOTAL_2="43" VAR="2.6189393939393937" WEIGHT="8.915231449482564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3837690973107855" CI_END="0.5849497112885115" CI_START="0.05246510026150716" DF="3.0" EFFECT_SIZE="0.17518403252206352" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="17" I2="0.0" ID="CMP-014.04.02" LOG_CI_END="-0.23288146904377277" LOG_CI_START="-1.280129492858098" LOG_EFFECT_SIZE="-0.7565054809509354" NO="2" P_CHI2="0.9435746391316078" P_Z="0.004630752186242717" STUDIES="4" TAU2="0.0" TOTAL_1="153" TOTAL_2="160" WEIGHT="100.0" Z="2.83165680536795">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="2.2888725603212716" CI_START="0.030547600081174204" EFFECT_SIZE="0.2644230769230769" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3596216127313347" LOG_CI_START="-1.51502290366837" LOG_EFFECT_SIZE="-0.5777006454685176" ORDER="264" O_E="0.0" SE="1.1011754685732027" STUDY_ID="STD-Chaisilwattana-1980" TOTAL_1="52" TOTAL_2="55" VAR="1.2125874125874128" WEIGHT="22.246093149336815"/>
<DICH_DATA CI_END="2.0950751431419397" CI_START="0.0064405905026598265" EFFECT_SIZE="0.11616161616161616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3211996042315032" LOG_CI_START="-2.1910743127193792" LOG_EFFECT_SIZE="-0.9349373542439382" ORDER="265" O_E="0.0" SE="1.475722134773402" STUDY_ID="STD-Hillstroem-1977" TOTAL_1="43" TOTAL_2="45" VAR="2.1777558190601667" WEIGHT="25.1765881122783"/>
<DICH_DATA CI_END="1.052715751474578" CI_START="0.0180433262516523" EFFECT_SIZE="0.13782051282051283" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.022311121203628045" LOG_CI_START="-1.7436833980813407" LOG_EFFECT_SIZE="-0.8606861384388562" ORDER="266" O_E="0.0" SE="1.0373539224418473" STUDY_ID="STD-Sandvei-1979" TOTAL_1="39" TOTAL_2="43" VAR="1.076103160405486" WEIGHT="43.54265793254339"/>
<DICH_DATA CI_END="6.907791933318855" CI_START="0.013028765323097881" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8393392478918953" LOG_CI_START="-1.8850967384525705" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="267" O_E="0.0" SE="1.600347184554374" STUDY_ID="STD-Serup-1978" TOTAL_1="19" TOTAL_2="17" VAR="2.5611111111111113" WEIGHT="9.034660805841494"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2656103544398438" CI_END="0.8729807076928919" CI_START="0.04377108366677897" DF="2.0" EFFECT_SIZE="0.19547713829476196" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" I2="0.0" ID="CMP-014.04.03" LOG_CI_END="-0.0589953538145903" LOG_CI_START="-1.358812701166725" LOG_EFFECT_SIZE="-0.7089040274906577" NO="3" P_CHI2="0.5310999055618322" P_Z="0.03252653295246931" STUDIES="3" TAU2="0.0" TOTAL_1="134" TOTAL_2="143" WEIGHT="100.0" Z="2.137879395451199">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="5.659147952923319" CI_START="0.04942055884815624" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7527510482909081" LOG_CI_START="-1.306092347899981" LOG_EFFECT_SIZE="-0.2766706498045365" ORDER="268" O_E="0.0" SE="1.2093748023617048" STUDY_ID="STD-Chaisilwattana-1980" TOTAL_1="52" TOTAL_2="55" VAR="1.4625874125874128" WEIGHT="18.419809729437958"/>
<DICH_DATA CI_END="8.328223511920122" CI_START="0.014581944090440085" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9205523722050446" LOG_CI_START="-1.8361845712535962" LOG_EFFECT_SIZE="-0.45781609952427577" ORDER="269" O_E="0.0" SE="1.6193209266555566" STUDY_ID="STD-Hillstroem-1977" TOTAL_1="43" TOTAL_2="45" VAR="2.622200263504611" WEIGHT="13.897510289454152"/>
<DICH_DATA CI_END="1.2432973017473525" CI_START="0.004325415787695954" EFFECT_SIZE="0.07333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.09457499112732581" LOG_CI_START="-2.363972138922238" LOG_EFFECT_SIZE="-1.1346985738974562" ORDER="270" O_E="0.0" SE="1.444162754195683" STUDY_ID="STD-Sandvei-1979" TOTAL_1="39" TOTAL_2="43" VAR="2.0856060606060605" WEIGHT="67.6826799811079"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" NO="15">
<NAME>Tinidazole versus nimorazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.322184487288553" CI_START="1.5084983588530352" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="0.9695176934279961" LOG_CI_START="0.17854484202744175" LOG_EFFECT_SIZE="0.5740312677277188" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.00444390245777387" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="45" WEIGHT="100.0" Z="2.844802090878464">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.322184487288553" CI_START="1.5084983588530352" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.9695176934279961" LOG_CI_START="0.17854484202744175" LOG_EFFECT_SIZE="0.5740312677277188" ORDER="271" O_E="0.0" SE="0.4646213682914464" STUDY_ID="STD-Chunge-1992" TOTAL_1="14" TOTAL_2="45" VAR="0.21587301587301588" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.56291658597223" CI_START="0.397117517933542" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="1.063067392685887" LOG_CI_START="-0.40108095460303805" LOG_EFFECT_SIZE="0.3309932190414244" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3755313695439322" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="45" WEIGHT="100.0" Z="0.8861599163081968">
<NAME>No clinical cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.56291658597223" CI_START="0.397117517933542" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="1.063067392685887" LOG_CI_START="-0.40108095460303805" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="272" O_E="0.0" SE="0.8600479868487221" STUDY_ID="STD-Chunge-1992" TOTAL_1="14" TOTAL_2="45" VAR="0.7396825396825396" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" NO="16">
<NAME>Tinidazole versus carnidazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="112.11501773732273" CI_START="0.2768658200568364" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.571428571428571" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="2.0496637899688666" LOG_CI_START="-0.5577306559443815" LOG_EFFECT_SIZE="0.7459665670122424" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.26208451786578035" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="38" WEIGHT="100.0" Z="1.1214778855624097">
<NAME>No parasitological cure (1 week)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="112.11501773732273" CI_START="0.2768658200568364" EFFECT_SIZE="5.571428571428571" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0496637899688666" LOG_CI_START="-0.5577306559443815" LOG_EFFECT_SIZE="0.7459665670122424" ORDER="273" O_E="0.0" SE="1.5315964043401074" STUDY_ID="STD-Chaudhuri-1980" TOTAL_1="34" TOTAL_2="38" VAR="2.345787545787546" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="103.43193856513268" CI_START="0.2542588701495604" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.128205128205129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="2.0146546644911494" LOG_CI_START="-0.5947238872161855" LOG_EFFECT_SIZE="0.709965388637482" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.28617848293600157" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="1.066542522999566">
<NAME>No parasitological cure (2 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="103.43193856513277" CI_START="0.2542588701495603" EFFECT_SIZE="5.128205128205129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.01465466449115" LOG_CI_START="-0.5947238872161857" LOG_EFFECT_SIZE="0.709965388637482" ORDER="274" O_E="0.0" SE="1.5327618779050367" STUDY_ID="STD-Chaudhuri-1980" TOTAL_1="38" TOTAL_2="39" VAR="2.3493589743589745" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-016.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="76" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Any side effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9080547462682512" CI_START="0.2672590761443856" EFFECT_SIZE="0.4926315789473684" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="25" LOG_CI_END="-0.04188796724381695" LOG_CI_START="-0.5730675371856304" LOG_EFFECT_SIZE="-0.30747775221472373" ORDER="275" O_E="0.0" SE="0.31201750876509865" STUDY_ID="STD-Chaudhuri-1980" TOTAL_1="76" TOTAL_2="78" VAR="0.0973549257759784" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" NO="17">
<NAME>Ornidazole versus nimorazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.93698314703089" CI_START="1.3407486982551702" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.461538461538462" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="0.9511909389620766" LOG_CI_START="0.12734738397493722" LOG_EFFECT_SIZE="0.539269161468507" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.010290989919869285" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="45" WEIGHT="100.00000000000001" Z="2.5658952553628662">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.93698314703089" CI_START="1.3407486982551702" EFFECT_SIZE="3.4615384615384617" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.9511909389620766" LOG_CI_START="0.12734738397493722" LOG_EFFECT_SIZE="0.5392691614685069" ORDER="276" O_E="0.0" SE="0.4839297822908135" STUDY_ID="STD-Chunge-1992" TOTAL_1="13" TOTAL_2="45" VAR="0.23418803418803416" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.374510068830123" CI_START="0.43035592983971044" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="1.0925280133740416" LOG_CI_START="-0.36617220854839044" LOG_EFFECT_SIZE="0.36317790241282566" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.32908492831912894" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="45" WEIGHT="100.00000000000001" Z="0.9759587309472448">
<NAME>No clinical cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.37451006883012" CI_START="0.4303559298397105" EFFECT_SIZE="2.3076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="1.0925280133740416" LOG_CI_START="-0.3661722085483904" LOG_EFFECT_SIZE="0.36317790241282566" ORDER="277" O_E="0.0" SE="0.8568477310397887" STUDY_ID="STD-Chunge-1992" TOTAL_1="13" TOTAL_2="45" VAR="0.7341880341880341" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" NO="18">
<NAME>Metronidazole low dose (1g or less) versus standard dose (1.5g or more)</NAME>
<DICH_OUTCOME CHI2="0.12324205046109694" CI_END="4.585855269258391" CI_START="1.9231034106136802" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.969692561342256" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="0.6614203441675127" LOG_CI_START="0.2840026380873537" LOG_EFFECT_SIZE="0.47271149112743327" METHOD="MH" NO="1" P_CHI2="0.7255445474622714" P_Q="0.0" P_Z="9.123150124970441E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="132" WEIGHT="100.0" Z="4.909666307447789">
<NAME>No parasitological cure (1-2 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.782517354372077" CI_START="1.6301925904646404" EFFECT_SIZE="2.792207792207792" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="14" LOG_CI_END="0.6796565546312425" LOG_CI_START="0.21223891485500443" LOG_EFFECT_SIZE="0.44594773474312344" ORDER="278" O_E="0.0" SE="0.2745634353591949" STUDY_ID="STD-Austin-1982" TOTAL_1="77" TOTAL_2="86" VAR="0.07538508003624281" WEIGHT="64.03598099117447"/>
<DICH_DATA CI_END="6.847258607707808" CI_START="1.5766774684388594" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="7" LOG_CI_END="0.83551673063927" LOG_CI_START="0.1977428613674019" LOG_EFFECT_SIZE="0.516629796003336" ORDER="279" O_E="0.0" SE="0.3746315278418642" STUDY_ID="STD-Spence-1997" TOTAL_1="52" TOTAL_2="46" VAR="0.14034878165312947" WEIGHT="35.96401900882553"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.076472144083391" CI_END="1.956646591940628" CI_START="0.34952346647803473" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8269787781361266" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-018.02" LOG_CI_END="0.2915123907933005" LOG_CI_START="-0.45652366106337505" LOG_EFFECT_SIZE="-0.08250563513503728" METHOD="MH" NO="2" P_CHI2="0.7827566478148792" P_Q="0.0" P_Z="0.665484372472771" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="277" TOTAL_2="310" WEIGHT="300.0" Z="0.4323536893306287">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.043662402079918" CI_START="0.23843298270947222" DF="0.0" EFFECT_SIZE="0.698051948051948" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-018.02.01" LOG_CI_END="0.3104091551499834" LOG_CI_START="-0.6226336683196613" LOG_EFFECT_SIZE="-0.15611225658483893" NO="1" P_CHI2="1.0" P_Z="0.5119119112944526" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="86" WEIGHT="100.0" Z="0.6558635740077899">
<NAME>Any side effect</NAME>
<DICH_DATA CI_END="2.043662402079918" CI_START="0.23843298270947222" EFFECT_SIZE="0.698051948051948" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.3104091551499834" LOG_CI_START="-0.6226336683196613" LOG_EFFECT_SIZE="-0.15611225658483893" ORDER="280" O_E="0.0" SE="0.5480739731425338" STUDY_ID="STD-Austin-1982" TOTAL_1="77" TOTAL_2="86" VAR="0.3003850800362428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1448596984124479" CI_END="9.895736982224651" CI_START="0.2876129537799811" DF="1.0" EFFECT_SIZE="1.6870513161393246" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-018.02.02" LOG_CI_END="0.9954481437061007" LOG_CI_START="-0.5411915576894517" LOG_EFFECT_SIZE="0.22712829300832446" NO="2" P_CHI2="0.703496959872232" P_Z="0.5623204021467026" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="138" WEIGHT="100.0" Z="0.5793983765512322">
<NAME>Nausea/vomiting</NAME>
<DICH_DATA CI_END="17.55326126697568" CI_START="0.0710653067715359" EFFECT_SIZE="1.1168831168831168" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2443578170223368" LOG_CI_START="-1.1483423648801652" LOG_EFFECT_SIZE="0.048007726071085825" ORDER="281" O_E="0.0" SE="1.4054839309064486" STUDY_ID="STD-Austin-1982" TOTAL_1="77" TOTAL_2="86" VAR="1.975385080036243" WEIGHT="50.159532039351234"/>
<DICH_DATA CI_END="24.123735680342648" CI_START="0.21188804498017413" EFFECT_SIZE="2.260869565217391" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3824445613344183" LOG_CI_START="-0.6738935461000057" LOG_EFFECT_SIZE="0.3542755076172063" ORDER="282" O_E="0.0" SE="1.207903183344778" STUDY_ID="STD-Spence-1997" TOTAL_1="46" TOTAL_2="52" VAR="1.4590301003344481" WEIGHT="49.840467960648766"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.9941084197413" CI_START="0.015369108336470464" DF="0.0" EFFECT_SIZE="0.3717948717948718" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-018.02.03" LOG_CI_END="0.9539581184789294" LOG_CI_START="-1.813351328061978" LOG_EFFECT_SIZE="-0.4296966047915243" NO="3" P_CHI2="1.0" P_Z="0.5427428401399921" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="86" WEIGHT="100.0" Z="0.608670541506121">
<NAME>Bitter taste</NAME>
<DICH_DATA CI_END="8.994108419741297" CI_START="0.015369108336470464" EFFECT_SIZE="0.3717948717948718" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9539581184789292" LOG_CI_START="-1.813351328061978" LOG_EFFECT_SIZE="-0.4296966047915243" ORDER="283" O_E="0.0" SE="1.625531267300814" STUDY_ID="STD-Austin-1982" TOTAL_1="77" TOTAL_2="86" VAR="2.6423519009725904" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" NO="19">
<NAME>Ornidazole 0.5-1g versus 1.5-2g</NAME>
<DICH_OUTCOME CHI2="4.030294307879059" CI_END="4.332160267699343" CI_START="0.38343285872523925" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2888338123667678" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="50.37583245248163" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="0.6367045149177223" LOG_CI_START="-0.4163106724919191" LOG_EFFECT_SIZE="0.11019692121290159" METHOD="MH" NO="1" P_CHI2="0.1333010117418183" P_Q="0.0" P_Z="0.6816472861960967" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="104" WEIGHT="100.0" Z="0.4102162995688385">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.362758616450488" CI_START="0.024662650279283858" EFFECT_SIZE="0.5740740740740741" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.1258961234262277" LOG_CI_START="-1.6079602554036194" LOG_EFFECT_SIZE="-0.2410320659886958" ORDER="284" O_E="0.0" SE="1.6058807697319817" STUDY_ID="STD-Chung-1978" TOTAL_1="17" TOTAL_2="30" VAR="2.578853046594982" WEIGHT="21.1502406063139"/>
<DICH_DATA CI_END="136.59163995086672" CI_START="0.5034611938890433" EFFECT_SIZE="8.292682926829269" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.1354241192992958" LOG_CI_START="-0.2980339986542559" LOG_EFFECT_SIZE="0.9186950603225197" ORDER="285" O_E="0.0" SE="1.4294253442978722" STUDY_ID="STD-Fugere-1983" TOTAL_1="40" TOTAL_2="19" VAR="2.0432568149210906" WEIGHT="12.899463684907294"/>
<DICH_DATA CI_END="2.8009855834715536" CI_START="0.007835768212888606" EFFECT_SIZE="0.14814814814814814" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.44731087353800414" LOG_CI_START="-2.105918419200054" LOG_EFFECT_SIZE="-0.829303772831025" ORDER="286" O_E="0.0" SE="1.4997795252431685" STUDY_ID="STD-Korner-1978" TOTAL_1="53" TOTAL_2="55" VAR="2.249338624338624" WEIGHT="65.95029570877881"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.90968600422924E-32" CI_END="240.11171810814295" CI_START="0.9523625522612568" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="15.121951219512196" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" I2="100.0" I2_Q="0.0" ID="CMP-019.02" LOG_CI_END="2.380413355332003" LOG_CI_START="-0.021197689774965747" LOG_EFFECT_SIZE="1.1796078327785184" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.05418371696295983" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="19" WEIGHT="100.0" Z="1.9253649526951324">
<NAME>No clinical cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="240.11171810814272" CI_START="0.9523625522612564" EFFECT_SIZE="15.121951219512194" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="2.3804133553320024" LOG_CI_START="-0.021197689774965896" LOG_EFFECT_SIZE="1.1796078327785184" ORDER="287" O_E="0.0" SE="1.4107182160622365" STUDY_ID="STD-Fugere-1983" TOTAL_1="40" TOTAL_2="19" VAR="1.990125885129819" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-019.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="111" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>Any side effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4240922338702975" CI_START="0.2156466323882884" EFFECT_SIZE="0.5541666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.15353811806749224" LOG_CI_START="-0.6662573195565327" LOG_EFFECT_SIZE="-0.2563596007445202" ORDER="288" O_E="0.0" SE="0.4815518981132159" STUDY_ID="STD-Fugere-1983" TOTAL_1="40" TOTAL_2="19" VAR="0.2318922305764411" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6231857732455021" CI_START="0.2508091644466557" EFFECT_SIZE="0.3953488372093023" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="43" LOG_CI_END="-0.20538246976344313" LOG_CI_START="-0.6006565986391821" LOG_EFFECT_SIZE="-0.40301953420131265" ORDER="289" O_E="0.0" SE="0.23218597994010326" STUDY_ID="STD-Korner-1978" TOTAL_1="71" TOTAL_2="71" VAR="0.05391032928074604" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" NO="20">
<NAME>Nimorazole dose comparisons</NAME>
<DICH_OUTCOME CHI2="4.13576714240075" CI_END="8.360865149103109" CI_START="0.8181254648179921" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="75.82068899025309" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.9222512188315207" LOG_CI_START="-0.08718008936068408" LOG_EFFECT_SIZE="0.41753556473541836" METHOD="MH" NO="1" P_CHI2="0.041986148905759135" P_Q="0.0" P_Z="0.10492818318040642" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="50" WEIGHT="200.0" Z="1.6214172524757677">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimantal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.100207372936071" CI_START="0.039022416538270696" DF="0.0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-020.01.01" LOG_CI_END="0.6128058222427412" LOG_CI_START="-1.4086858395868165" LOG_EFFECT_SIZE="-0.3979400086720376" NO="1" P_CHI2="1.0" P_Z="0.4403182037809835" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="20" WEIGHT="100.0" Z="0.7716560001032663">
<NAME>750mg versus 1000mg</NAME>
<DICH_DATA CI_END="4.100207372936071" CI_START="0.039022416538270696" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6128058222427412" LOG_CI_START="-1.4086858395868165" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="290" O_E="0.0" SE="1.1874342087037917" STUDY_ID="STD-Roncuzzi-1972" TOTAL_1="25" TOTAL_2="20" VAR="1.41" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="78.1173874035641" CI_START="1.2801247369345266" DF="0.0" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-020.01.02" LOG_CI_END="1.8927477100998285" LOG_CI_START="0.1072522899001715" LOG_EFFECT_SIZE="1.0" NO="2" P_CHI2="1.0" P_Z="0.02813285704814008" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="30" WEIGHT="100.0" Z="2.195428744724406">
<NAME>2g versus 3-4g</NAME>
<DICH_DATA CI_END="78.1173874035641" CI_START="1.2801247369345272" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.8927477100998285" LOG_CI_START="0.10725228990017172" LOG_EFFECT_SIZE="1.0" ORDER="291" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Chunge-1992" TOTAL_1="15" TOTAL_2="30" VAR="1.0999999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="246.76182666337377" CI_START="0.7454208324569105" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="13.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.02" LOG_CI_END="2.392277976464498" LOG_CI_START="-0.12759847407928904" LOG_EFFECT_SIZE="1.1323397511926048" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.07815865209292978" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="30" WEIGHT="100.0" Z="1.7614713849336685">
<NAME>No clinical cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="246.76182666337377" CI_START="0.7454208324569105" DF="0.0" EFFECT_SIZE="13.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-020.02.01" LOG_CI_END="2.392277976464498" LOG_CI_START="-0.12759847407928904" LOG_EFFECT_SIZE="1.1323397511926048" NO="1" P_CHI2="1.0" P_Z="0.07815865209292978" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="30" WEIGHT="100.0" Z="1.7614713849336685">
<NAME>2g versus 3-4g</NAME>
<DICH_DATA CI_END="246.76182666337377" CI_START="0.7454208324569105" EFFECT_SIZE="13.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.392277976464498" LOG_CI_START="-0.12759847407928904" LOG_EFFECT_SIZE="1.1323397511926048" ORDER="292" O_E="0.0" SE="1.4801879006390224" STUDY_ID="STD-Chunge-1992" TOTAL_1="15" TOTAL_2="30" VAR="2.1909562211981566" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" NO="21">
<NAME>Carnidazole 1.5g versus 2g</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.355333931992421" CI_START="1.162172536265472" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4947589098532497" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="0.7287865564563958" LOG_CI_START="0.0652706082484379" LOG_EFFECT_SIZE="0.3970285823524169" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.018997984577513786" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="85" WEIGHT="100.0" Z="2.345570515208904">
<NAME>No parasitological cure (1-3 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.355333931992421" CI_START="1.162172536265472" EFFECT_SIZE="2.4947589098532497" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.7287865564563958" LOG_CI_START="0.0652706082484379" LOG_EFFECT_SIZE="0.3970285823524169" ORDER="293" O_E="0.0" SE="0.38975255243426915" STUDY_ID="STD-Notowicz-1977" TOTAL_1="53" TOTAL_2="85" VAR="0.15190705212902772" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2008-10-08 14:45:28 +0100" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Intravaginal: fenticonazole 600 mg versus 1000 mg</NAME>
<DICH_OUTCOME CHI2="3.4423193261528375" CI_END="2.233113986922611" CI_START="0.9791493845121155" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4786994913912261" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="20" I2="41.899637700514695" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="0.34891089173603307" LOG_CI_START="-0.009151044744305812" LOG_EFFECT_SIZE="0.16987992349586362" METHOD="MH" NO="1" P_CHI2="0.17885890228194" P_Q="0.0" P_Z="0.06291640698957371" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="61" WEIGHT="100.0" Z="1.8597817741880818">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2610422012259788" CI_START="1.1980216983814258" EFFECT_SIZE="1.9765625" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5133564190577146" LOG_CI_START="0.07846468399818454" LOG_EFFECT_SIZE="0.2959105515279496" ORDER="294" O_E="0.0" SE="0.25545755792277564" STUDY_ID="STD-Gorlero-1992" TOTAL_1="32" TOTAL_2="33" VAR="0.06525856389986825" WEIGHT="56.29856274407182"/>
<DICH_DATA CI_END="2.033311793544033" CI_START="0.4209583879320268" EFFECT_SIZE="0.9251700680272109" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.30820397963806373" LOG_CI_START="-0.3757608323939808" LOG_EFFECT_SIZE="-0.03377842637795857" ORDER="295" O_E="0.0" SE="0.40176431626804604" STUDY_ID="STD-Gorlero-1994" TOTAL_1="21" TOTAL_2="17" VAR="0.1614145658263305" WEIGHT="36.86491002053222"/>
<DICH_DATA CI_END="8.025911702882953" CI_START="0.01647556188677972" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="296" O_E="0.0" SE="1.5787413475374117" STUDY_ID="STD-Manth-1989" TOTAL_1="10" TOTAL_2="11" VAR="2.492424242424242" WEIGHT="6.836527235395949"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" NO="23">
<NAME>Nifuratel 7 days versus 10 days</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9370423225127327" CI_START="0.5691667069875047" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="0.28713910973973095" LOG_CI_START="-0.24476051159985476" LOG_EFFECT_SIZE="0.021189299069938092" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8759082668460139" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="30" WEIGHT="100.0" Z="0.1561582726084032">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.937042322512733" CI_START="0.5691667069875046" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.287139109739731" LOG_CI_START="-0.24476051159985482" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="297" O_E="0.0" SE="0.3124404705204619" STUDY_ID="STD-Gjonnaess-1969" TOTAL_1="60" TOTAL_2="30" VAR="0.09761904761904763" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2008-10-08 14:45:41 +0100" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Oral metronidazole versus intravaginal clotrimazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.270492765573324" CI_START="0.04096350742130546" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.10526315789473684" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="-0.5678443457648055" LOG_CI_START="-1.3876028648128902" LOG_EFFECT_SIZE="-0.9777236052888478" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="2.9354322887136953E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="4.675286706202299">
<NAME>No parasitological cure (2-3 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimantal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.270492765573324" CI_START="0.04096350742130546" EFFECT_SIZE="0.10526315789473684" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="38" LOG_CI_END="-0.5678443457648055" LOG_CI_START="-1.3876028648128902" LOG_EFFECT_SIZE="-0.9777236052888478" ORDER="298" O_E="0.0" SE="0.4815302119589588" STUDY_ID="STD-DuBouchet-1997" TOTAL_1="45" TOTAL_2="45" VAR="0.23187134502923976" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.40728328179052053" CI_START="0.1242992341287363" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.225" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="-0.3901034165163585" LOG_CI_START="-0.9055315472609166" LOG_EFFECT_SIZE="-0.6478174818886375" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="8.359839241884534E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="4.926773908218879">
<NAME>No parasitological cure (4-6 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.40728328179052053" CI_START="0.1242992341287363" EFFECT_SIZE="0.225" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="40" LOG_CI_END="-0.3901034165163585" LOG_CI_START="-0.9055315472609166" LOG_EFFECT_SIZE="-0.6478174818886375" ORDER="299" O_E="0.0" SE="0.30276503540974914" STUDY_ID="STD-DuBouchet-1997" TOTAL_1="45" TOTAL_2="45" VAR="0.09166666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-024.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Any side effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="266.07824396881443" CI_START="0.9160545677023499" EFFECT_SIZE="15.612244897959183" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4250093656804257" LOG_CI_START="-0.03807865543021742" LOG_EFFECT_SIZE="1.193465355125104" ORDER="300" O_E="0.0" SE="1.4468300960827338" STUDY_ID="STD-DuBouchet-1997" TOTAL_1="48" TOTAL_2="50" VAR="2.0933173269307725" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2008-10-08 14:45:52 +0100" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Oral metronidazole versus intravaginal AVC suppositories</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.31999951482641964" CI_START="0.04750716983075359" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12329749103942653" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="-0.49485068014374545" LOG_CI_START="-1.3232408412603893" LOG_EFFECT_SIZE="-0.9090457607020674" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="1.69577730145715E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="43" WEIGHT="100.0" Z="4.3015888766066395">
<NAME>No parasitological cure (2-3 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3199995148264197" CI_START="0.04750716983075359" EFFECT_SIZE="0.12329749103942653" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="31" LOG_CI_END="-0.49485068014374534" LOG_CI_START="-1.3232408412603893" LOG_EFFECT_SIZE="-0.9090457607020674" ORDER="301" O_E="0.0" SE="0.4866004812373478" STUDY_ID="STD-DuBouchet-1997" TOTAL_1="45" TOTAL_2="43" VAR="0.23678002834041845" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.233699530377452E-31" CI_END="0.4484226975630415" CI_START="0.1346397283906303" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24571428571428575" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="35" I2="99.99999999999999" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="-0.34831241307772587" LOG_CI_START="-0.8708267731356898" LOG_EFFECT_SIZE="-0.6095695931067079" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="4.807430079787115E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="43" WEIGHT="100.0" Z="4.573020532593009">
<NAME>No parasitological cure (4-6 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4484226975630414" CI_START="0.1346397283906303" EFFECT_SIZE="0.24571428571428572" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="35" LOG_CI_END="-0.348312413077726" LOG_CI_START="-0.8708267731356898" LOG_EFFECT_SIZE="-0.6095695931067079" ORDER="302" O_E="0.0" SE="0.3069275215858446" STUDY_ID="STD-DuBouchet-1997" TOTAL_1="45" TOTAL_2="43" VAR="0.09420450350682909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-025.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Any side effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.952229398441849" CI_START="0.5808370543531189" EFFECT_SIZE="1.859375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7746796605347358" LOG_CI_START="-0.23594568571744856" LOG_EFFECT_SIZE="0.2693669874086436" ORDER="303" O_E="0.0" SE="0.5936463310646791" STUDY_ID="STD-DuBouchet-1997" TOTAL_1="48" TOTAL_2="51" VAR="0.35241596638655465" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" NO="26">
<NAME>Oral plus intravaginal versus intravaginal</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9371207184180955" CI_START="0.3751696359331461" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5929411764705882" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="-0.0282044603759421" LOG_CI_START="-0.42577231816159283" LOG_EFFECT_SIZE="-0.22698838926876747" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.025217566474737847" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="21" WEIGHT="100.0" Z="2.238053500368256">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9371207184180955" CI_START="0.3751696359331461" DF="0.0" EFFECT_SIZE="0.5929411764705882" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" I2="0.0" ID="CMP-026.01.01" LOG_CI_END="-0.0282044603759421" LOG_CI_START="-0.42577231816159283" LOG_EFFECT_SIZE="-0.22698838926876747" NO="1" P_CHI2="1.0" P_Z="0.025217566474737847" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="21" WEIGHT="100.0" Z="2.238053500368256">
<NAME>Oral Aminitrozole plus intravaginal Acigel versus intravaginal Acigel</NAME>
<DICH_DATA CI_END="0.9371207184180955" CI_START="0.3751696359331461" EFFECT_SIZE="0.5929411764705882" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="-0.0282044603759421" LOG_CI_START="-0.42577231816159283" LOG_EFFECT_SIZE="-0.22698838926876747" ORDER="304" O_E="0.0" SE="0.2335333276559267" STUDY_ID="STD-Barnes-1957" TOTAL_1="25" TOTAL_2="21" VAR="0.05453781512605041" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2008-10-08 14:46:28 +0100" MODIFIED_BY="[Empty name]" NO="27">
<NAME>Oral metronidazole versus intravaginal nonoxynol 9</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5655368139009167" CI_START="0.0023571666659295038" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.036511156186612576" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="-0.24753911920247224" LOG_CI_START="-2.6276097091453754" LOG_EFFECT_SIZE="-1.437574414173924" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.017901176774369868" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="17" WEIGHT="100.0" Z="2.36765589120174">
<NAME>No parasitological cure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5655368139009167" CI_START="0.0023571666659295038" EFFECT_SIZE="0.036511156186612576" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="14" LOG_CI_END="-0.24753911920247224" LOG_CI_START="-2.6276097091453754" LOG_EFFECT_SIZE="-1.437574414173924" ORDER="305" O_E="0.0" SE="1.3980652460718919" STUDY_ID="STD-Antonelli-2000" TOTAL_1="16" TOTAL_2="17" VAR="1.9545864322740594" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>